<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">105544</article-id><article-id pub-id-type="doi">10.7554/eLife.105544</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Understanding the global rise of artemisinin resistance: Insights from over 100,000 <italic>Plasmodium falciparum</italic> samples</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Balmer</surname><given-names>Andrew J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7446-3428</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>White</surname><given-names>Nina FD</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7110-7874</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ünlü</surname><given-names>Eyyüb S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2200-0928</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Chiyun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2103-5184</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pearson</surname><given-names>Richard D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7386-3566</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Almagro-Garcia</surname><given-names>Jacob</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0595-7333</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ariani</surname><given-names>Cristina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-0887-5993</contrib-id><email>cristina.ariani@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05cy4wa09</institution-id><institution>Genomic Surveillance Unit, Wellcome Sanger Institute</institution></institution-wrap><addr-line><named-content content-type="city">Hinxton</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ferreira</surname><given-names>Marcelo U</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>University of São Paulo</institution></institution-wrap><country>Brazil</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>10</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e105544</elocation-id><history><date date-type="received" iso-8601-date="2024-12-06"><day>06</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-08-15"><day>15</day><month>08</month><year>2025</year></date></history><permissions><copyright-statement>© 2025, Balmer, White, Ünlü et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Balmer, White, Ünlü et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-105544-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-105544-figures-v1.pdf"/><abstract><p>Artemisinin partial resistance (ART-R) in <italic>Plasmodium falciparum</italic> is a major challenge to malaria control globally. Over the last two decades, ART-R has spread widely across Southeast Asia, undermining public health strategies and hindering elimination. As of 2024, ART-R has now emerged in East Africa, with the potential to dramatically impact current efforts to control malaria in the region. Mitigating its spread requires detailed genomic surveillance of point mutations in the <italic>kelch13</italic> gene, the primary known determinant of artemisinin resistance. Although extensive surveillance data on these markers is available, it is distributed across many literature studies and open databases. In this review, we aggregate spatiotemporal data for 112,933 <italic>P. falciparum</italic> samples collected between 1980 and 2023 into a single resource, providing the most comprehensive overview of <italic>kelch13</italic> markers to date. We outline the history and current status of these mutations globally, with particular focus on their emergence in Southeast Asia and East/Northeast Africa. Concerningly, we find the recent increases in ART-R in Africa mirror patterns observed in Southeast Asia 10–15 years ago. We examine factors that may influence its spread, including fitness costs, treatment strategies, and local epidemiological dynamics, before discussing potential scenarios for how resistance may spread in Africa in coming years. This review provides a comprehensive account of how the situation of ART-R has unfolded globally so far, highlighting insights for researchers and public health bodies which aim to reduce its negative effects.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>artemisinin</kwd><kwd>resistance</kwd><kwd><italic>Plasmodium falciparum</italic></kwd><kwd>genomic surveillance</kwd><kwd>artemisinin combination therapy</kwd><kwd>malaria</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>Plasmodium falciparum</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>The Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>INV-001927</award-id><principal-award-recipient><name><surname>Balmer</surname><given-names>Andrew J</given-names></name><name><surname>White</surname><given-names>Nina FD</given-names></name><name><surname>Ünlü</surname><given-names>Eyyüb S</given-names></name><name><surname>Lee</surname><given-names>Chiyun</given-names></name><name><surname>Pearson</surname><given-names>Richard D</given-names></name><name><surname>Almagro-Garcia</surname><given-names>Jacob</given-names></name><name><surname>Ariani</surname><given-names>Cristina</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>The Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>INV-068808</award-id><principal-award-recipient><name><surname>Balmer</surname><given-names>Andrew J</given-names></name><name><surname>White</surname><given-names>Nina FD</given-names></name><name><surname>Ünlü</surname><given-names>Eyyüb S</given-names></name><name><surname>Lee</surname><given-names>Chiyun</given-names></name><name><surname>Pearson</surname><given-names>Richard D</given-names></name><name><surname>Almagro-Garcia</surname><given-names>Jacob</given-names></name><name><surname>Ariani</surname><given-names>Cristina</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Spatiotemporal analysis of global <italic>kelch13</italic> surveillance data reveals that artemisinin resistance is increasing in East Africa, mirroring patterns previously observed in Southeast Asia.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Artemisinin-based combination therapies (ACTs) are the most important antimalarial treatment currently available. By combining a fast-acting artemisinin derivative with a longer-acting partner drug, ACTs provide a highly effective treatment for uncomplicated malaria. The artemisinin derivative reduces parasite biomass over the first 3 days of treatment, before the partner drug clears the remaining infection (<xref ref-type="bibr" rid="bib105">Nosten and White, 2007</xref><ext-link ext-link-type="uri" xlink:href="https://www.zotero.org/google-docs/?42oCwK">)</ext-link>. Because of their effectiveness, the WHO has recommended ACTs as primary treatment for uncomplicated malaria, and as a follow-up treatment for severe malaria, since 2006 (<xref ref-type="bibr" rid="bib158">World Health Organization, 2006</xref>). As of 2024, ACTs remain the most widely used antimalarial globally in treating infection by <italic>Plasmodium falciparum</italic> and have been adopted as a primary malaria treatment strategy by 84 countries (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). Currently, around 65% of all uncomplicated malaria cases are treated with ACTs, with up to 70% of infections in Africa treated using the ACT artemether-lumefantrine (<xref ref-type="bibr" rid="bib39">Dhorda et al., 2024</xref>). While new drugs are in development to replace ACTs, the lengthy testing and clinical trial process means ACTs will likely remain the primary treatment for the foreseeable future (<xref ref-type="bibr" rid="bib46">Erhunse and Sahal, 2021</xref>).</p><p>Given their critical role in malaria treatment, preventing resistance to ACTs remains a major priority for the malaria community. Initially, there was optimism that resistance to artemisinin may not occur, or would occur more slowly than resistance to previous drugs, due to the combination of an artemisinin derivative with a partner drug (<xref ref-type="bibr" rid="bib172">Yeung et al., 2004</xref>; <xref ref-type="bibr" rid="bib113">Pongtavornpinyo et al., 2008</xref>). However, this optimism faded in 2008, when reports of reduced efficacy of artemisinin-based drugs emerged from the Thai-Cambodian border. These were the first recorded instances of what we now refer to as artemisinin ‘partial resistance’ (ART-R) (<xref ref-type="bibr" rid="bib104">Noedl et al., 2008</xref>; <xref ref-type="bibr" rid="bib42">Dondorp et al., 2009</xref>; <xref ref-type="bibr" rid="bib11">Ashley et al., 2014</xref>; <xref ref-type="bibr" rid="bib163">World Health Organization, 2016</xref>). ART-R is characterised by delayed parasite clearance time following treatment with an artemisinin derivative, where high parasitaemia persists beyond day 3 of treatment, or if parasite clearance half-life exceeds 5 hours (<xref ref-type="bibr" rid="bib120">Rosenthal, 2021</xref>). It is termed ‘partial’ resistance because parasite clearance is delayed rather than prevented, leaving more parasites for the partner drug to clear (<xref ref-type="bibr" rid="bib17">Behrens et al., 2021</xref>). While this does not immediately lead to treatment failure, it increases selective pressure for partner drug resistance, potentially leading to parasites which are resistant to both drugs and a higher likelihood of overall treatment failure.</p><p>After emerging on the Thai-Cambodia border in 2008, ART-R then spread across the Greater Mekong Subregion into Myanmar, Vietnam, and Laos throughout the early 2010s (<xref ref-type="bibr" rid="bib11">Ashley et al., 2014</xref>; <xref ref-type="bibr" rid="bib144">Tun et al., 2015</xref>). As with resistance to previous antimalarials chloroquine and sulfadoxine–pyrimethamine (<xref ref-type="bibr" rid="bib124">Roux et al., 2021</xref>; <xref ref-type="bibr" rid="bib89">Mita et al., 2009</xref>), Southeast Asia had become the initial hotspot for artemisinin resistance. With those drugs, resistant parasites then spread westwards to East Africa, before dispersing widely across the continent and causing a major public health crisis with effects still felt decades later (<xref ref-type="bibr" rid="bib142">Trape, 2001</xref>; <xref ref-type="bibr" rid="bib94">Murray et al., 2012</xref>). Now, a major concern is whether ART-R will follow the same trajectory. As Africa carries 94% of the global malaria burden, with over 233 million cases annually, if a decline in artemisinin efficacy caused widespread ACT failure, the consequences could be catastrophic (<xref ref-type="bibr" rid="bib39">Dhorda et al., 2024</xref>; <xref ref-type="bibr" rid="bib44">Duffey et al., 2021</xref>; <xref ref-type="bibr" rid="bib167">World Health Organization, 2023</xref>). Alarmingly, reports of reduced therapeutic efficacy have been increasing in East and Northeast Africa since 2019 (<xref ref-type="bibr" rid="bib15">Balikagala et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Assefa et al., 2024</xref>; <xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>). Although ACTs remain largely effective, several countries have reported efficacies below 90%, including Angola, the DRC, Burkina Faso, Uganda, and Tanzania (<xref ref-type="bibr" rid="bib66">Ishengoma et al., 2024</xref>; <xref ref-type="bibr" rid="bib92">Moriarty et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Dimbu et al., 2021</xref>; <xref ref-type="bibr" rid="bib45">Ebong et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Gansané et al., 2021</xref>). Monitoring and preventing the spread of ART-R is therefore a major global health priority.</p><sec id="s1-1"><title>Monitoring ART-R</title><p>ART-R can be monitored using several methods, each of which has their own costs and benefits (<xref ref-type="bibr" rid="bib106">Nsanzabana et al., 2018</xref>). These can include therapeutic efficacy studies (TES), randomised clinical trials which assess treatment outcomes for ACTs in patients over several weeks and provide crucial evidence for shaping antimalarial policies (<xref ref-type="bibr" rid="bib106">Nsanzabana et al., 2018</xref>; <xref ref-type="bibr" rid="bib159">World Health Organization, 2009</xref>). Notably, TES assesses the efficacy of both artemisinin derivatives and their partner drugs, with parasite clearance half-life serving as a specific measure for ART-R (<xref ref-type="bibr" rid="bib120">Rosenthal, 2021</xref>). Surveillance of ART-R can also involve <italic>in vitro</italic> assays to test for phenotypic resistance, by exposing parasites to varying concentrations of antimalarials to assess their susceptibility (<xref ref-type="bibr" rid="bib159">World Health Organization, 2009</xref>). Alongside these methods, genomic surveillance has emerged as a key strategy for monitoring ART-R.</p><p>Genomic surveillance of ART-R was made possible by the identification of mutations in the <italic>kelch13</italic> gene as the primary determinant of ART-R. Initial evidence for their role was provided by <italic>in vitro</italic> experiments, which associated mutations in the propeller domain of the Kelch13 protein with higher survival rates of ring-stage parasites during drug exposure (<xref ref-type="bibr" rid="bib10">Ariey et al., 2014</xref>). Gene editing experiments then confirmed this by demonstrating that artemisinin-susceptible parasites could be made resistant by introducing ART-R-associated <italic>kelch13</italic> mutations (<xref ref-type="bibr" rid="bib136">Straimer et al., 2015</xref>). Further studies, including genome-wide association analysis and selection scans, later identified additional <italic>kelch13</italic> mutations which were strongly associated with resistance (<xref ref-type="bibr" rid="bib28">Cerqueira et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Anderson et al., 2017</xref>). Today, the WHO maintains a list of 23 <italic>kelch13</italic> mutations linked to ART-R, all within the BTB/POZ or propeller domain, which are classified as either validated or candidate mutation depending on the strength of their association with ART-R (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). While <italic>kelch13</italic> remains the primary and most well-studied molecular marker, other loci, including <italic>pfcoronin</italic>, <italic>ubp1,</italic> and <italic>pfap2mu</italic>, have also been implicated in artemisinin partial resistance and may contribute through complementary mechanisms (<xref ref-type="bibr" rid="bib38">Demas et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Ndiaye et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Henriques et al., 2014</xref>).</p><p>Genomic surveillance of <italic>kelch13</italic> markers has since become a scalable method for monitoring ART-R prevalence at population levels and has been increasingly implemented in malaria endemic countries (<xref ref-type="bibr" rid="bib98">Ndiaye et al., 2021</xref>). Although the method does not directly measure patient outcomes, it can be particularly informative when combined with therapeutic efficacy or <italic>in vitro</italic> work (<xref ref-type="bibr" rid="bib171">Yeka et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Ippolito et al., 2020</xref>). Given the wide applicability of genomic surveillance, several strategies now exist to monitor ART-R molecular markers over time and across regions, including targeted amplicon and whole genome sequencing, as reviewed in <xref ref-type="bibr" rid="bib99">Neafsey et al., 2021</xref>. These methods have enabled the collection of extensive datasets on prevalence of <italic>kelch13</italic> markers at population levels (<xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>). For example, <xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref> and <xref ref-type="bibr" rid="bib71">Kayiba et al., 2021</xref> each characterised the spatial and temporal spread of ART-R at continental scales, underscoring the effectiveness of genomic surveillance for measuring ART-R. While these studies provided valuable insights, a global analysis of ART-R spread utilising publicly available data remains elusive. This is because although extensive surveillance data on <italic>kelch13</italic> markers is available, it is distributed across numerous studies and open databases. Synthesising this information on a global scale would significantly enhance our understanding of the worldwide distribution and dynamics of ART-R.</p><p>In this review, we offer a global perspective on the emergence, spread, and potential future developments of ART-R. We consolidate publicly available data on <italic>kelch13</italic> mutations into a single resource–encompassing 112,933 samples–to provide the most comprehensive overview to date. Our global summary then traces the history and current status of ART-R, providing detailed analyses of its spread in Southeast Asia and East/Northeast Africa. By integrating both literature and existing data, we then articulate several potential scenarios for the future trajectory of ART-R in Africa. Finally, we examine the critical role of genomic surveillance in advancing effective malaria control strategies.</p></sec></sec><sec id="s2"><title>Global overview of <italic>kelch13 markers</italic> in 112,933 samples</title><p>We compiled a global dataset of publicly available <italic>kelch13</italic> mutation data for 112,933 samples collected between 1980 and 2023, from 73 countries (see Methods). These data and metadata were compiled from three sources: the MalariaGEN Pf7 release (<xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>), the Worldwide Antimalarial Resistance Network (WWARN) Artemisinin Resistance Molecular Surveyor, and a literature search. Mutations were annotated based on their artemisinin resistance status using the most recent WHO guidelines: either ‘validated’, ‘candidate’, or ‘no status’ (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Parasites with the 3D7 reference <italic>kelch13</italic> sequence or the A578S mutation were classified as artemisinin-susceptible (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). Throughout this work, we refer to all BTB/POZ and propeller mutations (codons 349–726) as ‘propeller mutations’. Samples from each country were assigned to one of thirteen broader populations, allowing us to assess trends at continental scales (see Methods). These populations included: South America, West Africa, Central Africa, North Africa, Northeast Africa, East Africa, Southern Africa, Western Asia, Eastern South Asia, Far-Eastern South Asia, Western Southeast Asia, Eastern Southeast Asia, and Oceania.</p><sec id="s2-1"><title>Global geographic overview</title><p>Across the samples, we observed 492 unique, non-synonymous mutations in the BTB/POZ and propeller domains of <italic>kelch13</italic> (Supp. Dataset S2). Most samples had the 3D7 reference sequence (85.5%, n=96,574), with the most common mutation being the WHO validated marker C580Y (6.5%, n=7,307). The other most common mutations were all WHO validated/candidate markers: F446I (1.5%), R561H (0.7%), P441L (0.7%), and R539T (0.4%). Southeast Asia had the highest proportion of samples with a <italic>kelch13</italic> propeller mutation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). For example, over half of samples from Eastern Southeast Asia (52%) had a <italic>kelch13</italic> propeller mutation, with over 98% of these having a WHO validated/candidate marker. Similarly, in Western Southeast Asia, 35% of samples had a <italic>kelch13</italic> propeller domain mutation, with 94% of these having a WHO validated/candidate mutation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). These populations also showed the highest diversity of WHO validated/candidate markers relative to unique <italic>kelch13</italic> propeller mutations (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Global trends in <italic>kelch13</italic> propeller mutations over time.</title><p>Panel A shows the distribution of <italic>kelch13</italic> mutations globally for samples collected between 1980 and 2023. Countries from which samples were included are coloured according to their geographic population assignment. All populations are labelled with a fraction, denoting the number of samples with any <italic>kelch13</italic> propeller mutation (excluding A578S, which is known to be artemisinin susceptible) over the total number of samples from each population. No WHO mutations were detected in the North African samples. For each population, pie charts show the proportion of samples with a WHO validated/candidate mutation in red, the proportion of any other propeller domain mutation in blue, and the proportion of samples with a 3D7 reference <italic>kelch13</italic> sequence or A578S mutation in white. Proportions of each category at 25% or more are labelled. Panel B shows the number of unique <italic>kelch13</italic> propeller domain markers for each population against their total number of unique WHO validated/candidate mutations. Populations are labelled with their ratio of WHO validated/candidate markers to the total number of unique propeller domain markers. Populations falling in the blue shaded area have fewer WHO validated/candidate markers relative to their total count of <italic>kelch13</italic> mutations than populations falling in red areas. The upper plot of panel C shows the total number of samples over time. Grey areas denote years with fewer than 25 samples. The bottom panel shows the proportion of samples from each population for each year, with years with no samples coloured white. Note the limited number of samples from Southeast Asia after 2019, which coincided with an increased proportion of resistant samples in East and Northeast Africa. Panel D illustrates a schematic representation of the <italic>kelch13</italic> protein (residues 1–726), with functional domains—including N-terminal, coiled-coil, BTB/POZ, and six-blade <italic>kelch13</italic> repeat propeller (KREP) domains—annotated using InterProScan (version 5.73). WHO-validated (green) and candidate markers (blue) are mapped to their respective amino acid positions.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title><italic>kelch13</italic> genotypes and sample metadata for 112,933 <italic>Plasmodium falciparum</italic> isolates.</title></caption><media mimetype="application" mime-subtype="octet-stream" xlink:href="elife-105544-fig1-data1-v1.csv"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig1-v1.tif"/></fig><p>The East and Northeast African populations had an increased frequency of WHO validated/candidate markers (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). For example, 10% of Northeast African samples had a <italic>kelch13</italic> propeller mutation, ~80% of which were WHO validated/candidate markers. Similarly, in East Africa, 4% of samples had a <italic>kelch13</italic> propeller mutation, and ~25% of these were WHO validated/candidate markers for ART-R (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The East and Northeast regions of Africa also had a high number of WHO validated/candidate mutations relative to unique <italic>kelch13</italic> propeller mutations (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). In contrast, the proportion of mutant samples was low in other areas of Africa (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In West and Central Africa, for example, mutant samples made up just 2% of the total samples, and this was even lower in Southern Africa (~1%). Similarly, the proportion of samples with a WHO validated/candidate mutation in West, Central, and Southern Africa was also low, typically below 0.13% (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Even though West Africa was the largest study population and had the largest number of unique <italic>kelch13</italic> propeller mutations (n=185), only five unique WHO validated/candidate mutations were observed there (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Together with lower overall frequencies of WHO mutations, this may imply that there is weaker selective pressure for WHO validated/candidate mutations in West Africa.</p><p>Other global populations had low frequencies of <italic>kelch13</italic> mutations and low mutational diversity (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). For example, only 0.45% of South American samples had a <italic>kelch13</italic> propeller mutation, and only three unique mutations were reported in the region (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). One of these was a WHO validated/candidate mutation (C580Y), which was found in 0.41% of all South American samples (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Similarly, in Western Asia (the second smallest population), only 0.64% of samples had mutations, none of which had WHO validated/candidate status (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In Eastern South Asia, 3% of all samples had a <italic>kelch13</italic> propeller mutation. In this region, only 13 unique mutations were observed, four of which were WHO validated/candidate mutations, accounting for 0.54% of samples (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In Far-Eastern South Asia, levels of <italic>kelch13</italic> mutation diversity were also very low. Only 0.52% of samples had a <italic>kelch13</italic> propeller mutation, and no WHO validated/candidate mutations were recorded. In Oceania, ~2% of all samples had a mutation in the <italic>kelch13</italic> propeller domain (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). While 24 unique <italic>kelch13</italic> propeller mutations were observed in Oceania, only one had WHO validated/candidate status (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). For a complete list of mutation metrics in all populations, see (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p></sec><sec id="s2-2"><title>Global temporal overview</title><p>The first documented <italic>kelch13</italic> propeller domain mutation observed in the dataset was from 1991, with the first WHO validated/candidate mutation identified in Thailand in 1997 (R359T). No other ART-R markers were detected before 2000, likely due to limited sampling of <italic>kelch13</italic> propeller mutations pre-2000, with an average of just 138 samples per year (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). After 2000, sample numbers increased, reaching up to 17,980 in 2014, coinciding with an increase in global ACT use (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). The total number of unique <italic>kelch13</italic> mutations and validated/candidate mutations also both rose throughout the 2000s (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). By the time ACTs were introduced as first-line treatments in 2006, over half of the currently known WHO validated/candidate mutations had been observed, predominantly in Southeast Asia (<xref ref-type="fig" rid="fig2">Figure 2</xref>). By this time, artemisinin derivatives were already widely used in the region, likely creating an evolutionary pressure for these mutations to emerge and spread (see Section ‘Southeast Asia’). As of the most recent observed years, ART-R-associated mutations have reached high frequency throughout Southeast Asia (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cumulative count of unique WHO validated/candidate <italic>kelch13</italic> mutations over time across the whole dataset (grey), Southeast Asia (blue) and Africa (red).</title><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title><italic>kelch13</italic> genotypes and sample metadata for 112,933 <italic>Plasmodium falciparum</italic> isolates.</title></caption><media mimetype="application" mime-subtype="octet-stream" xlink:href="elife-105544-fig2-data1-v1.csv"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Number of unique WHO validated/candidate <italic>kelch13</italic> mutations and other propeller mutations over time.</title><p>(<bold>A</bold>) Global overview of unique mutations (<bold>B</bold>) Unique mutations over time split by population. Darker hue = WHO-validated/candidate mutations, lighter hue = other propeller domain mutations. Bars represent stacked mutation counts. North Africa is not shown as no mutations were reported there.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig2-figsupp1-v1.tif"/></fig></fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Proportions of <italic>kelch13</italic> mutations over time from 2000 to 2024 for ten populations, with African populations in the left-hand column.</title><p>Years with fewer than 25 samples are shaded in grey with white stripes. Three populations (North Africa, Western Asia, Far-Eastern South Asia) are not displayed due to lack of data. Several of the most common WHO validated/candidate markers are highlighted. Other WHO validated/candidate markers are denoted by ‘Other WHO-V/C’. Mutations in the <italic>kelch13</italic> BTB/POZ or propeller domain without validated/candidate status are categorised as ‘Other’. The 3D7 reference <italic>kelch13</italic> sequence and the A578S mutation are known to not confer ART-R, so are categorised together as ‘Susceptible’. The high percentage of ‘Other’ mutations in East Africa in 2000 is due to our aggregation of samples from 1996 to 2003 to the median year of 2000 from a single study by <xref ref-type="bibr" rid="bib37">de Laurent et al., 2018</xref>. Similarly, the percentages of ‘Other’ mutations in West Africa (2005) and Central Africa (2007) result from single studies (<xref ref-type="bibr" rid="bib108">Ouattara et al., 2015</xref>; <xref ref-type="bibr" rid="bib140">Taylor et al., 2015</xref>) where multiple different mutations were identified.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig3-v1.tif"/></fig><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Proportion of samples from each country and geographical population with a WHO validated/candidate <italic>kelch13</italic> mutation (red) or other <italic>kelch13</italic> mutation in the BTB/POZ or propeller domain (blue).</title><p>Bars show the weighted average percentage of samples from the three most recent observed years with at least 25 samples. Averages were weighted by the total number of samples observed between the years. Date ranges show the range of years for the three most recent years, with at least 25 samples each. Countries with fewer than 3 years with at least 25 samples are marked with an asterisk.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig4-v1.tif"/></fig><p>In contrast, ART-R mutations were uncommon in Africa before 2010, with only three unique WHO mutations observed in just two samples each (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Several WHO validated/candidate markers then increased in frequency in East and Northeast Africa after 2018 (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>). For example, seven unique mutations increased in prevalence in Northeast Africa after 2020 (<xref ref-type="fig" rid="fig3">Figure 3</xref>), with the WHO-validated mutations A675V and C469Y increasing in frequency between 2020–2022 (from 4.7% to 9.4% and 6.9% to 9%, respectively). Another mutation, C469F, almost tripled in frequency, although overall frequency remained low, increasing from 0.9% in 2020 to 2.5% by 2022. Three WHO validated/candidate mutations were detected in East Africa in 2023: C469F (2.8%), A675V (5.6%), and R561H (declined from 22.5% in 2021 to 8.9% in 2023). In Central Africa, validated/candidate markers P441L, R561H, and C469Y were each detected in single years, although all occurred in fewer than 0.5% of samples. These data support the growing concern that ART-R has begun to emerge in Africa (see Section ‘East and Northeast Africa’).</p></sec><sec id="s2-3"><title>Data limitations</title><p>While aggregating such a large dataset allowed us to identify trends in the spread of <italic>kelch13</italic> mutations, it also highlighted biases in the available data. For example, sampling has consistently declined in the past decade (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Between 2020 and 2023, the average number of samples was just 1,513–a tenfold decrease compared to 2014 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Strikingly, there were no data from Southeast Asia in our dataset after 2019, despite the high proportion of mutant samples and variety of <italic>kelch13</italic> mutations in the region before this time. Therefore, trends in ART-R described in this decade are most relevant to Africa. A similar decrease occurred in Southeast Asian samples between 2014 and 2019, although sampling continued. This drop in sample sizes may be explained by a lag in publication of samples after 2019, combined with difficulties in sample collection during the COVID-19 pandemic<italic>,</italic> although this does not explain the decrease before this time. According to the 2023 world malaria report, total funding of malaria control in 2022 was US$3.7 billion, below the estimated total required to meet global technical strategy targets for malaria control and elimination (<xref ref-type="bibr" rid="bib167">World Health Organization, 2023</xref>). It is possible that this inadequate funding contributed to reduced sampling; however, more evidence would be needed to establish this.</p><p>There were also geographical biases in the dataset, with most samples coming from Africa (58%) and Southeast Asia (29%). This geographic bias reflects Africa’s status as a region with a high <italic>P. falciparum</italic> malaria burden and Southeast Asia’s role as the epicentre of ART-R. As a result, these regions have generated a significant proportion of the data relevant to this review. Thus, the trends described here are most applicable to these regions, despite sampling from a global range. This bias was especially pronounced between 2014 and 2016, with most samples coming from West Africa during this time (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). There were also biases within continents; for example, West Africa made up 52% of African samples in 2014, but by 2019, this was just 5%. Similarly, in Northeast Africa, these proportions were 9% in 2014 and 25% in 2019. Since 2019, there was no year in which all of the regions most impacted by malaria were adequately represented. At a smaller scale, we also saw an under-representation of some countries within populations (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><p>A further source of potential bias is in the different SNP detection methods used across data sources, with DNA sequencing using capillary electrophoresis (also known as Sanger sequencing) accounting for 77.01% of samples, while next-generation sequencing (NGS) methods represented 22.10% (Source Data S1). A key limitation of dideoxy sequencing is its reduced sensitivity in detecting low-frequency variants, particularly in highly mixed infections. This limitation may have led to an underestimation of some variants, especially in settings with high within-host diversity.</p><p>Sampling biases can arise from various sources, including the variation in location or number of health facilities between regions and differing sampling regimes between national control programmes (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>). Going forwards, having systematic, longitudinal sampling in Africa that is made publicly available as soon as possible will be crucial for providing robust insights into the effectiveness of ACTs. While aggregating such a large dataset still allows us to make robust comparisons within and between populations, these biases mean the findings need to be interpreted carefully.</p></sec></sec><sec id="s3"><title>Spread of artemisinin partial resistance</title><p>In the previous section, we highlighted how markers of ART-R have been found across the globe, but until recently, had been mostly localised in Southeast Asia. Concerningly, several WHO validated/candidate mutations have now emerged in parts of Africa, with potentially widespread consequences for human health. Here, we provide detailed case studies for Southeast Asia and East/Northeast Africa, focusing on how resistance-associated <italic>kelch13</italic> markers emerged and spread, summarising their current frequencies, and highlighting key questions on their geographical distributions. We then discuss <italic>kelch13</italic> substitutions observed in other regions, including West and Central Africa, South America, and Oceania.</p><sec id="s3-1"><title>Southeast Asia</title><sec id="s3-1-1"><title>How did <italic>kelch13</italic> mutants initially emerge and spread in Southeast Asia?</title><p>Artemisinin combination therapies have been used extensively across Southeast Asia since the mid-1990s, where they were quickly adopted by national governments seeking alternatives to drugs such as chloroquine, which had developed widespread resistance. Thailand, for example, adopted ACTs in 1995, shortly followed by Cambodia in 2000, Myanmar in 2002 and Vietnam in 2003 (<xref ref-type="bibr" rid="bib55">Hassett and Roepe, 2019</xref>; <xref ref-type="bibr" rid="bib126">Satimai et al., 2012</xref>). While ART-R was only discovered in Southeast Asia in 2008, the proportion of samples with a validated/candidate mutation had in fact already been high by 2006 (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref>). ART-R associated <italic>kelch13</italic> mutations then emerged independently across several locations in Southeast Asia, before a hard selective sweep drove a multidrug resistant co-lineage to dominance across the region (KEL1/PLA1, containing the C580Y <italic>kelch13</italic> mutation) (<xref ref-type="bibr" rid="bib139">Takala-Harrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Imwong et al., 2020</xref>; <xref ref-type="bibr" rid="bib6">Amato et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Hamilton et al., 2019</xref>). Analysis of genomic regions flanking the <italic>kelch13</italic> gene suggested this migration occurred several times, with the C580Y mutation initially spreading eastward from Cambodia to Vietnam, and later, from Cambodia to Thailand and Laos around 2013–15 (<xref ref-type="bibr" rid="bib139">Takala-Harrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>). Over the next 10–12 years, the C580Y mutation reached near-fixation frequencies in several of these countries (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In contrast, in Myanmar, C580Y emerged and spread independently on a different parasite genetic background (<xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>). This pattern of identical <italic>kelch13</italic> mutations arising independently, alongside migration events between countries, would become a repeated occurrence across Southeast Asia, with several of the most common <italic>kelch13</italic> mutations spreading via both mechanisms (<xref ref-type="bibr" rid="bib139">Takala-Harrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Imwong et al., 2020</xref>; <xref ref-type="bibr" rid="bib52">Hamilton et al., 2019</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Regional prevalence and temporal changes of <italic>kelch13</italic> propeller mutations in Southeast Asia.</title><p>Panel (<bold>A</bold>) shows the distribution of <italic>kelch13</italic> propeller mutations across Southeast Asia. The percentage of samples with any <italic>kelch13</italic> propeller mutation are included in the country labels, above the number of samples with any <italic>kelch13</italic> propeller mutation and the total number of samples collected for each country, respectively. Among only the samples with any observed <italic>kelch13</italic> propeller mutation, pie charts show the proportions with markers of interest, where proportions above 25% are labelled accordingly. ‘Other’ denotes low-frequency mutations in the propeller domain which are not WHO validated/candidate markers, aggregated into a single category. Samples with the 3D7 reference sequence for <italic>kelch13</italic> or A578S are denoted as ‘Susceptible’ (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). Panel (<bold>B</bold>) shows all samples collected over time for each country as a stacked bar chart, where the proportion of samples with each marker is coloured. Years with fewer than 25 samples are highlighted with grey dashed lines.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Scatter plot showing the results of TES monitoring three commonly used ACTs across populations, using the data from the WHO Malaria Threats Map (<ext-link ext-link-type="uri" xlink:href="https://apps.who.int/malaria/maps/threats/">https://apps.who.int/malaria/maps/threats/</ext-link>).</title><p>The x-axis represents delayed clearance, while the y-axis represents treatment failure rates. Scattered data points are colour-coded by region. Red dashed lines indicate the 10% threshold established by the WHO for policy change.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Genomic epidemiology played a critical role in identifying these patterns of emergence and migration in Southeast Asia. While it was initially thought there had been a single emergence of ART-R in the region, comparison of parasite genetic backgrounds revealed it had in fact emerged independently across several countries (<xref ref-type="bibr" rid="bib99">Neafsey et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Amato et al., 2018</xref>; <xref ref-type="bibr" rid="bib151">Verity et al., 2020</xref>). This enabled policy makers to focus on slowing local resistance through improved surveillance and access to malaria prevention, rather than focusing solely on preventing parasite migration across borders (<xref ref-type="bibr" rid="bib162">World Health Organization, 2015b</xref>; <xref ref-type="bibr" rid="bib78">Manzoni et al., 2024</xref>). Data from these surveillance efforts then became a cornerstone for developing mitigation strategies in the region. One such strategy, the ‘WHO Strategy for Malaria Elimination in the Greater Mekong Subregion’ (2015–2030), leveraged this evidence to achieve significant reductions in overall malaria burden of 77% (<xref ref-type="bibr" rid="bib162">World Health Organization, 2015b</xref>; <xref ref-type="bibr" rid="bib78">Manzoni et al., 2024</xref>). This underscores the importance of accurate and consistent molecular surveillance data in formulating effective public health policies and interventions.</p></sec><sec id="s3-1-2"><title>What is the current distribution and frequency of <italic>kelch13</italic> mutations across Southeast Asia?</title><p>The proportion of samples with a WHO validated or candidate <italic>kelch13</italic> substitution remained high as of 2019. Based on the latest data, between 37.9–75.8% of samples had a validated/candidate mutation in most Southeast Asian countries (<xref ref-type="fig" rid="fig5">Figure 5</xref>). For example, the proportion of samples with a WHO validated/candidate mutation in Vietnam (2019) and Thailand (2017) was 75.8% and 67.5%, respectively (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Similarly, in Cambodia, these frequencies fluctuated between 80% and –90% from 2016 to 2018. In 2019, 52.1% of Cambodian samples had a WHO validated/candidate mutation; however, data for this year were limited to three sites from a single study (<xref ref-type="bibr" rid="bib112">Peto et al., 2022</xref>). Laos showed a slightly lower frequency of 37.9% (2018), although it exhibited significant year-to-year variability, with a peak of 89% in 2014 (based on 111 samples). In contrast, Myanmar showed both a lower frequency and slower increase in the proportion of samples with a <italic>kelch13</italic> mutation between 2004 and 2019 (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>), although frequencies were still high as of the most recent year (51.5%). Between 1993 and 2019, there were 117 unique <italic>kelch13</italic> mutations present across Southeast Asia, although only 22 of these were observed in more than 25 samples (<xref ref-type="table" rid="table1">Table 1</xref>). While the C580Y mutation, a WHO-validated marker, was initially only one of several markers to emerge, it later rose to high frequency in many countries, such as Thailand, Laos, Cambodia, and Vietnam.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Most common <italic>kelch13</italic> mutations across Southeast Asia, where mutations occur in at least 25 samples across the two populations (western and eastern Southeast Asia).</title><p>Countries represented in this summary are Myanmar, China, Thailand, Cambodia, Laos, and Vietnam. Total refers to the total number of samples from these countries with each marker.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Marker</th><th align="left" valign="bottom">WHO status</th><th align="left" valign="bottom">Total</th><th align="left" valign="bottom">Proportion (%)</th></tr></thead><tbody><tr><td align="left" valign="bottom">3D7 reference sequence</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">18,958</td><td align="left" valign="bottom">58.08</td></tr><tr><td align="left" valign="bottom">C580Y</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">7,271</td><td align="left" valign="bottom">22.27</td></tr><tr><td align="left" valign="bottom">F446I</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">1,644</td><td align="left" valign="bottom">5.04</td></tr><tr><td align="left" valign="bottom">P441L</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">672</td><td align="left" valign="bottom">2.06</td></tr><tr><td align="left" valign="bottom">R561H</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">666</td><td align="left" valign="bottom">2.04</td></tr><tr><td align="left" valign="bottom">R539T</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">478</td><td align="left" valign="bottom">1.46</td></tr><tr><td align="left" valign="bottom">Y493H</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">437</td><td align="left" valign="bottom">1.34</td></tr><tr><td align="left" valign="bottom">I543T</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">391</td><td align="left" valign="bottom">1.20</td></tr><tr><td align="left" valign="bottom">G449A</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">355</td><td align="left" valign="bottom">1.09</td></tr><tr><td align="left" valign="bottom">P574L</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">292</td><td align="left" valign="bottom">0.89</td></tr><tr><td align="left" valign="bottom">P553L</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">226</td><td align="left" valign="bottom">0.69</td></tr><tr><td align="left" valign="bottom">M476I</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">173</td><td align="left" valign="bottom">0.53</td></tr><tr><td align="left" valign="bottom">N458Y</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">140</td><td align="left" valign="bottom">0.43</td></tr><tr><td align="left" valign="bottom">G538V</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">126</td><td align="left" valign="bottom">0.39</td></tr><tr><td align="left" valign="bottom">A675V</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom">0.29</td></tr><tr><td align="left" valign="bottom">G533S</td><td align="left" valign="bottom">no status</td><td align="left" valign="bottom">86</td><td align="left" valign="bottom">0.26</td></tr><tr><td align="left" valign="bottom">N537I</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">0.15</td></tr><tr><td align="left" valign="bottom">A676D</td><td align="left" valign="bottom">no status</td><td align="left" valign="bottom">44</td><td align="left" valign="bottom">0.13</td></tr><tr><td align="left" valign="bottom">V568G</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">0.12</td></tr><tr><td align="left" valign="bottom">M562I</td><td align="left" valign="bottom">no status</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">0.11</td></tr><tr><td align="left" valign="bottom">T474I</td><td align="left" valign="bottom">no status</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">0.09</td></tr><tr><td align="left" valign="bottom">C469F</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">0.09</td></tr><tr><td align="left" valign="bottom">E461G</td><td align="left" valign="bottom">no status</td><td align="left" valign="bottom">27</td><td align="left" valign="bottom">0.08</td></tr></tbody></table></table-wrap><p>As of 2019, C580Y remains dominant, with the majority of samples with any <italic>kelch13</italic> mutation showing this marker. For instance, 83% of all samples from Cambodia with a <italic>kelch13</italic> mutation had C580Y. A similar trend was observed in Thailand (54%) and Vietnam (65%). While other <italic>kelch13</italic> substitutions were circulating in these countries, such as R539T and R561H, these were at much lower frequencies. Notably, Thailand showed a larger diversity of other markers than Cambodia, Vietnam, or Laos. This is most likely due to the malaria-free corridor which separates parasite populations in east and west Thailand. Eastern Thailand tends to have higher proportions of C580Y, while western Thailand more closely reflects the diversity in bordering Myanmar (<xref ref-type="bibr" rid="bib72">Kobasa et al., 2018</xref><ext-link ext-link-type="uri" xlink:href="https://www.zotero.org/google-docs/?heyz00">)</ext-link>. In Myanmar, several unique <italic>kelch13</italic> mutations were circulating at moderate frequencies in 2019, with no single substitution reaching fixation. C580Y is not the dominant mutation in Myanmar, where mutations such as F446I, R561H, and P441L have all continued circulating (<xref ref-type="bibr" rid="bib24">Bonnington et al., 2017</xref>). This pattern of several circulating markers has remained consistent between 2004 and 2019, whereas countries such as Thailand and Laos saw C580Y overtake others during the same time period. In total, of the 22 most common <italic>kelch13</italic> mutations, 8 of these were unique to Myanmar and China within Southeast Asia, including: E461G, A675V, M562I, F446I, A676D, G538V, R561H, P441L.</p><p>The high frequency of <italic>kelch13</italic> mutations in Southeast Asia has translated into increased negative clinical outcomes, evidenced by delayed clearance rates above 10% in TES <xref ref-type="supplementary-material" rid="supp6 supp6">(Supplementary files 6)</xref>. We obtained the results of studies which monitor the therapeutic efficacy of common ACTs from the WHO Malaria Threats Map (<xref ref-type="bibr" rid="bib78">Manzoni et al., 2024</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Out of 94 studies across Southeast Asia, 52 (55%) reported delayed clearance rates (&gt;10%) for dihydroartemisinin-piperaquine (DHA-PPQ) treatment, with 18 (19%) reporting treatment failure rates over 10%. Artesunate-mefloquine (AS-MQ) paints a similar picture: of 38 studies, 21 (55%) reported delayed clearance rates, with 2 (5%) reporting treatment failure rates over 10%. In contrast, artemether-lumefantrine (AL) has shown slightly better outcomes, with only 15 of 131 studies (11%) reporting delayed clearance rates of &gt;10%, and four (3%) reporting treatment failure rates &gt;10%. This lower delayed clearance rate for AL may be attributed to the fact that AL has only been a first-line treatment in Laos and Myanmar, where ART-R is lower (<xref ref-type="bibr" rid="bib167">World Health Organization, 2023</xref>; <xref ref-type="bibr" rid="bib162">World Health Organization, 2015b</xref>; <xref ref-type="bibr" rid="bib164">World Health Organization, 2021</xref>; <xref ref-type="bibr" rid="bib67">Jacob et al., 2021</xref>). The high frequency of delayed clearance and treatment failure indicates the growing challenge in malaria treatment using ACTs in Southeast Asia.</p><p>These findings underscore the need for ongoing genomic surveillance to establish the composition and frequencies of circulating parasite populations in Southeast Asia. However, data from the region are limited by the lack of systematic, longitudinal sampling, without which it is difficult to properly estimate the frequencies of resistance (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>). For example, in our data, no information was available for Southeast Asian countries after 2019. Additionally, many countries showed considerable between-year variation in the proportion of samples with <italic>kelch13</italic> mutations, which may be due to a disproportionately large number of samples from a single study or region and inconsistent sampling. One major challenge for surveillance is that it becomes more challenging to collect samples as overall numbers are driven down, as is the case in Southeast Asia. While systematic genomic surveillance is still key to interpreting the frequencies of <italic>kelch13</italic> mutations, going forwards, additional strategies may also be required to account for lower case numbers. These could include enhanced collaborations and data sharing to pool data, and compensatory statistical techniques like time-aggregated sampling.</p></sec><sec id="s3-1-3"><title>Did fitness costs affect the spread of kelch13 mutations across Southeast Asia?</title><p>Experimental studies have assessed the fitness costs of <italic>kelch13</italic> mutations using various methods, including growth and competition assays, as well as measurements of metabolic and transcriptional responses (see <xref ref-type="box" rid="box1"><xref ref-type="box" rid="box1"><xref ref-type="box" rid="box1"><xref ref-type="box" rid="box1">Box 1</xref></xref></xref></xref> for an overview). Although validated and candidate mutations have so far been described in this review as conferring a unified ‘resistant’ phenotype, in reality, individual mutations can differ in their effects on both parasite fitness and clearance rate, and these effects may vary further depending on the context in which the parasite is treated with artemisinin (<xref ref-type="bibr" rid="bib18">Behrens et al., 2023</xref>; <xref ref-type="bibr" rid="bib169">WWARN K13 Genotype-Phenotype Study Group, 2019</xref>).</p><boxed-text id="box1"><label>Box 1.</label><caption><title>Fitness costs associated with ART-R.</title></caption><p>Fitness costs could significantly impact the spread of ART-R. In the presence of the drug, resistant parasites have a selective advantage, making them more likely to transmit between individuals and spread within a population (<xref ref-type="bibr" rid="bib155">White, 2004</xref>). However, if there are fitness costs to being resistant, then in the absence of the drug, resistant parasites would be outcompeted by susceptible genotypes, making them more likely to remain at low frequency (<xref ref-type="bibr" rid="bib118">Rosenthal, 2013</xref>).</p><p>Numerous <italic>in vitro</italic> studies have demonstrated fitness costs associated with <italic>kelch13</italic> mutations, such as decreased parasite blood stage growth rate (<xref ref-type="bibr" rid="bib137">Straimer et al., 2017</xref>) and competitive growth disadvantage (<xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>; <xref ref-type="bibr" rid="bib96">Nair et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Mathieu et al., 2020</xref>). Delayed parasite clearance under artemisinin exposure is linked to decreased haemoglobin endocytosis, limiting the parasite’s ability to utilise important amino acids (<xref ref-type="bibr" rid="bib25">Bunditvorapoom et al., 2018</xref>). <italic>kelch13</italic> mutant parasites also have lower heme levels during the trophozoite stage, which may cause growth defects (<xref ref-type="bibr" rid="bib58">Heller and Roepe, 2018b</xref>; <xref ref-type="bibr" rid="bib57">Heller et al., 2018a</xref>). <italic>kelch13</italic> mutations may also affect stability of the protein, leading to transcriptional stress responses and cell development issues (<xref ref-type="bibr" rid="bib91">Mok et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Behrens et al., 2024</xref>; <xref ref-type="bibr" rid="bib170">Yang et al., 2019</xref>). Moreover, different <italic>kelch13</italic> mutations can confer differing levels of ART-R and fitness costs. For example, C580Y and R561H show similar increased survival under drug treatment <italic>in vitro</italic>, but differing fitness costs (<xref ref-type="bibr" rid="bib96">Nair et al., 2018</xref>). The F446I mutation, common in Myanmar, provides a small survival advantage during drug treatment, but lower competitive growth <italic>in vitro</italic> than C580Y (<xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>). While other regions of the genome have also been associated with decreased clearance rate for artemisinin (<xref ref-type="bibr" rid="bib28">Cerqueira et al., 2017</xref>; <xref ref-type="bibr" rid="bib93">Mukherjee et al., 2017</xref>), these mechanisms are complex and require further experimental validation of potential fitness costs (for a review, see <xref ref-type="bibr" rid="bib110">Pandit et al., 2023</xref>).</p><p>The presence of these costs is unsurprising given the highly conserved nature of the kelch13 propeller domains, yet may have important consequences for selection for ART-R (<xref ref-type="bibr" rid="bib10">Ariey et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Miotto et al., 2015</xref>). Fitness costs may be one reason why <italic>kelch13</italic> mutations are typically observed in isolation, rather than multiple mutations within a single parasite. This effect was seen in our aggregated dataset, where only one double <italic>kelch13</italic> propeller mutation (M579T/N657H) occurred in a single study (<xref ref-type="bibr" rid="bib88">Mishra et al., 2017</xref>). However, as neither M579T nor N657H was found individually or together in other studies, this double mutation may have arisen from laboratory cross-contamination or a mixed-strain infection.</p></boxed-text><p>Interestingly, differences in the clearance rate and fitness effects of different <italic>kelch13</italic> mutations are correlated with their geographic distribution across Southeast Asia (<xref ref-type="bibr" rid="bib136">Straimer et al., 2015</xref>; <xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>). For example, although the R539T mutation has a larger effect in ring-stage survival assays (RSA) than C580Y, it also generates a larger fitness cost <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib11">Ashley et al., 2014</xref>; <xref ref-type="bibr" rid="bib136">Straimer et al., 2015</xref>; <xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>). This difference corresponds closely with their frequency in Southeast Asia, with C580Y generally being the more prevalent substitution across much of Eastern Thailand, Laos, and Cambodia (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Another example is the F446I mutation, which confers a lower degree of resistance than C580Y, but also a lower fitness cost in competition assays (<xref ref-type="bibr" rid="bib11">Ashley et al., 2014</xref>; <xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>). This again correlates with their relative geographical distributions, with C580Y more common across Eastern Southeast Asia, while F446I is more common in parts of Myanmar and Western Thailand (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Interestingly, there is known to be increased transmission, lower drug pressure, and higher competition between parasites in Myanmar relative to other areas of Southeast Asia, suggesting the lower fitness cost of the F446I mutation may provide a selective advantage over C580Y in these areas (<xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Imwong et al., 2020</xref>). This may have resulted in several mutations with lower fitness costs being more strongly selected for than mutations which cause greater ART-R, potentially explaining the relatively stable frequencies of several mutations observed there between 2004 and 2019. In a further example, R561H shows similar survival rates to C580Y under treatment, but a decreased fitness cost <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib96">Nair et al., 2018</xref>). This could mean R561H has the potential to spread more widely, which is concerning as it has increased in frequency in Myanmar since 2016 (<xref ref-type="bibr" rid="bib52">Hamilton et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>).</p><p>Notably, individual <italic>kelch13</italic> substitutions have been shown to not only have different phenotypic and fitness effects, but these effects can also differ depending on the genetic background of the parasite in question (<xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>; <xref ref-type="bibr" rid="bib130">Siddiqui et al., 2021</xref>; <xref ref-type="bibr" rid="bib135">Stokes et al., 2022</xref>). For example, gene-editing studies have demonstrated that after introducing <italic>kelch13</italic> mutations into parasites of Southeast Asian origin, they exert a lower fitness cost and a greater effect on RSA survival than parasites from Africa (<xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>; <xref ref-type="bibr" rid="bib135">Stokes et al., 2022</xref>). There is also evidence of ‘genetic backgrounds’ which are specifically associated with <italic>kelch13</italic> mutations, and tend to be more common in parasites from areas in Southeast Asia where ART-R has emerged and spread extensively (<xref ref-type="bibr" rid="bib28">Cerqueira et al., 2017</xref>; <xref ref-type="bibr" rid="bib86">Miotto et al., 2015</xref>; <xref ref-type="bibr" rid="bib148">Uwimana et al., 2021</xref>). For example, genomic changes have been identified which may compensate for the fitness costs of the <italic>kelch13</italic> mutations, such as altering nutrient permeable channels in the parasite vacuole membrane and allowing uptake of important amino acids. These backgrounds are more common in Southeast Asia, which could be one possible reason why ART-R emerged and spread in this region so quickly, alongside early and widespread ACT use (<xref ref-type="bibr" rid="bib83">Mesén-Ramírez et al., 2021</xref>). Although speculative, these effects could mean resistance mutations are more likely to appear (and therefore spread) on certain genetic backgrounds, or in combination with important genetic changes (<xref ref-type="bibr" rid="bib28">Cerqueira et al., 2017</xref>; <xref ref-type="bibr" rid="bib134">Stokes et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Miotto et al., 2015</xref>). While other regions of the genome have also been associated with decreased clearance rate for artemisinin, information on how these mechanisms may interact with fitness costs is more limited (for a review, see <xref ref-type="bibr" rid="bib87">Miotto et al., 2024</xref>).</p><p>As novel <italic>kelch13</italic> mutations emerge and spread, understanding their fitness costs across different geographical regions and in relation to parasite genetic backgrounds may be crucial. This understanding will require assessing fitness costs through <italic>in vitro</italic> assays and integrating these findings with genomic surveillance to reveal broader patterns. Genomic surveillance may aid in generating models which can predict the spread of resistance given the frequency of certain genetic backgrounds. These patterns also highlight the advantages of whole genome sequencing over targeted amplicon sequencing, as this additional information can be used to inform models using the genetic background of resistant parasites.</p></sec></sec><sec id="s3-2"><title>East and Northeast Africa</title><sec id="s3-2-1"><title>How did <italic>kelch13</italic> mutants initially emerge and spread in East and Northeast Africa?</title><p>ACTs have been used extensively across Africa, particularly after 2006 (<xref ref-type="bibr" rid="bib100">Newton et al., 2006</xref><xref ref-type="supplementary-material" rid="supp6 supp7">Supplementary files 6 and 7</xref>). By 2008, almost all African countries had implemented ACTs as the primary treatment for malaria, meaning the emergence and spread of ART-R in Southeast Asia around 2008 occurred in tandem with a growing reliance on ACTs in Africa (<xref ref-type="bibr" rid="bib159">World Health Organization, 2009</xref>). This led to fears that similar mutations could not only arise in Africa, but would result in a wave of resistant parasites. In the last 5 years, those fears are beginning to be realised, with reports of WHO validated/candidate <italic>kelch13</italic> mutations in several countries across East and Northeast Africa. This started with the identification of the R561H mutation in Rwanda in 2019. This mutation was shown to have been circulating in the region since 2013–2015, before increasing to ~13% in 2019, with demonstrated effects on parasite clearance rate (<xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib148">Uwimana et al., 2021</xref>). This was then mirrored by the dramatic increase in both A675V and C469Y mutations in Uganda between 2 015 and 2019, which were also associated with delayed parasite clearance (<xref ref-type="bibr" rid="bib15">Balikagala et al., 2021</xref>). Given the extent of ACT use in Africa over the past two decades, it is unclear why ART-R has only emerged now, around 10–15 years behind Southeast Asia, although it is most likely due to the slower initial rollout of ACTs in Africa, combined with differences in case-by-case drug exposure (<xref ref-type="bibr" rid="bib55">Hassett and Roepe, 2019</xref>). Other factors, such as higher immunity, intra-host competition, or differences in effective population sizes in Africa may have also slowed ART-R (see Section ‘Scenario 3: Lower frequency and slower spread of ART-R in Africa than Southeast Asia’).</p><p>After detecting ART-R associated <italic>kelch13</italic> mutations in Africa, an initial concern was that these mutations had been introduced via gene flow from Southeast Asian parasites, as was the case with resistance to chloroquine and sulfadoxine–pyrimethamine (<xref ref-type="bibr" rid="bib154">Wellems and Plowe, 2001</xref>; <xref ref-type="bibr" rid="bib49">Gregson and Plowe, 2005</xref>). However, evidence from genomic surveillance suggests that the <italic>kelch13</italic> mutations observed so far in Africa have emerged independently. For example, ART-R parasites from Uganda are genetically more similar to African parasites than those from Southeast Asia, suggesting an independent African emergence (<xref ref-type="bibr" rid="bib61">Ikeda et al., 2018</xref>). Similarly, analysis of <italic>kelch13</italic> flanking microsatellites and genome-wide single-nucleotide polymorphisms suggests Ugandan parasites with C469F, C469Y, and A675V form a clade distinct from Southeast Asian parasites, implying a single evolutionary origin and clonal expansion within Africa (<xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>). A further example is A675V, C469Y, and R561H mutants from Uganda, Rwanda, and Tanzania, which have different <italic>kelch13</italic> flanking haplotypes to parasites with these mutations from Southeast Asia, again pointing to a single evolutionary origin which arose independently in Africa (<xref ref-type="bibr" rid="bib15">Balikagala et al., 2021</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Ishengoma et al., 2024</xref>). Together, these analyses show clear evidence of independent emergence of <italic>kelch13</italic> markers in Africa, suggesting local conditions are prompting the emergence and selection of ART-R. Nevertheless, ongoing genomic surveillance will be needed to identify migratory pathways between continents should they occur.</p></sec><sec id="s3-2-2"><title>What is the current distribution and frequency of <italic>kelch13</italic> mutations in East and Northeast Africa?</title><p>As of 2024, WHO validated/candidate mutations have been identified in several countries across East and Northeast Africa, including Uganda, Rwanda, Sudan, Eritrea, Tanzania, Kenya, and Ethiopia (<xref ref-type="bibr" rid="bib47">Fola et al., 2023</xref>; <xref ref-type="fig" rid="fig6">Figure 6</xref>). Concerningly, the frequency of these mutations has increased dramatically since 2018, particularly in Uganda, Rwanda, Tanzania, and Eritrea. In 2022, 26% of samples from Uganda had a WHO validated/candidate mutation, an increase from ~1% in 2013. Similarly, 17% and 15% of samples from Rwanda and Eritrea had a WHO mutation in 2023 and 2019, respectively. Tanzania also had a high proportion of parasites with WHO mutations in 2021 (23%), increasing from ~0.1% to 0.2% between 2017 and 2019. However, Tanzanian samples from 2021 were all from close to the borders with Uganda and Rwanda, which have high levels of ART-R, suggesting a possible geographic sampling bias. Sudan showed a small proportion of parasites with a WHO mutation, reaching 2.2% in 2020. Similarly, Kenya, DRC, Zambia, and Mozambique each showed a small proportion of samples with a WHO mutation, although the total frequencies of samples with any propeller domain mutation in these countries remained ~4% or less. Concerningly, these trends are strikingly similar to those observed in Southeast Asia around 2008, where the initial emergence of validated/candidate mutations was followed by exponential increases in the frequency of resistant parasites over a decade.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Regional prevalence and temporal changes of <italic>kelch13</italic> propeller mutations in East and Northeast Africa.</title><p>Panel (<bold>A</bold>) shows the distribution of <italic>kelch13</italic> propeller mutations across East and Northeast Africa. The percentage of samples with any <italic>kelch13</italic> propeller mutation is included in the country labels, above the number of samples with any <italic>kelch13</italic> propeller mutation and the total number of samples collected for each country, respectively. Among only the samples with any observed <italic>kelch13</italic> propeller mutation, pie charts show the proportions with markers of interest, where proportions above 25% are labelled accordingly. ‘Other’ denotes low-frequency mutations in the propeller domain which are not WHO validated/candidate markers, pooled into a single category. Samples with the 3D7 reference sequence for <italic>kelch13</italic> or A578S are denoted as ‘Susceptible’ (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). Panel (<bold>B</bold>) shows all samples collected over time for each country as a stacked bar chart, where the proportion of samples with each marker is coloured. Years with fewer than 25 samples are highlighted with grey dashed lines. Notably, Uganda and Rwanda have shown a consistent increase in diversity among <italic>kelch13</italic> mutations between 2016–2023. (<bold>C</bold>) shows all mutations with at least 25 samples across Africa and Southeast Asia on the x axis. Coloured bars show which subpopulation these samples came from across Africa and Southeast Asia. WHO validated or candidate mutations are suffixed with an asterisk.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig6-v1.tif"/></fig><p>Alongside an increase in WHO validated/candidate mutations, many East and Northeast African countries also had an increase in frequency of propeller domain <italic>kelch13</italic> mutations which are not assigned WHO validated/candidate status. These countries included Kenya, Rwanda, Tanzania, Eritrea, South Sudan, Sudan, and Uganda. The phenotypic effects of these mutations are unclear, but in some cases, <italic>in vitro</italic> evidence suggests they could have phenotypic effects on artemisinin clearance rates (<xref ref-type="bibr" rid="bib169">WWARN K13 Genotype-Phenotype Study Group, 2019</xref>; <xref ref-type="bibr" rid="bib93">Mukherjee et al., 2017</xref>). Tracking the changes in frequency of these mutations is important, as they may in fact provide some degree of ART-R.</p><p>As of 2024, we have not seen any single WHO validated/candidate mutation rise to prominence in East or Northeast Africa, although this may occur in coming years - as with C580Y in Southeast Asia. In the past 5 years, several WHO validated/candidate markers have circulated simultaneously, with individual mutations mostly localised to specific countries within the region, similar to patterns seen in the early period of ART-R in Southeast Asia (<xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="table" rid="table2">Table 2</xref>). For example, the most common WHO validated/candidate mutation, A675V, has risen to high frequencies in Uganda and Rwanda (9.4% in 2022 and 5.6% in 2023, respectively), but has not been observed in neighbouring countries. Similarly, Rwanda, and Tanzania have a high frequency of parasites with the R561H mutation (8.9% in 2023 and 22.5% in 2021), but this mutation is uncommon elsewhere. A third example is R622I, which was the most common mutation in Eritrea (15.2% in 2019) and Sudan (2% in 2020), but rare outside Northeast Africa. Several of these mutations have increased in frequency over the past 5 years, with A675V, C459Y and P441L all increasing in frequency in Uganda since 2018. A similar situation occurred in Rwanda, where three validated/candidate mutations increased in frequency between 2019 and 2023; A675V from 1.5% to 5.6%, C469F from 1.5% to 2.8%, and R561H from 4.5% to 8.9%. The emergence and spread of different <italic>kelch13</italic> mutations in separate regions of East and Northeast Africa suggests they are emerging independently in response to local conditions, rather than migrating between areas (<xref ref-type="bibr" rid="bib12">Assefa et al., 2024</xref>; <xref ref-type="bibr" rid="bib3">Abera et al., 2021</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Most common <italic>kelch13</italic> mutations across East and Northeast Africa, where mutations occur in at least 25 samples.</title><p>Countries represented in these populations are Burundi, Comoros, Kenya, Madagascar, Malawi, Rwanda, Somalia, Tanzania, Eritrea, Ethiopia, Saudi Arabia, South Sudan, Sudan, Uganda, and Yemen. Note A578S is not associated with ART-R (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). Total refers to the total number of samples from these countries with each marker.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Marker</th><th align="left" valign="bottom">WHO status</th><th align="left" valign="bottom">Total</th><th align="left" valign="bottom">Proportion (%)</th></tr></thead><tbody><tr><td align="left" valign="bottom">3D7 reference sequence</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">22,219</td><td align="left" valign="bottom">92.95</td></tr><tr><td align="left" valign="bottom">A675V</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">306</td><td align="left" valign="bottom">1.28</td></tr><tr><td align="left" valign="bottom">C469Y</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">301</td><td align="left" valign="bottom">1.26</td></tr><tr><td align="left" valign="bottom">R622I</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">184</td><td align="left" valign="bottom">0.77</td></tr><tr><td align="left" valign="bottom">R561H</td><td align="left" valign="bottom">validated</td><td align="left" valign="bottom">158</td><td align="left" valign="bottom">0.66</td></tr><tr><td align="left" valign="bottom">A578S</td><td align="left" valign="bottom">not associated</td><td align="left" valign="bottom">149</td><td align="left" valign="bottom">0.62</td></tr><tr><td align="left" valign="bottom">C469F</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">97</td><td align="left" valign="bottom">0.41</td></tr><tr><td align="left" valign="bottom">P441L</td><td align="left" valign="bottom">candidate</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">0.27</td></tr><tr><td align="left" valign="bottom">V555A</td><td align="left" valign="bottom">no status</td><td align="left" valign="bottom">29</td><td align="left" valign="bottom">0.12</td></tr></tbody></table></table-wrap><p>Interestingly, the WHO validated/candidate <italic>kelch13</italic> mutations which have arisen in East and Northeast Africa are different to those found in Southeast Asia (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). For example, the most common <italic>kelch13</italic> mutations in Southeast Asia are C580Y and F446I, but these are uncommon in Africa, with C580Y only observed in seven samples across the entire continent. Other common substitutions in Southeast Asia were also rare in Africa, including R539T, P574L, F446I, and G449A, all with fewer than five samples. Similarly, of the most common WHO validated/candidate markers in Africa (A675V, C469Y, R622I, R561H, and C469F), only R561H was found regularly in Southeast Asia. This could be due to differences in ACT use between continents. For example, artemether-lumefantrine is the most common treatment for malaria in Africa, but in Southeast Asia, dihydroartemisinin-piperaquine and artesunate-mefloquine are used more often (<xref ref-type="bibr" rid="bib146">Tun et al., 2018</xref>; <xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). Theoretically, these differences could promote different <italic>kelch13</italic> mutations, because their partner drugs are associated with selection for different genetic backgrounds with differing resistance mutations. For example, R539T has been associated with mefloquine-resistant parasites, whereas C580Y has been associated with piperaquine-resistant parasites, because changes in <italic>mdr1</italic> and <italic>plasmepsin2/3,</italic> respectively, alter the fitness costs of <italic>kelch13</italic> mutations in the presence of these different drugs (<xref ref-type="bibr" rid="bib111">Parobek et al., 2017</xref>). It is also possible that differences in the phenotypic effects of the substitutions, alongside variation in transmission rates, fitness costs or genetic backgrounds in Africa, have selected for different <italic>kelch13</italic> mutations relative to Southeast Asia, although this remains speculative.</p></sec><sec id="s3-2-3"><title>Why is ART-R centred in Eastern and Northeastern Africa?</title><p>It is unclear why WHO validated/candidate mutations have arisen in Northeast and East Africa first, or why we have not seen a wider spread of these mutations across Africa, despite extensive ACT use. One possibility is higher drug pressure in the region. For example, household survey data from 2003 to 2015 suggests ACT use among symptomatic children was significantly higher in Eastern Africa compared to Central or West Africa, particularly around 2015 (<xref ref-type="bibr" rid="bib20">Bennett et al., 2017</xref>). During this time in Uganda, 70.2% of symptomatic children received an ACT, compared to an average of 19.7% across the continent (<xref ref-type="bibr" rid="bib20">Bennett et al., 2017</xref>). Inappropriate use of artemisinin monotherapies has also been observed in some areas of Uganda, with inadequate dosing of artemether-lumefantrine observed in ~12% of children and ~16% of adults in some districts (<xref ref-type="bibr" rid="bib152">Wang et al., 2018</xref>). However, anecdotal reports also suggest this issue occurs more widely across Africa. Another possibility is that unstable transmission rates of parasites in East and Northeast Africa have promoted the development of ART-R, because when there is a switch from low to high malaria incidence in an area, host immunity is temporarily weakened and drugs need to be used more frequently (<xref ref-type="bibr" rid="bib121">Rosenthal et al., 2024</xref>). This is relevant in East and Northeast Africa, as there are many highland regions which are known to be centres of unstable transmission (<xref ref-type="bibr" rid="bib117">Rodó et al., 2021</xref>) and in particular may have been a factor in northern Uganda, where the discontinuation of an effective indoor residual spraying program could have contributed to a sudden resurgence in malaria cases and an increase in drug pressure (<xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>). Indeed, Uganda accounted for 5% of all global malaria cases in 2022, with higher transmission rates relative to many other African countries (only Nigeria and the DRC had more cases in that year; <xref ref-type="bibr" rid="bib167">World Health Organization, 2023</xref>).</p></sec><sec id="s3-2-4"><title>Could fitness costs, genetic backgrounds, or ecological factors slow the emergence of ART-R in Africa?</title><p>Although fitness costs of <italic>kelch13</italic> mutations are interesting conceptually, what potential do they have to slow the emergence of ART-R in Africa? Despite WHO validated/candidate <italic>kelch13</italic> mutations having arisen several times in East and Northeast Africa, so far there does not seem to be strong selective pressure for resistant parasites across the continent (Section ‘Rest of the World’; <xref ref-type="bibr" rid="bib120">Rosenthal, 2021</xref>; <xref ref-type="bibr" rid="bib15">Balikagala et al., 2021</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib121">Rosenthal et al., 2024</xref>). This suggests these mutants are being outcompeted in many areas, possibly due to a combination of higher fitness costs and different genetic backgrounds, alongside differences in competition between parasites (<xref ref-type="bibr" rid="bib31">Cohen et al., 2012</xref>; <xref ref-type="bibr" rid="bib153">Wasakul et al., 2023</xref>). For example, elevated transmission rates, combined with lower levels of drug pressure, may increase the disadvantage generated by fitness costs (<xref ref-type="bibr" rid="bib2">Abebaw et al., 2022</xref>; <xref ref-type="bibr" rid="bib4">Agaba et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Bylicka-Szczepanowska and Korzeniewski, 2022</xref>). This is reflected in African countries where ART-R is relatively more common, such as Eritrea. In some cases, these are areas which have made substantial reductions in total malaria burden and reduced transmission, both of which may mean the fitness costs of resistance mutations are less important, giving resistant genotypes a larger advantage (<xref ref-type="bibr" rid="bib47">Fola et al., 2023</xref>). Although local-context specific, this could slow the emergence and spread of ART-R in some areas of Africa.</p><p>However, it is important to note that the role of fitness costs and genetic backgrounds in determining population level parasite dynamics remains mostly speculative. To date, many of these effects have only been established <italic>in vitro</italic> (see <xref ref-type="box" rid="box1">Box 1</xref> for details), and in <italic>in vivo</italic> settings, these costs likely interact with many other important factors which affect the relative competition between parasites, including drug use, vector dynamics, and antigenicity (<xref ref-type="bibr" rid="bib31">Cohen et al., 2012</xref>; <xref ref-type="bibr" rid="bib95">Myers-Hansen et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">He et al., 2024</xref>). Moreover, even if these factors do play a role, it is clearly still possible for ART-R to emerge independently on divergent genetic backgrounds and can be associated with varying degrees of selective pressure depending on local conditions, as seen in Southeast Asia (<xref ref-type="bibr" rid="bib139">Takala-Harrison et al., 2015</xref>). Lastly, while the focus of this review has been on <italic>kelch13</italic> markers, it is not implausible that resistance in Africa could emerge through an alternative mechanism, and the fitness dynamics determining its spread may differ substantially (<xref ref-type="bibr" rid="bib38">Demas et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Ndiaye et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Henriques et al., 2014</xref>).</p><p>In addition to parasite-specific factors, ecological and epidemiological differences between Africa and Southeast Asia could play a role in slowing the emergence of ART-R. For example, higher levels of population immunity among African populations can reduce parasite biomass during infection, lowering the likelihood of needing treatment and therefore decreasing drug pressure (<xref ref-type="bibr" rid="bib43">Doolan et al., 2009</xref>). High rates of transmission and mixed-genotype infections can further increase within-host competition, reducing the likelihood that resistant parasites reach fixation. Moreover, the high genetic diversity generated by intensive transmission may have the effect of breaking up resistant haplotypes, hindering their spread (<xref ref-type="bibr" rid="bib156">White et al., 2009</xref>). While the relative impact of these factors remains difficult to quantify, their combined effect may partially explain the slower rise of ART-R in Africa to date.</p><p>Future studies should work toward combining genomic surveillance of parasites with <italic>in vitro</italic> and population level estimates of effects on both transmission and fitness, as this may allow for improved modelling of epidemiological dynamics. This should be combined with whole-genome sequencing, as this would allow improved understanding of the role of these factors on ART-R dynamics. If their relative importance could be quantified, it could be crucial for genomic surveillance, as it could affect the relative priority given to tracking cases of specific mutations/genetic backgrounds and their spread between areas (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>).</p></sec></sec><sec id="s3-3"><title>Rest of the world</title><p>We identified many <italic>kelch13</italic> mutations circulating across the rest of Africa, in particular West and Central Africa (<xref ref-type="fig" rid="fig7">Figure 7</xref>). For example, WHO validated/candidate mutations were detected at very low frequencies in Ghana, Mali, Nigeria, Equatorial Guinea, and the DRC (<xref ref-type="fig" rid="fig7">Figure 7</xref>). However, most mutations in West and Central Africa did not have WHO-validated/candidate status and therefore have unknown phenotypic effects. For instance, non-WHO validated/candidate <italic>kelch13</italic> mutations were detected in Benin and Burkina Faso in West Africa, and in the Central African Republic, Chad, the DRC, and Equatorial Guinea in Central Africa (<xref ref-type="fig" rid="fig7">Figure 7</xref>). While the phenotypic effects of these mutations are unclear, some may affect phenotypic resistance. For example, we observed a mutation, R539I, at the same <italic>kelch13</italic> position as the WHO-validated R539T in Togo, Ghana, Mali, and the DRC (<xref ref-type="fig" rid="fig7">Figure 7</xref>). This mutation should be surveyed closely and assessed in phenotypic assays of ART-R due to its position at a known resistance locus in <italic>kelch13</italic>.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Distribution of <italic>kelch13</italic> propeller domain markers across West and Central Africa (<bold>A</bold>), South America (<bold>B</bold>) and Oceania (<bold>C</bold>).</title><p>The percentage of samples with any <italic>kelch13</italic> mutation is included in the country labels, above the number of samples with any <italic>kelch13</italic> mutation, and the total number of samples collected for each country, respectively. Among only the samples with any observed <italic>kelch13</italic> propeller domain mutation, pie charts show the proportions with markers of interest, where proportions above 25% are labelled accordingly. ‘Other’ denotes several low-frequency mutations in the propeller domain which are not WHO validated/candidate markers, pooled into a single category.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig7-v1.tif"/></fig><p>WHO validated/candidate mutations were uncommon in other populations. In South America, one WHO mutation, C580Y, was detected in 19 samples from Guyana (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Aside from this, only two other mutations were detected in South America, each in one sample (A617S in Peru in 2016 and A504T in Colombia in 2018; <xref ref-type="fig" rid="fig7">Figure 7</xref>). In Oceania, <italic>kelch13</italic> mutations were present in Indonesia, Papua New Guinea, the Solomon Islands, and Vanuatu. Evidence of ART-R was found in Papua New Guinea, where C580Y was present in 10 samples. The T474A was also circulating in Oceania, predominantly in Indonesia. From 1998 to 2020, 25 non-WHO validated or candidate mutations were detected in Oceania. A675V, F446I, R539T, and R561H were also present in India (<xref ref-type="fig" rid="fig5">Figure 5</xref>). These markers are also seen across Southeast Asia (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>), highlighting the potential for ART-R in India. In contrast, in Far-East South Asia, non-validated/candidate mutations were detected in only five samples (0.002% of population). Similarly, Afghanistan, Iran, and Pakistan all showed very low proportions of mutant samples (&lt;0.2% of samples), none of which had WHO validated/candidate status.</p></sec></sec><sec id="s4"><title>Anticipating the next stage of ART-R in Africa</title><p>Given the emergence of ART-R in Africa, one obvious question is: what are the most likely scenarios for its spread? With the lessons learned from ART-R in Southeast Asia, it is useful to consider potential future scenarios on how ART-R might emerge and spread in Africa within the near future. Here, we articulate three possible scenarios regarding the frequency of <italic>kelch13</italic> mutations in Africa: a spread of similar magnitude to that of Southeast Asia, and two more optimistic scenarios. We then discuss broader trends we might observe going forwards, including the human cost of ART-R in Africa, the effect of mitigation efforts, regional variation in ART-R and its dynamics over the next few years. In doing so, we hope this will inform long-term strategic thinking on mitigation strategies, and in properly allocating resources for future surveillance. It is important to note that these scenarios are largely speculative and need to be continually updated with new data as the situation progresses.</p><sec id="s4-1"><title>Scenario 1: Continued or increased spread of ART-R across Africa, similar to that seen in Southeast Asia</title><p>The emergence and spread of ART-R throughout Southeast Asia provides an example of how the situation might develop in Africa. In Southeast Asia, ART-R emerged in several independent locations, before a single drug-resistant lineage spread across the region (<xref ref-type="bibr" rid="bib52">Hamilton et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>). The C580Y mutation then reached near-fixation (~86%) in parts of Cambodia within a period of around 12–16 years (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="bibr" rid="bib104">Noedl et al., 2008</xref>; <xref ref-type="bibr" rid="bib42">Dondorp et al., 2009</xref>; <xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref>). This offers one plausible scenario as to how ART-R might progress in Africa, although it does not preclude the possibility that it could spread even faster than in Southeast Asia. It should also be noted that a worse possible scenario would be the spread of ‘full’ (as opposed to ‘partial’) artemisinin resistance, but since this has not been reported in the field, a more likely scenario is the continued spread of ART-R.</p><p>As of 2024, this ‘partial’ resistance has now emerged independently in at least Uganda, Tanzania, Rwanda, Sudan, and Eritrea (<xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). Importantly, there is evidence of an increase in the proportion of samples with mutant <italic>kelch13</italic> markers in several of these countries since 2014, with similar increases in frequency to those observed in Southeast Asia around 10–15 years ago (<xref ref-type="fig" rid="fig8">Figure 8</xref>). If these areas were to follow a similar trajectory to Cambodia, we could see frequencies of over 54% delayed clearance under ACT treatment by around 2030 (<xref ref-type="bibr" rid="bib132">Slater et al., 2016</xref>). However, we stress that the trends presented here are illustrative rather than predictive and do not represent model-based projections (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Additionally, the most recent data for Southeast Asia were from 2019, so these increases may not reflect more recent trajectories of ART-R in the region.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Proportion of samples with a WHO validated/candidate <italic>kelch13</italic> mutations over time (<xref ref-type="table" rid="table2">Table 2</xref>).</title><p>Each country is shown using a logistic regression curve fitted to the observed data (see <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref> for model fits). Timepoints with no line indicate years with no available data. The black dashed line highlights 2006 - the year in which the WHO recommended ACT therapy as a first-line treatment measure in Africa (<xref ref-type="bibr" rid="bib158">World Health Organization, 2006</xref>). Notably, the rapid increase in prevalence of WHO <italic>kelch13</italic> markers in East and Northeast African countries is similar to that observed in Southeast Asian countries between 2007 and 2016. However, it is also important to note these trends have so far only been observed in a few countries in East/Northeast Africa and are based on smaller sample sizes (<xref ref-type="bibr" rid="bib12">Assefa et al., 2024</xref>). While these curves indicate the frequency of resistance has increased, we have deliberately avoided quantitative extrapolation beyond the most recent observed time range. This analysis should therefore not be interpreted as a predictive model.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Percentage of samples with WHO validated/candidate <italic>kelch13</italic> propeller mutations over time.</title><p>The observed data for each country is shown as a dashed line, coloured by population. The black line is the curve of a logistic model fitted to the observed data, which is forced to begin at 0 and end at 100%. The size of each point represents the number of samples collected in that country for each year. Time points with no line or value indicate years with no available data. Countries with fewer than 3 years with at least 25 samples each were excluded. Countries which showed no clear increase during this time were also excluded (Mali, Guyana, India, Ethiopia, China, and Equatorial Guinea). The grey dashed line highlights the year in which the fitted curve reached its steepest point - that is the year with the fastest increase in frequency. The goodness-of-fit of the logistic curves varied substantially across countries (R<sup>2</sup>=0.22–1.00). Notably, Tanzania had a very high growth rate, although this was based on a single year where the frequency was above 2%. To assess the robustness of the descriptive fits, we performed sensitivity analyses using bootstrap resampling within country-year groupings and a jackknife procedure where each individual year was excluded and the curve refit accomplished. These consistently reproduced the overall pattern of rising ART-R frequencies. While exact slopes and inflection points varied, the trend of increased ART-R prevalence in East and Northeast Africa remained robust. We emphasise that these are descriptive summaries of observed data and are not intended as predictive models.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-fig8-figsupp1-v1.tif"/></fig></fig-group><p>Nevertheless, this scenario is further supported by estimates of selection coefficients in Uganda, which suggest current selective pressures are comparable to those observed in Southeast Asia between 2003 and 2018. These estimates imply the frequency of mutant <italic>kelch13</italic> parasites could reach as high as 95% between 2028 and 2033 (<xref ref-type="bibr" rid="bib81">Meier-Scherling et al., 2024</xref>). Modelling also suggests that under the continued use of ACT therapies, <italic>kelch13</italic> mutations could become established in some areas (up to 57–88% frequency depending on model assumptions), although this will depend on their initial frequency and could be reduced using TACT strategies (see <xref ref-type="box" rid="box2">Box 2</xref>; <xref ref-type="bibr" rid="bib103">Nguyen et al., 2023b</xref>).</p><boxed-text id="box2"><label>Box 2.</label><caption><title>What treatment strategies could slow the spread of treatment failure?</title></caption><p>ART-R is a major concern because of its broader role in ACT treatment failure. In essence, ART-R increases selective pressure for partner drug resistance, which in turn increases the likelihood of ACT treatment being unsuccessful. Several strategies have been proposed to slow the spread of treatment failure, including ACT cycling, multiple first-line therapies (MFTs), and triple artemisinin combination therapies (TACTs). Each of these methodshas been used at various times and locations, although all have varying costs, benefits, and degrees of evidence for their efficacy (<xref ref-type="bibr" rid="bib23">Boni, 2022</xref>; <xref ref-type="bibr" rid="bib150">van der Pluijm et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Chen and Hsiang, 2022</xref>). It is important to note under each of these strategies, mutants which are resistant to both artemisinin derivatives and partner drugs may eventually arise (<xref ref-type="fig" rid="box2fig1">Box 2—figure 1</xref>). Having a strategy for if this occurs will be paramount, and will require careful genomic surveillance to identify cases where they emerge (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>).</p><p><italic>ACT cycling</italic></p><p>As of 2022, the WHO recommends a policy of ‘ACT cycling’, which involves using a single first-line ACT, before switching to a second once efficacy decreases below a certain threshold in the population (~ 90%) (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib161">World Health Organization, 2015a</xref>). Theoretically, this should reduce the frequency of resistance to the first drug, by providing time for resistance to decline in frequency while the second drug is in use (<xref ref-type="fig" rid="box2fig1">Box 2—figure 1</xref>; ; <xref ref-type="bibr" rid="bib102">Nguyen et al., 2023a</xref>; <xref ref-type="bibr" rid="bib23">Boni, 2022</xref>; <xref ref-type="bibr" rid="bib22">Boni et al., 2008</xref>). This strategy initially proved effective in Cambodia, where artesunate-mefloquine was replaced with dihydroartemisinin–piperaquine, before reverting back after resistant parasites reduced in frequency (<xref ref-type="bibr" rid="bib114">Rasmussen et al., 2022</xref>; <xref ref-type="bibr" rid="bib122">Ross et al., 2018</xref>). However, there is some evidence to suggest the strategy later drove the emergence of triply resistant mutants in the northeast of the country (<xref ref-type="bibr" rid="bib123">Rossi et al., 2017</xref>).</p><p><italic>Multiple front-line therapies</italic></p><p>More recently, several countries have adopted the use of MFTs, that is using multiple ACT therapies concurrently within a population (<xref ref-type="bibr" rid="bib164">World Health Organization, 2021</xref>). Importantly, modelling studies have found MFTs have similar efficacy to cycling strategies but are less likely to accelerate the emergence and spread of resistance (<xref ref-type="bibr" rid="bib101">Nguyen et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Boni et al., 2008</xref>; <xref ref-type="bibr" rid="bib133">Smith et al., 2010</xref>). This work suggests MFTs are most effective when using partner drugs with different mechanisms of action, as this reduces the chances of cross-resistance to both drugs (<xref ref-type="bibr" rid="bib75">Li et al., 2024</xref>). However, the WHO has stopped short of recommending MFTs more generally (<xref ref-type="bibr" rid="bib160">World Health Organization, 2013</xref>), citing contradictions in results from modelling work, and challenges in locations with both high drug use and resistance (<xref ref-type="bibr" rid="bib23">Boni, 2022</xref>; <xref ref-type="bibr" rid="bib9">Antao and Hastings, 2012</xref>). For example, the high frequency of the artemisini- resistant lineage in Cambodia means there is a lack of alternative treatments should MFTs fail (<xref ref-type="bibr" rid="bib114">Rasmussen et al., 2022</xref>; <xref ref-type="bibr" rid="bib122">Ross et al., 2018</xref>).</p><p><italic>Triple artemisinin-based combination therapies (TACTs)</italic></p><p>Another alternative is TACTs, which combine an artemisinin derivative with two partner drugs. Theoretically, this method preserves treatment efficacy, because of the rarity of parasites acquiring resistance to both partner drugs over a course of treatment (<xref ref-type="bibr" rid="bib149">van der Pluijm et al., 2020</xref>). Recently, large-scale clinical trials in Southeast Asia have demonstrated TACTs are effective at national scales, even in situations where multidrug-resistant parasites are present (<xref ref-type="bibr" rid="bib112">Peto et al., 2022</xref>; <xref ref-type="bibr" rid="bib149">van der Pluijm et al., 2020</xref>). Modelling studies suggest that TACTs could significantly delay the emergence and spread of ART-R compared to other strategies (<xref ref-type="bibr" rid="bib173">Zupko et al., 2023</xref>; <xref ref-type="bibr" rid="bib75">Li et al., 2024</xref>; <xref ref-type="bibr" rid="bib102">Nguyen et al., 2023a</xref>). However, their effectiveness diminishes once resistant parasites reach a threshold frequency in the population, which can be as low as 1%. A further drawback of TACTs is that because three drugs in total are being administered, the frequency of negative side-effects on patient health is more common (<xref ref-type="bibr" rid="bib112">Peto et al., 2022</xref>; <xref ref-type="bibr" rid="bib150">van der Pluijm et al., 2021</xref>; <xref ref-type="bibr" rid="bib149">van der Pluijm et al., 2020</xref>). While promising, for TACTs to be useful at population scales, several practical issues need to be ironed out, such as correct dosing and formulation of partner drugs for overall safety, alongside increased cost-effectiveness and regional availability (for a review, see <xref ref-type="bibr" rid="bib107">Nsanzabana, 2021</xref>). Moreover, their use requires public acceptance, as the reduced risk of emergent resistance is being balanced against an increased risk of side effects for any individual taking the drugs (<xref ref-type="bibr" rid="bib150">van der Pluijm et al., 2021</xref>; <xref ref-type="bibr" rid="bib149">van der Pluijm et al., 2020</xref>).</p><fig position="float" id="box2fig1"><label>Box 2—figure 1.</label><caption><title>Evolutionary scenarios and within-host dynamics under cycling, MFT and TACT strategies.</title><p>(<bold>A</bold>) There are three possible evolutionary scenarios during cycling, MFT or TACT strategies. In the idealised cycling/MFT scenario (top panel), resistance will cycle between two states of elevated resistance to a given ACT combination therapy, but not both, at any given time (red/blue points). However, these strategies could promote dual resistant escape mutants through stepwise increases over time (middle panel). This may occur even if resistance to any individual ACT decreases in the short term (red and blue lines). In contrast, triple artemisinin-based combination therapies (bottom panel) may directly select for triple resistant escape mutants (black solid line). While the likelihood of this occurring may be lower than under cycling or MFT strategies, this could result in mutants which are resistant to multiple partner drugs, leaving limited options to change strategy image adapted from <xref ref-type="bibr" rid="bib16">Baym et al., 2016</xref>. (<bold>B</bold>) TACTs involve the use of two partner drugs throughout treatment. Here, a theoretical example of parasite density over time within a patient is shown for artemisinin-resistant and -susceptible parasites (red and blue lines respectively). In cases where parasites are resistant to artemisinin, their density remains higher after initial artemisinin exposure (~3 days), resulting in more parasites for the partner drug to treat (shaded area), and therefore stronger selection for resistance to that drug. TACTs use two partner drugs (black dashed line), which in theory means selection for any individual drug is lower, and the chance of triply resistant parasites emerging within any given infection is less likely <xref ref-type="bibr" rid="bib26">Bushman et al., 2018</xref> image adapted from <xref ref-type="bibr" rid="bib54">Hanboonkunupakarn and White, 2022</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105544-box2-fig1-v1.tif"/></fig></boxed-text><p>These increases in ART-R would in turn increase selective pressure for resistance to partner drugs, raising the likelihood of overall treatment failure. Indeed, there is evidence of treatment failure potentially occurring in some areas of Angola and the Democratic Republic of the Congo (<xref ref-type="bibr" rid="bib41">Dimbu et al., 2024</xref>;<xref ref-type="bibr" rid="bib92">Moriarty et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Dimbu et al., 2021</xref>; <xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). Were such failures to become widespread, the human and economic consequences for the region would be disastrous (see Section ‘Widespread ART-R in Africa would be associated with significant human and economic costs’). Alarmingly, the observed increases in ART-R across East and Northeast Africa in recent years suggest this scenario is fast becoming a reality.</p></sec><sec id="s4-2"><title>Scenario 2: ART-R is limited in Africa by additional control interventions</title><p>It is clear that a massive and coordinated effort is urgently required to prevent the worst effects of ART-R from being realised (<xref ref-type="bibr" rid="bib39">Dhorda et al., 2024</xref>). This will require several mitigation strategies to be implemented to reduce the emergence and spread of ART-R. These strategies include the wide-scale implementation of Triple Artemisinin Combination Therapies (TACT), or possibly Multiple Frontline Treatment (MFT) strategies (see <xref ref-type="box" rid="box2">Box 2</xref>), which modelling suggests could reduce treatment failure by 49–92% over a period of 5 years (<xref ref-type="bibr" rid="bib101">Nguyen et al., 2015</xref>; <xref ref-type="bibr" rid="bib173">Zupko et al., 2023</xref>; <xref ref-type="bibr" rid="bib75">Li et al., 2024</xref>). If these strategies were implemented quickly and effectively, it may be possible to limit mutant <italic>kelch13</italic> to low frequencies in most areas, although regions where ART-R has already increased in frequency, such as Uganda, may see smaller reductions. These strategies could be combined with the recently approved RTS,S and R21/Matrix-M vaccines, which in addition to improved vector control and case management, could reduce transmission chains in regions of high ART-R (<xref ref-type="bibr" rid="bib78">Manzoni et al., 2024</xref>; <xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib35">Datoo et al., 2024</xref>). This could provide much-needed time to develop additional antimalarial treatments. However, while these strategies will likely reduce overall malaria burden, it should be noted they may actually promote resistance in the short term (see Section ‘The drive towards malaria elimination may promote resistance in the short term’; <xref ref-type="bibr" rid="bib153">Wasakul et al., 2023</xref>).</p><p>However, whether TACTs/MFTs could be implemented quickly and effectively is dependent upon overcoming a series of financial, systemic, and ethical challenges (<xref ref-type="bibr" rid="bib141">Tindana et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">de Haan et al., 2023</xref>; <xref ref-type="bibr" rid="bib73">Kokori et al., 2024</xref>). Administering and cycling multiple drugs will inevitably increase costs and place higher demands on procurement, storage, and distribution systems. Moreover, TACTs are not yet included in many national malaria treatment guidelines, and gaining support from global health authorities such as the WHO may be complex and time-consuming, yet is essential for wide-spread adoption. Lastly, there are also ethical considerations in asking patients to take treatments with additional potential side effects, but without immediate personal benefit, and raises concerns around adherence and acceptability. Their rollout will need to be supported by robust surveillance systems to guide deployment based on partner drug resistance and local ART-R dynamics, alongside strong operational capacity and community engagement (<xref ref-type="bibr" rid="bib138">Straimer et al., 2022</xref>).</p><p>The success of these strategies may also depend on the speed with which they are implemented. For example, introducing TACTs after ACT-resistant parasites have reached even low frequency would likely have less of a preventative effect, with <xref ref-type="bibr" rid="bib101">Nguyen et al., 2015</xref> estimating this frequency could be as low as ~1%. Moreover, the size and scale of parasite populations in Africa means any interventions will be complex and time-consuming, giving ART-R mutations a chance to rise to high frequency before mitigations are in place (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). It is therefore a race against time to implement these strategies as quickly and effectively as possible, both to minimise the spread of ART-R and reduce overall malaria burden (<xref ref-type="bibr" rid="bib39">Dhorda et al., 2024</xref>). Given progress in reducing malaria burden in Africa has mostly plateaued since 2015, any single strategy is unlikely to reduce incidence to a level where widespread ART-R would not have dire consequences (<xref ref-type="bibr" rid="bib39">Dhorda et al., 2024</xref>). It will therefore be crucial to combine mitigation strategies with careful genomic surveillance of parasite populations, as it may be possible to minimise the short-term spread of ART-R by tailoring interventions to local conditions.</p></sec><sec id="s4-3"><title>Scenario 3: Lower frequency and slower spread of ART-R in Africa than Southeast Asia</title><p>While Scenario 1 and 2 are more likely scenarios, there are some reasons to think ART-R in Africa may not reach as high frequencies as Southeast Asia, or that if it were to, it may at least occur more slowly (<xref ref-type="bibr" rid="bib114">Rasmussen et al., 2022</xref>). For example, some areas of Southeast Asia, such as Myanmar, showed a slightly lower overall frequency and slower spread of ART-R than Cambodia and Thailand, with several mutations reaching high frequency (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="bibr" rid="bib144">Tun et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref>). One possibility is that differences in the phenotypic effects of <italic>kelch13</italic> mutations (e.g. clearance rate or fitness costs), or genetic backgrounds, slowed the spread of ART-R in these regions. Another possibility is that ecological factors have limited or slowed the spread of ART-R in Africa. For example, many African populations have higher rates of asymptomatic infection, stronger population immunity and greater parasite diversity than Southeast Asia (<xref ref-type="bibr" rid="bib153">Wasakul et al., 2023</xref>; <xref ref-type="bibr" rid="bib2">Abebaw et al., 2022</xref>; <xref ref-type="bibr" rid="bib4">Agaba et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Bylicka-Szczepanowska and Korzeniewski, 2022</xref>). These factors are likely to increase within-host competition, which may reduce the chance that resistant parasites increase to fixation (<xref ref-type="bibr" rid="bib26">Bushman et al., 2018</xref>). Regional differences in vector ecology may also play a role. Variation in mosquito species, biting behaviour, or transmission patterns could influence how quickly resistant parasites are able to spread (<xref ref-type="bibr" rid="bib30">Churcher et al., 2015</xref>; <xref ref-type="bibr" rid="bib131">Sinka et al., 2010</xref>). While the role of these factors remains speculative, if they do play a role, their combined effects may be larger in African contexts, both because the effects of immunity and competition are more pronounced, and because the parasite population and geographical area in which resistance needs to spread are much larger, slowing its relative spread.</p><p>Differences in both drug policy and treatment quality may also affect the spread of resistance. For example, Southeast Asia has had more consistent drug policies, different first-line ACT choices, and higher-quality ACT distribution than areas of Africa, which may have exerted stronger selection pressures for resistance (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). Similarly, drug pressure may be lower in parts of Africa, because higher immunity reduces the rate of symptomatic infections, meaning they are less likely to require drug treatment (<xref ref-type="bibr" rid="bib43">Doolan et al., 2009</xref>; <xref ref-type="bibr" rid="bib157">Whitlock et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Ataide et al., 2017</xref>). The presence of substandard and counterfeit drugs in Africa may mean there is also reduced drug use in these areas (<xref ref-type="bibr" rid="bib146">Tun et al., 2018</xref>; <xref ref-type="bibr" rid="bib102">Nguyen et al., 2023a</xref>). In East Africa, for example, the presence of counterfeit artemisinin-based drugs has been confirmed–one study in Uganda found ~37% of 57 stores were selling counterfeit ACTs (<xref ref-type="bibr" rid="bib21">Björkman Nyqvist et al., 2022</xref>), and anecdotal reports exist of fake artesunate from Tanzania and Cameroon (<xref ref-type="bibr" rid="bib100">Newton et al., 2006</xref>). The effect of these drugs likely depends on their contents: if counterfeit ACTs contain insufficient doses of artemisinin, this is likely to increase selection for ART-R. In contrast, if counterfeit ACTs containing no artemisinin are widespread in Africa, this may lessen selection for ART-R—although of course at the cost of effectively treating patients with malaria.</p><p>While it is difficult to estimate the precise effect these combined factors might have, one scenario could be ART-R frequencies in Africa will be similar to regions of Southeast Asia which have lower prevalence, such as Western and South Myanmar (<xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref>). In this case, we may regularly see moderate frequencies of resistant <italic>kelch13</italic> markers, but these could reach much higher frequencies in some regions, depending on the success of mitigation efforts (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). This would result in ART-R being relatively common, although it may not be the norm across the continent. Nevertheless, this would still put increased pressure on partner drugs, increasing selection for resistance and increasing the likelihood of treatment failure. These factors could also interact with mitigation strategies, which in some cases could negatively affect their rollout or overall effectiveness. It will be necessary to conduct careful genomic surveillance to estimate the effects of these trends on ART-R.</p></sec><sec id="s4-4"><title>Broader trends and likely trajectories of ART-R in Africa</title><sec id="s4-4-1"><title>Widespread ART-R in Africa would be associated with significant human and economic costs</title><p>Given limited alternatives to ACT treatment, any increase in ART-R which led to increased partner drug failure would be catastrophic for human mortality in the region (<xref ref-type="bibr" rid="bib32">Conrad and Rosenthal, 2019</xref>). While the scale of the problem has been widely acknowledged, few studies have quantified the human and economic impacts of widespread ACT resistance (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib132">Slater et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Lubell et al., 2014</xref>). Modelling work suggests highly negative outcomes, depending on the frequency of artemisinin/partner-drug resistance. For example, <xref ref-type="bibr" rid="bib76">Lubell et al., 2014</xref> found widespread ART-R (a conservative estimate of ~30% ACT failure rate) could cause an additional 116,000 deaths annually, with medical costs of US$32 million. Moreover, decreased productivity could be over US$385 million annually during the remaining lifetime of ACTs as the first-line treatment (<xref ref-type="bibr" rid="bib76">Lubell et al., 2014</xref>). A second model considered several possible scenarios for ART-R and partner drug resistance in Africa, if resistance reached similar prevalence to various provinces in Southeast Asia (<xref ref-type="bibr" rid="bib132">Slater et al., 2016</xref>). This model suggested if ART-R and partner drug resistance in Africa reached levels seen in Oddar Meanchey province in Cambodia (~54%), this could result in around 16 million additional cases per year (~7% overall increase) due to delayed parasite clearance and parasite recrudescence (<xref ref-type="bibr" rid="bib132">Slater et al., 2016</xref><ext-link ext-link-type="uri" xlink:href="https://www.zotero.org/google-docs/?er43I3">)</ext-link>. Were this to take place, this could mean an additional 20,000 deaths and an economic impact of US$1.1 billion per year due to increased morbidity and mortality (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib132">Slater et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Hailu et al., 2017</xref>). Unfortunately, these models offer conservative estimates and may even underestimate the true severity of the situation. The impact could be significantly worse if additional factors, such as diminished economic growth or lower educational outcomes, were taken into account (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib132">Slater et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Lubell et al., 2014</xref>).</p></sec><sec id="s4-4-2"><title>The drive towards malaria elimination may promote resistance in the short term</title><p>Given the potential scale of the problem, national and international public health agencies have developed extensive plans to reduce total malaria burden (<xref ref-type="bibr" rid="bib164">World Health Organization, 2021</xref>; <xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). For example, the WHO has a stated goal to eliminate malaria in 35 countries by 2030 (<xref ref-type="bibr" rid="bib164">World Health Organization, 2021</xref>; <xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). While their success so far has been debated (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib119">Rosenthal et al., 2019</xref>), as the total number of cases decreases, it is likely the proportion of drug-resistant parasites will increase (<xref ref-type="bibr" rid="bib155">White, 2004</xref>; <xref ref-type="bibr" rid="bib127">Scott et al., 2018</xref>). This is for two reasons; firstly, since ACTs are a main strategy in treating infection, and ACT use selects for resistant parasites, resistant parasites are more likely to increase in the population (<xref ref-type="bibr" rid="bib155">White, 2004</xref>). Secondly, as the overall parasite population and rate of infection are reduced, this will decrease immunity within the human population (<xref ref-type="bibr" rid="bib4">Agaba et al., 2022</xref>). As this occurs, the rate of asymptomatic infections–currently the most common kind of infection in many parts of Africa–may decrease, meaning more need for drug treatment and a further increase in selection for resistance (<xref ref-type="bibr" rid="bib27">Bylicka-Szczepanowska and Korzeniewski, 2022</xref>).</p><p>This process is already being observed in some countries in Africa, such as Eritrea (<xref ref-type="bibr" rid="bib47">Fola et al., 2023</xref>; <xref ref-type="bibr" rid="bib2">Abebaw et al., 2022</xref>; <xref ref-type="bibr" rid="bib84">Mihreteab et al., 2023</xref>; <xref ref-type="bibr" rid="bib69">Jeang et al., 2024</xref>). Over the past two decades, concerted public health efforts, such as vector control, ACT treatment, and case management, have reduced infections in this region. However, some evidence suggests the success of these strategies means the proportion of ART-R parasites has increased, despite a reduction in overall burden (<xref ref-type="bibr" rid="bib47">Fola et al., 2023</xref>). This trend has also been observed in several parts of Southeast Asia, such as Myanmar (<xref ref-type="bibr" rid="bib78">Manzoni et al., 2024</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Imwong et al., 2020</xref>). This underscores the importance of careful genomic surveillance, as it can be used to identify patterns of selection on resistant parasites (<xref ref-type="bibr" rid="bib81">Meier-Scherling et al., 2024</xref>). This would, in turn, inform mitigation strategies and help ensure that as overall parasite numbers are reduced, they are not replaced by resistant parasites.</p></sec><sec id="s4-4-3"><title>The prevalence of ART-R is likely to vary substantially between regions</title><p>A consequence of variation in reducing malaria burden is that the frequency of ART-R is also likely to be highly variable across the African continent, particularly over the next 1–5 years. This is not only because different African countries currently have very different malaria burdens, but are likely to have different rates of success in eliminating the disease (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>). This variable distribution is observed in Southeast Asia, where some regions, such as districts of Cambodia, show near fixation of mutant <italic>kelch13</italic> haplotypes, while others, such as West and South Myanmar, have less than 20% prevalence (<xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref><ext-link ext-link-type="uri" xlink:href="https://www.zotero.org/google-docs/?FBvqli">)</ext-link>. Unfortunately, the consequence of this is that some regions could become hubs for the spread of ART-R into other areas (<xref ref-type="bibr" rid="bib11">Ashley et al., 2014</xref>; <xref ref-type="bibr" rid="bib145">Tun et al., 2017</xref>). A similar effect was also observed in other regions of Southeast Asia, where waves of selection assisted in spreading resistant lineages across the region (<xref ref-type="bibr" rid="bib11">Ashley et al., 2014</xref>; <xref ref-type="bibr" rid="bib163">World Health Organization, 2016</xref>; <xref ref-type="bibr" rid="bib145">Tun et al., 2017</xref>). There are concerns these patterns could re-occur among African countries, as resistance-associated <italic>kelch13</italic> markers have so far only been observed in specific regions, such as Uganda, Rwanda, and Eritrea (<xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Agaba et al., 2022</xref>). So far, it is not possible to determine whether a clonal spread of resistant genotypes is spreading in all of these countries due to the limited number of samples, although evidence suggests that so far these instances have emerged independently (<xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>; <xref ref-type="bibr" rid="bib4">Agaba et al., 2022</xref>). This again highlights the importance of genomic surveillance and rapid data sharing, as when migration routes do arise, these can only be identified by monitoring and sequencing parasite populations, and used to inform mitigation strategies (<xref ref-type="bibr" rid="bib145">Tun et al., 2017</xref>).</p></sec><sec id="s4-4-4"><title>The dynamics we observe in the next few years will determine the prevalence of ART-R in 10 years’ time</title><p>The patterns of resistance we see over the next 1–5 years will be crucial in determining the patterns we observe over the next decade. This is for four main reasons; firstly, the areas in which resistance first emerges indicate areas where resistance is currently under strong selection and therefore likely to reach higher frequencies. This effect was observed in Southeast Asia, where the regions in which resistant parasites initially emerged gave a strong indication as to where they would later reach high frequency, such as Cambodia and Thailand (<xref ref-type="bibr" rid="bib70">Kagoro et al., 2022</xref>; <xref ref-type="bibr" rid="bib62">Imwong et al., 2017</xref>). Secondly, resistance frequencies may reach critical thresholds in some areas within the next 1–5 years, beyond which mitigation strategies will be more difficult. For example, modelling studies suggest MFTs and TACTs are less likely to be effective if they are implemented only when the initial frequency of resistance is already high, with efficacy decreasing substantially when this frequency exceeds 1%. Thirdly, these years will give a strong indication whether fitness costs and genetic background have a slowing effect on the spread of resistance in Africa, and this could assist in making predictive models for further spread. Lastly, we may see the initial effects of RTS,S and R21/Matrix-M vaccines during the next 1–5 years, and we can observe how this might affect selective pressures on the parasite (<xref ref-type="bibr" rid="bib35">Datoo et al., 2024</xref>).</p><p>Unfortunately, this period is also the time in which it is most difficult to alter mitigation strategies, simply because their planning and implementation takes time and resources from public health organisations. The next 1–5 years will therefore be where genomic surveillance and rapid data sharing is most crucial, as this could provide a warning system to identify at-risk areas and provide indications on how to best mitigate the spread of resistance. Incorporating whole genome sequencing into routine sampling will be particularly important, as this would enable discovery of new markers of resistance and detection of signatures of genomic adaptation to antimalarials, such as clonal population expansion. Whole genomes would also offer improved inferences on parasite dynamics, such as migration, population structure, and selection pressure, all of which will be crucial in tracking the spread of resistance.</p></sec></sec></sec><sec id="s5"><title>The role of genomic surveillance going forward</title><p>Throughout this review, we have highlighted the vital role genomic surveillance has played in understanding the global emergence and spread of ART-R in <italic>P. falciparum</italic>. In Southeast Asia, genomic surveillance helped to identify instances of migration of resistant parasites between countries and quantify the frequencies of resistance in different areas (see Section ‘Spread of Artemisinin Partial Resistance’). Now, in East and Northeast Africa, genomic surveillance continues to demonstrate its usefulness, by identifying the independent emergence and spread of <italic>kelch13</italic> mutations in Sudan, Uganda, Eritrea, and Rwanda (<xref ref-type="bibr" rid="bib33">Conrad et al., 2023</xref>; <xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Mihreteab et al., 2023</xref>; <xref ref-type="bibr" rid="bib90">Mohamed et al., 2020</xref>; <xref ref-type="bibr" rid="bib109">Owoloye et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Jalei et al., 2023</xref>). These discoveries were only possible due to the enhanced sensitivity of genomic surveillance in detecting low-frequency genetic variants - as several TES from the region suggested treatment efficacy remained high (&gt;95%) (<xref ref-type="bibr" rid="bib12">Assefa et al., 2024</xref>). However, TES primarily aids in understanding treatment failure due to partner drug resistance, so is not expected to inform on ART-R in the same way as genomic surveillance is able to do. Moving forward, it is essential to use the information gathered from both genomic surveillance and TES, along with lessons learned from ART-R in South-East Asia, to develop and implement mitigation strategies, such as properly allocating healthcare resources (<xref ref-type="bibr" rid="bib12">Assefa et al., 2024</xref>; <xref ref-type="bibr" rid="bib162">World Health Organization, 2015b</xref>; <xref ref-type="bibr" rid="bib164">World Health Organization, 2021</xref>).</p><sec id="s5-1"><title>The need for a more systematic approach to genomic surveillance</title><p>Genomic surveillance of ART-R in Africa is at a crucial inflection point. As of 2024, limitations on resources, time, and training, alongside the scale of parasite populations in Africa, mean surveillance efforts remain localised, often with limited numbers of samples from key areas (<xref ref-type="bibr" rid="bib165">World Health Organization, 2022a</xref>; <xref ref-type="bibr" rid="bib107">Nsanzabana, 2021</xref>). This is a problem because surveillance is most valuable as a warning system when it is detailed enough to identify low-frequency variants (e.g. less than 1%), and these can easily be missed if not enough samples have been analysed (<xref ref-type="bibr" rid="bib147">Uwimana et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>; <xref ref-type="bibr" rid="bib13">Asua et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Boni, 2022</xref>). This highlights a fundamental challenge for the surveillance of ART-R, in that if resistance is circulating at lower frequencies, it is simply harder to detect using any method, and quantifying changes in those frequencies can be difficult without detailed sampling over time within the same areas (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>). While identifying resistance mutations at frequencies of around 5% or more is still very valuable, detecting mutations at lower frequencies gives more time to delay the establishment of resistant parasites or reduce their spread to neighbouring regions. These issues mean increases in resistance mutation frequencies may only be identified when they have effects on clinical efficacy (<xref ref-type="bibr" rid="bib173">Zupko et al., 2023</xref>).</p><p>A significant increase in genomic surveillance is needed, alongside a more systematic approach to sample collection. Surveillance could be improved by using networks of health facilities which routinely monitor ART-R frequencies within regions and conduct longitudinal sampling of areas over time (<xref ref-type="bibr" rid="bib106">Nsanzabana et al., 2018</xref>; <xref ref-type="bibr" rid="bib159">World Health Organization, 2009</xref>; <xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>; <xref ref-type="bibr" rid="bib50">Guillot et al., 2022</xref>). Adapting sampling for more novel surveillance approaches, including genomic surveillance, could help to maximise the available information on resistant allele frequencies and improve the detection of low-frequency variants (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>). This could involve performing a priori power analyses to guide sampling efforts, based on predefined estimates of mutation prevalence and desired margins of error (<xref ref-type="bibr" rid="bib80">Mayor et al., 2023</xref>).</p><p>More generally, the complementary use of whole genome sequencing and amplicon sequencing will be crucial to best tackle ART-R. Both technologies are more sensitive for detecting low-frequency variants than traditional approaches such as sequencing using capillary electrophoresis. This is particularly important for molecular surveillance in Africa, where high proportions of mixed infections can hinder the identification of low-frequency variants. As amplicon sequencing is likely to continue to be the most accessible genomic sequencing method in the near future, we must strive to use whole genome information to inform and improve amplicon sequencing. For example, whole genome sequencing can shed light on the ‘unknown unknowns’ of ART-R, such as novel drug resistance mechanisms, including the effect of mutations in the N-terminal region of the <italic>kelch13</italic> gene, as well as those outside the <italic>kelch13</italic> gene, such as <italic>pfcoronin</italic>, <italic>ubp1</italic> and <italic>pfap2mu</italic>, which could then be incorporated into amplicon sequencing panels (<xref ref-type="bibr" rid="bib28">Cerqueira et al., 2017</xref>). Aside from improving amplicon sequencing, whole genome data can also provide insights to partner drug resistance genotypes and parasite population dynamics (<xref ref-type="bibr" rid="bib6">Amato et al., 2018</xref>; <xref ref-type="bibr" rid="bib111">Parobek et al., 2017</xref>). Such information could inform models which characterise selective pressures in response to interventions like drug usage (<xref ref-type="bibr" rid="bib103">Nguyen et al., 2023b</xref>). Whole genome data can also highlight important changes in genomic architecture which can be indicative of evolution in response to control measures (<xref ref-type="bibr" rid="bib86">Miotto et al., 2015</xref>). For example, identifying copy number variations in drug resistance genes, or deletions and breakpoints which lead to rapid diagnostic test failures (<xref ref-type="bibr" rid="bib116">Rocamora and Winzeler, 2020</xref>). Moreover, increasing overall whole genome sequencing data and making it publicly available as soon as possible after collection would ensure maximum value from surveillance efforts.</p><p>Lastly, a major focus should be on building sequencing and data processing capabilities in malaria endemic countries, particularly in the African continent. Currently, the substantive cost of reagents and issues with supply chain logistics can hinder efforts for in-country data generation (<xref ref-type="bibr" rid="bib99">Neafsey et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Hamilton et al., 2023</xref>). Additionally, training of local scientists in specialist fields such as bioinformatics, genomics, and data science would further enable the ability to turn sequencing data into interpretable findings (<xref ref-type="bibr" rid="bib65">Ishengoma et al., 2019</xref>). Challenges exist around obtaining sustained funding for long and short-term data storage, while the difficulties of data compartmentalisation, standardisation, and administrative burdens will also need to be addressed to best leverage ongoing genomic surveillance efforts. Moving forwards, it will be critical to expand surveillance by enabling the use of sequencing more widely in Africa (<xref ref-type="bibr" rid="bib65">Ishengoma et al., 2019</xref>). These improvements could include nanopore long-read technology, which has been demonstrated to be well-suited to surveillance needs through its increased portability, lower up-front costs, and real-time data output (<xref ref-type="bibr" rid="bib53">Hamilton et al., 2023</xref>). Several combined strategies could vastly enhance the region’s ability to respond to future outbreaks, both for <italic>Plasmodium</italic> and other pathogens. These strategies include the systematic investment in local surveillance infrastructure and workflows, changes in sampling strategy (towards a framework informed by genomic surveillance), and a focus on building a critical mass of expertise in areas where gaps have been identified.</p></sec><sec id="s5-2"><title>Improved models to analyse large spatiotemporal datasets</title><p>In addition to enhanced genomic surveillance, developing new models to analyse increasingly large spatiotemporal datasets is crucial. Improved epidemiological models could characterise outbreaks as they unfold or even forecast how they may progress. For example, models which can estimate identity-by-descent among large numbers of parasites would enable inferences on population scale changes in genetic diversity (<xref ref-type="bibr" rid="bib85">Miotto et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Henden et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Amambua-Ngwa et al., 2019</xref>). This capability would enhance quantification of selective pressures for ART-R, identify migration pathways between regions, and help categorise population diversity (<xref ref-type="bibr" rid="bib6">Amato et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Meier-Scherling et al., 2024</xref>; <xref ref-type="bibr" rid="bib5">Amambua-Ngwa et al., 2019</xref>). Improved models could also study changes in the frequency of drug-resistant lineages and facilitate the interpretation of these changes in relation to other factors, such as drug use, vector populations, or climate change (<xref ref-type="bibr" rid="bib35">Datoo et al., 2024</xref>; <xref ref-type="bibr" rid="bib125">Ryan et al., 2020</xref>; <xref ref-type="bibr" rid="bib128">Sherrard-Smith et al., 2022</xref>; <xref ref-type="bibr" rid="bib115">Redding et al., 2024</xref>). Moreover, developing methods to identify novel resistance markers is crucial—not only for <italic>kelch13</italic> and partner drug resistance genes, but also for other genomic loci that may contribute to ART-R through complementary or polygenic mechanisms (<xref ref-type="bibr" rid="bib38">Demas et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Miotto et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Nayak et al., 2024</xref>). For example, linkage disequilibrium has been identified between non-propeller mutations R255K, K189N, and K189T in <italic>kelch13</italic>, as well as between these mutations and other drug resistance linked genes such as <italic>mdr1</italic> in Mali (<xref ref-type="bibr" rid="bib34">Coulibaly et al., 2022</xref>). While not validated or candidate mutations, K189T and R255K were recently associated with delayed parasite clearance in one study from Nigeria (<xref ref-type="bibr" rid="bib7">Amusan et al., 2025</xref><ext-link ext-link-type="uri" xlink:href="https://www.zotero.org/google-docs/?9oI5Yj">)</ext-link>. Initially, the search for novel resistance mechanisms could include polymorphisms in the N-terminal region of the <italic>kelch13</italic> protein, but should then extend to those outside the <italic>kelch13</italic> gene. This is especially important in African parasite populations, where resistance-conferring mutations beyond <italic>kelch13</italic> have already been identified and may interact with genetic backgrounds in ways that influence their emergence and spread (<xref ref-type="bibr" rid="bib86">Miotto et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Demas et al., 2018</xref>; <xref ref-type="bibr" rid="bib143">Tumwebaze et al., 2022</xref>). This will be particularly important during the rollout of MFT or TACT strategies, as any triply resistant mutants which arise can be more easily identified using genomic surveillance, and this information could inform optimal timing to rotate drugs (<xref ref-type="bibr" rid="bib173">Zupko et al., 2023</xref>; <xref ref-type="bibr" rid="bib73">Kokori et al., 2024</xref>; <xref ref-type="bibr" rid="bib23">Boni, 2022</xref>).</p></sec><sec id="s5-3"><title>Improved data sharing, public access to data and training opportunities</title><p>Ensuring that surveillance data and analysis methods are publicly available is crucial for the malaria community, as these resources are essential in building skills and capacity for bioinformatic analysis. Public access to large surveillance datasets has repeatedly empowered novel analyses on the basic biology of <italic>Plasmodium</italic>, possible only because of the open nature of these datasets and the willingness of the community to share data (<xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>). For example, recent analysis of the Pf7 open dataset of whole genome sequencing samples led to the identification of a novel ‘cryptotype’ of <italic>P. falciparum</italic>, present in 13 countries across Africa (<xref ref-type="bibr" rid="bib87">Miotto et al., 2024</xref>). Additionally, making the outputs of genomic surveillance data available through centralised platforms like MalariaGEN, WWARN, and WHO’s malaria threat maps has provided the malaria community with invaluable resources to study the distribution, migration and spread of ART-R (<xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>; <xref ref-type="bibr" rid="bib129">Sibley et al., 2007</xref>). Similarly, web applications like Pf-HaploAtlas have been developed to leverage these resources, facilitating analysis of genomic surveillance data without the need for specialised technical knowledge (<xref ref-type="bibr" rid="bib74">Lee et al., 2024</xref>). It is imperative to continue this work by ensuring these tools and resources are accessible and user-friendly, particularly for those with limited training, and to support the malaria community in making their data publicly available as soon as possible after collection. This approach will enhance contributions and coordination within the community, and help in informing strategies to mitigate the spread of ART-R.</p></sec></sec><sec id="s6"><title>Conclusions and outlook</title><p>Given the emergence of ART-R associated with <italic>kelch13</italic> markers in Africa, it is likely only a matter of time before these begin to spread widely across the continent (<xref ref-type="bibr" rid="bib39">Dhorda et al., 2024</xref>; <xref ref-type="bibr" rid="bib121">Rosenthal et al., 2024</xref>). This review has highlighted the crucial role of genomic surveillance in alerting public health agencies to the spread of ART-R and in planning the use of limited resources to contain it. Recent years have seen limitations on funding, political instability, and other public health priorities, such as the COVID-19 pandemic, divert already limited resources away from genomic surveillance of <italic>P. falciparum</italic>, jeopardising the surveillance of ART-R in Africa (<xref ref-type="bibr" rid="bib77">Lyimo et al., 2022</xref>; <xref ref-type="bibr" rid="bib82">Mensah et al., 2022</xref>). Despite these challenges, it will be crucial to continually develop and champion the use of genomic surveillance as a vital part of the surveillance toolkit for ART-R, which also contains methods such as treatment efficacy studies and <italic>in vitro</italic> phenotypic studies. Without coordinating these surveillance tools, increases in ART-R may only be identified when they have already spread widely, negatively affecting patient outcomes and compromising our ability to implement mitigation strategies (<xref ref-type="bibr" rid="bib173">Zupko et al., 2023</xref>). This means continuing surveillance is vital, not only for containing the spread of ART-R, but also for minimising the human costs it will cause.</p></sec><sec id="s7" sec-type="methods"><title>Methods</title><sec id="s7-1"><title>Data aggregation</title><p>We compiled publicly available <italic>kelch13</italic> mutation data for 112,933 samples collected between 1980 and 2023, across 73 countries (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>, Source Data S1). This dataset, along with associated metadata, was sourced from the MalariaGEN Pf7 release (<xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>), the Worldwide Antimalarial Resistance Network (WWARN) Artemisinin Resistance Molecular Surveyor, and our own literature search. For the purposes of this study, all BTB/POZ and propeller mutations (codons 349–726) are collectively referred to as ‘propeller mutations’. Mutations were classified according to their status for association with ART-R from the latest WHO guidelines - either ‘validated’, ‘candidate’, or ‘no status’ (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Parasites with the 3D7 reference <italic>kelch13</italic> sequence, or the mutation A578S, were considered susceptible to artemisinin (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>). As only non-synonymous mutations were included in this study, samples with synonymous amino acid mutations only were classified as having the 3D7 reference sequence.</p><p>While we focused our analysis on the BTB/POZ and propeller domains, which include all WHO-validated and candidate ART-R mutations, additional variation exists in the N-terminal region of <italic>kelch13</italic>. Some of these upstream mutations may have functional or compensatory effects, although their role remains unclear. However, the WWARN dataset—which makes up most of our aggregated data—only includes sequences from codon 440 onwards, limiting our ability to systematically assess upstream diversity. To ensure consistency and comparability across sources, we therefore restricted analysis to the BTB/POZ and propeller domains. Samples with a mutation outside of codons 349–726 were therefore classified as having the 3D7 reference sequence. In some cases, samples with two <italic>kelch13</italic> mutations were identified. When one mutation was outside of the propeller domain, we counted only the propeller domain mutation for that sample. Where both mutations were detected within the propeller domain, we recorded both mutations for the sample, meaning it could be a mixed strain or poly-mutant.</p><p>Mutations were recorded alongside sample ID, continent, country, collection year, publication source, and method of SNP detection (Source Data S1 and S2). No exclusions were applied based on geographical or temporal metadata. Samples from each country were assigned to one of the 13 broader populations: South America, West Africa, Central Africa, North Africa, Northeast Africa, East Africa, Southern Africa, Western Asia, Eastern South Asia, Far-Eastern South Asia, Western Southeast Asia, Eastern Southeast Asia, and Oceania (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), in accordance with the Pf7 dataset (<xref ref-type="bibr" rid="bib1">Abdel Hamid et al., 2023</xref>). In Pf7, Kenya, India, and Thailand were split across two populations. We therefore assigned samples from these countries to the neighbouring population which overall held most samples. All samples from Thailand were allocated to Western Southeast Asia, all samples from Kenya were allocated to East Africa, and all samples from India were allocated to Eastern South Asia. Three extra populations were created for this analysis to account for samples which did not fit into pre-existing Pf7 populations: Southern Africa (Angola, Mozambique, South Africa, Zambia, Zimbabwe), North Africa (Algeria, Libya), Western Asia (Afghanistan, Iran, Pakistan) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Pf7 samples from Mozambique were also re-allocated to Southern Africa.</p><p>In analysing and visualising these data, we applied a multi-level aggregation approach: while we provide the dataset at the sample level, our analysis and visualisations aggregate prevalences either at country, subpopulation or continent levels. This structure enables broader geographic insights and facilitates interpretation of large-scale trends. Of the two <italic>kelch13</italic> molecular surveyor databases, the WHO Threats Map presents figures at the district level (<xref ref-type="bibr" rid="bib168">World Health Organization, Global Malaria Programme, 2024</xref>), and WWARN provides both data and visualisations at the study level. Our decision to use country- and region-level aggregation was driven by the need for comparability across heterogeneous data sources and to maximise sample sizes. This approach is particularly suited for identifying geographic and temporal patterns at a global scale, whereas study-level and site-specific surveillance—such as that offered by WWARN and WHO Threats Map—is useful for ongoing monitoring efforts and intervention planning.</p></sec><sec id="s7-2"><title>Source-specific data processing</title><sec id="s7-2-1"><title>Pf7</title><p>Whole genome data from 16,203 QC-passed Pf7 samples were processed using custom Python scripts to generate haplotypes for <italic>kelch13</italic>. During QC, duplicate samples were removed. For each sample, we applied nucleotide variants from the GT field of the sample’s VCF file to the 3D7 reference sequence. These sequences were translated into amino acids, and mutations were identified. We excluded any sample with a missing genotype call (n=1,056). After removal of heterozygous samples (n=2,292), 12,855 samples from Pf7 were included in the final dataset.</p></sec><sec id="s7-2-2"><title>WWARN database</title><p><italic>A</italic>ll <italic>kelch13</italic> data from WWARN’s Artemisinin Molecular Surveyor were downloaded. We reviewed 63 studies where only a range of years, rather than a single year, was provided. If we were not able to gather single-year data for all samples from the original publication, we recorded the median year of the range for the study. In cases where the year range was 2 years, we selected the year with the largest number of samples. We investigated potential duplicate or missing data in the full texts of 34 WWARN publications that had different total numbers of recorded mutations and tested samples. Of these, 17 studies were included after correcting a mismatch between the publication and the WWARN data file and one was included after being flagged as containing multiple propeller mutations per sample. The remainder were excluded for containing heterozygous samples, or due to missing data for most samples, or because the publication was inaccessible. We assumed no other duplicate samples were included within the WWARN dataset. Ultimately, we included data from 291 WWARN publications covering 86,870 samples.</p></sec><sec id="s7-2-3"><title>Literature search</title><p>To ensure our database was as comprehensive and up to date as possible, we performed an additional literature search for relevant papers published after 2020 to supplement the WWARN database. We searched the Web of Science and PubMed using: ‘K13 OR kelch OR kelch13 OR pfkelch13 AND (half-life OR parasite clearance OR resistance)’, restricting results to articles only. We also searched ‘kelch13 mutations <italic>falciparum</italic> artemisinin’ in Google Scholar for articles published between 2023 and 2024. We excluded articles which genotyped <italic>kelch13</italic> after ACT treatment (i.e. not day 0 patients) or in cultured lab strains, articles which did not provide country-level information or sample size information, articles which only provided genotypes for a subset of samples tested, articles already included in the WWARN database, and articles not available in English or not accessible. We yielded 28 additional unique studies after reviewing full texts and applying both the article and mutation inclusion criteria. We ensured that no missing data were present by checking that the total number of ‘tested’ samples and the number of samples with a reported <italic>kelch13</italic> genotype were equal. In any instance where wildtype genotypes were not reported and the number of samples with a <italic>kelch13</italic> mutation was below the total number of tested samples, we added wildtype counts to complete the study data. A further 13,208 samples were collected from this search.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s8"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s9"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>this should reduce the frequency of resistance to the first drCriteria for classifying <italic>kelch13</italic> mutations as validated or candidate markers of artemisinin partial resistance, based on WHO guidelines (<xref ref-type="bibr" rid="bib166">World Health Organization, 2022b</xref>).</title><p>Includes the current list of accepted mutations in each category.</p></caption><media xlink:href="elife-105544-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Populations included in this analysis, with countries and sample sizes listed for each.</title><p>Ten populations are based on MalariaGEN’s Pf7 geographic/genetic groupings; three additional populations (Southern Africa, North Africa, Western Asia) were defined for samples not fitting existing groupings. “Proportion of population” = percent of samples from each country within a population. “Proportion of total” = percent of total dataset contributed by each country.</p><p>DRC = Democratic Republic of the Congo.</p></caption><media xlink:href="elife-105544-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Number of unique <italic>kelch13</italic> propeller mutations identified in each population.</title><p>C/V = WHO-classified candidate or validated marker.</p></caption><media xlink:href="elife-105544-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Proportion of total samples per year from each population.</title></caption><media xlink:href="elife-105544-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Summary statistics from logistic regression models of ART-R transmission dynamics in selected countries.</title></caption><media xlink:href="elife-105544-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Therapeutic efficacy studies (TES) in Africa reporting delayed parasite clearance or &gt;10% 1455 treatment failure following ACT administration.</title></caption><media xlink:href="elife-105544-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Adoption of first-line ACT regimens by country and population as of end-2022, according to 1459 WHO reports.</title><p>The number of countries in each population using each regimen for 1460 uncomplicated malaria. Abbreviations: A – artemether, L – lumefantrine, AS – artesunate, 1461 AQ – amodiaquine, MQ – mefloquine, DHA – dihydroartemisinin, PYR – pyronaridine, CQ – 1462 chloroquine, PPQ – piperaquine, PQ – primaquine.</p></caption><media xlink:href="elife-105544-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>README file for Source Data S1.</title></caption><media xlink:href="elife-105544-supp8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>README file for Source Data S2.</title></caption><media xlink:href="elife-105544-supp9-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank all those who gave useful feedback on the manuscript and figures, in particular Kate Rowlands and Vikki Simpson. We are also grateful to the Worldwide Antimalarial Resistance Network (WWARN) for providing early access to data for 2021–2024 prior to publication on WWARN’s artemisinin molecular surveyor. This work was supported by The Bill &amp; Melinda Gates Foundation [INV-001927, INV-068808].</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel Hamid</surname><given-names>MM</given-names></name><name><surname>Abdelraheem</surname><given-names>MH</given-names></name><name><surname>Acheampong</surname><given-names>DO</given-names></name><name><surname>Ahouidi</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Almagro-Garcia</surname><given-names>J</given-names></name><name><surname>Amambua-Ngwa</surname><given-names>A</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Amenga-Etego</surname><given-names>L</given-names></name><name><surname>Andagalu</surname><given-names>B</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>Andrianaranjaka</surname><given-names>V</given-names></name><name><surname>Aniebo</surname><given-names>I</given-names></name><name><surname>Aninagyei</surname><given-names>E</given-names></name><name><surname>Ansah</surname><given-names>F</given-names></name><name><surname>Ansah</surname><given-names>PO</given-names></name><name><surname>Apinjoh</surname><given-names>T</given-names></name><name><surname>Arnaldo</surname><given-names>P</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Auburn</surname><given-names>S</given-names></name><name><surname>Awandare</surname><given-names>GA</given-names></name><name><surname>Ba</surname><given-names>H</given-names></name><name><surname>Baraka</surname><given-names>V</given-names></name><name><surname>Barry</surname><given-names>A</given-names></name><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Bertin</surname><given-names>GI</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Borrmann</surname><given-names>S</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Bouyou-Akotet</surname><given-names>M</given-names></name><name><surname>Branch</surname><given-names>O</given-names></name><name><surname>Bull</surname><given-names>PC</given-names></name><name><surname>Cheah</surname><given-names>H</given-names></name><name><surname>Chindavongsa</surname><given-names>K</given-names></name><name><surname>Chookajorn</surname><given-names>T</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Claessens</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><name><surname>Corredor</surname><given-names>V</given-names></name><name><surname>Courtier</surname><given-names>E</given-names></name><name><surname>Craig</surname><given-names>A</given-names></name><name><surname>D’Alessandro</surname><given-names>U</given-names></name><name><surname>Dama</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>N</given-names></name><name><surname>Denis</surname><given-names>B</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Diakite</surname><given-names>M</given-names></name><name><surname>Djimde</surname><given-names>A</given-names></name><name><surname>Dolecek</surname><given-names>C</given-names></name><name><surname>Dondorp</surname><given-names>A</given-names></name><name><surname>Doumbia</surname><given-names>S</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Duffy</surname><given-names>P</given-names></name><name><surname>Echeverry</surname><given-names>DF</given-names></name><name><surname>Egwang</surname><given-names>TG</given-names></name><name><surname>Enosse</surname><given-names>SMM</given-names></name><name><surname>Erko</surname><given-names>B</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Faiz</surname><given-names>A</given-names></name><name><surname>Fanello</surname><given-names>CA</given-names></name><name><surname>Fleharty</surname><given-names>M</given-names></name><name><surname>Forbes</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Gamboa</surname><given-names>D</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name><name><surname>Golassa</surname><given-names>L</given-names></name><name><surname>Goncalves</surname><given-names>S</given-names></name><name><surname>Harrison</surname><given-names>GLA</given-names></name><name><surname>Healy</surname><given-names>SA</given-names></name><name><surname>Hendry</surname><given-names>JA</given-names></name><name><surname>Hernandez-Koutoucheva</surname><given-names>A</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Hill</surname><given-names>CA</given-names></name><name><surname>Hombhanje</surname><given-names>F</given-names></name><name><surname>Hott</surname><given-names>A</given-names></name><name><surname>Htut</surname><given-names>Y</given-names></name><name><surname>Hussein</surname><given-names>M</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Ishengoma</surname><given-names>D</given-names></name><name><surname>Jackson</surname><given-names>SA</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Jeans</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>KJ</given-names></name><name><surname>Kamaliddin</surname><given-names>C</given-names></name><name><surname>Kamau</surname><given-names>E</given-names></name><name><surname>Keatley</surname><given-names>J</given-names></name><name><surname>Kochakarn</surname><given-names>T</given-names></name><name><surname>Konate</surname><given-names>DS</given-names></name><name><surname>Konaté</surname><given-names>A</given-names></name><name><surname>Kone</surname><given-names>A</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Kyaw</surname><given-names>MP</given-names></name><name><surname>Kyle</surname><given-names>D</given-names></name><name><surname>Lawniczak</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Lemnge</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Lon</surname><given-names>C</given-names></name><name><surname>Loua</surname><given-names>KM</given-names></name><name><surname>Mandara</surname><given-names>CI</given-names></name><name><surname>Marfurt</surname><given-names>J</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Maïga-Ascofaré</surname><given-names>O</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Mobegi</surname><given-names>V</given-names></name><name><surname>Mohamed</surname><given-names>AO</given-names></name><name><surname>Mokuolu</surname><given-names>OA</given-names></name><name><surname>Montgomery</surname><given-names>J</given-names></name><name><surname>Morang’a</surname><given-names>CM</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Murie</surname><given-names>K</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Ngo Duc</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>T-N</given-names></name><name><surname>Nguyen Thi Kim</surname><given-names>T</given-names></name><name><surname>Nguyen Van</surname><given-names>H</given-names></name><name><surname>Noedl</surname><given-names>H</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Noviyanti</surname><given-names>R</given-names></name><name><surname>Ntui</surname><given-names>VN-N</given-names></name><name><surname>Nzila</surname><given-names>A</given-names></name><name><surname>Ochola-Oyier</surname><given-names>LI</given-names></name><name><surname>Ocholla</surname><given-names>H</given-names></name><name><surname>Oduro</surname><given-names>A</given-names></name><name><surname>Omedo</surname><given-names>I</given-names></name><name><surname>Onyamboko</surname><given-names>MA</given-names></name><name><surname>Ouedraogo</surname><given-names>J-B</given-names></name><name><surname>Oyebola</surname><given-names>K</given-names></name><name><surname>Oyibo</surname><given-names>WA</given-names></name><name><surname>Pearson</surname><given-names>R</given-names></name><name><surname>Peshu</surname><given-names>N</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Price</surname><given-names>RN</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Quang</surname><given-names>HH</given-names></name><name><surname>Randrianarivelojosia</surname><given-names>M</given-names></name><name><surname>Rayner</surname><given-names>JC</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Rosanas-Urgell</surname><given-names>A</given-names></name><name><surname>Rovira-Vallbona</surname><given-names>E</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Ruiz</surname><given-names>L</given-names></name><name><surname>Saunders</surname><given-names>D</given-names></name><name><surname>Shayo</surname><given-names>A</given-names></name><name><surname>Siba</surname><given-names>P</given-names></name><name><surname>Simpson</surname><given-names>VJ</given-names></name><name><surname>Sissoko</surname><given-names>MS</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>X-Z</given-names></name><name><surname>Sutherland</surname><given-names>C</given-names></name><name><surname>Takala-Harrison</surname><given-names>S</given-names></name><name><surname>Talman</surname><given-names>A</given-names></name><name><surname>Tavul</surname><given-names>L</given-names></name><name><surname>Thanh</surname><given-names>NV</given-names></name><name><surname>Thathy</surname><given-names>V</given-names></name><name><surname>Thu</surname><given-names>AM</given-names></name><name><surname>Toure</surname><given-names>M</given-names></name><name><surname>Tshefu</surname><given-names>A</given-names></name><name><surname>Verra</surname><given-names>F</given-names></name><name><surname>Vinetz</surname><given-names>J</given-names></name><name><surname>Wellems</surname><given-names>TE</given-names></name><name><surname>Wendler</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Whitton</surname><given-names>G</given-names></name><name><surname>Yavo</surname><given-names>W</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><collab>MalariaGEN</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Pf7: an open dataset of <italic>Plasmodium falciparum</italic> genome variation in 20,000 worldwide samples</article-title><source>Wellcome Open Research</source><volume>8</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.18681.1</pub-id><pub-id pub-id-type="pmid">36864926</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abebaw</surname><given-names>A</given-names></name><name><surname>Aschale</surname><given-names>Y</given-names></name><name><surname>Kebede</surname><given-names>T</given-names></name><name><surname>Hailu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The prevalence of symptomatic and asymptomatic malaria and its associated factors in Debre Elias district communities, Northwest Ethiopia</article-title><source>Malaria Journal</source><volume>21</volume><elocation-id>e167</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-022-04194-7</pub-id><pub-id pub-id-type="pmid">35659661</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abera</surname><given-names>D</given-names></name><name><surname>Kibet</surname><given-names>CK</given-names></name><name><surname>Degefa</surname><given-names>T</given-names></name><name><surname>Amenga-Etego</surname><given-names>L</given-names></name><name><surname>Bargul</surname><given-names>JL</given-names></name><name><surname>Golassa</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genomic analysis reveals independent evolution of <italic>Plasmodium falciparum</italic> populations in Ethiopia</article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>e129</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-03660-y</pub-id><pub-id pub-id-type="pmid">33663492</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agaba</surname><given-names>BB</given-names></name><name><surname>Rugera</surname><given-names>SP</given-names></name><name><surname>Mpirirwe</surname><given-names>R</given-names></name><name><surname>Atekat</surname><given-names>M</given-names></name><name><surname>Okubal</surname><given-names>S</given-names></name><name><surname>Masereka</surname><given-names>K</given-names></name><name><surname>Erionu</surname><given-names>M</given-names></name><name><surname>Adranya</surname><given-names>B</given-names></name><name><surname>Nabirwa</surname><given-names>G</given-names></name><name><surname>Odong</surname><given-names>PB</given-names></name><name><surname>Mukiibi</surname><given-names>Y</given-names></name><name><surname>Ssewanyana</surname><given-names>I</given-names></name><name><surname>Nabadda</surname><given-names>S</given-names></name><name><surname>Muwanguzi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Asymptomatic malaria infection, associated factors and accuracy of diagnostic tests in a historically high transmission setting in Northern Uganda</article-title><source>Malaria Journal</source><volume>21</volume><elocation-id>e392</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-022-04421-1</pub-id><pub-id pub-id-type="pmid">36550492</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amambua-Ngwa</surname><given-names>A</given-names></name><name><surname>Amenga-Etego</surname><given-names>L</given-names></name><name><surname>Kamau</surname><given-names>E</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name><name><surname>Golassa</surname><given-names>L</given-names></name><name><surname>Randrianarivelojosia</surname><given-names>M</given-names></name><name><surname>Ishengoma</surname><given-names>D</given-names></name><name><surname>Apinjoh</surname><given-names>T</given-names></name><name><surname>Maïga-Ascofaré</surname><given-names>O</given-names></name><name><surname>Andagalu</surname><given-names>B</given-names></name><name><surname>Yavo</surname><given-names>W</given-names></name><name><surname>Bouyou-Akotet</surname><given-names>M</given-names></name><name><surname>Kolapo</surname><given-names>O</given-names></name><name><surname>Mane</surname><given-names>K</given-names></name><name><surname>Worwui</surname><given-names>A</given-names></name><name><surname>Jeffries</surname><given-names>D</given-names></name><name><surname>Simpson</surname><given-names>V</given-names></name><name><surname>D’Alessandro</surname><given-names>U</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Djimde</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Major subpopulations of <italic>Plasmodium falciparum</italic> in sub-Saharan Africa</article-title><source>Science</source><volume>365</volume><fpage>813</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1126/science.aav5427</pub-id><pub-id pub-id-type="pmid">31439796</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Almagro-Garcia</surname><given-names>J</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Stalker</surname><given-names>J</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study</article-title><source>The Lancet. Infectious Diseases</source><volume>18</volume><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30068-9</pub-id><pub-id pub-id-type="pmid">29398391</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amusan</surname><given-names>A</given-names></name><name><surname>Akinola</surname><given-names>O</given-names></name><name><surname>Akano</surname><given-names>K</given-names></name><name><surname>Hernández-Castañeda</surname><given-names>M</given-names></name><name><surname>Dick</surname><given-names>JK</given-names></name><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Hart</surname><given-names>G</given-names></name><name><surname>Gbotosho</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Polymorphisms in Pfkelch13 domains before and after the introduction of artemisinin-based combination therapy in Southwest Nigeria</article-title><source>PLOS ONE</source><volume>20</volume><elocation-id>e0316479</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0316479</pub-id><pub-id pub-id-type="pmid">40163420</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>TJC</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>McDew-White</surname><given-names>M</given-names></name><name><surname>Cheeseman</surname><given-names>IH</given-names></name><name><surname>Nkhoma</surname><given-names>S</given-names></name><name><surname>Bilgic</surname><given-names>F</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Pyae Phyo</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Population parameters underlying an ongoing soft sweep in Southeast Asian malaria parasites</article-title><source>Molecular Biology and Evolution</source><volume>34</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1093/molbev/msw228</pub-id><pub-id pub-id-type="pmid">28025270</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antao</surname><given-names>T</given-names></name><name><surname>Hastings</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach</article-title><source>Malaria Journal</source><volume>11</volume><elocation-id>e422</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-11-422</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Witkowski</surname><given-names>B</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Beghain</surname><given-names>J</given-names></name><name><surname>Langlois</surname><given-names>A-C</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Duru</surname><given-names>V</given-names></name><name><surname>Bouchier</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Leang</surname><given-names>R</given-names></name><name><surname>Duong</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Chuor</surname><given-names>CM</given-names></name><name><surname>Bout</surname><given-names>DM</given-names></name><name><surname>Ménard</surname><given-names>S</given-names></name><name><surname>Rogers</surname><given-names>WO</given-names></name><name><surname>Genton</surname><given-names>B</given-names></name><name><surname>Fandeur</surname><given-names>T</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Le Bras</surname><given-names>J</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Barale</surname><given-names>J-C</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Benoit-Vical</surname><given-names>F</given-names></name><name><surname>Mercereau-Puijalon</surname><given-names>O</given-names></name><name><surname>Ménard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A molecular marker of artemisinin-resistant <italic>Plasmodium falciparum</italic> malaria</article-title><source>Nature</source><volume>505</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nature12876</pub-id><pub-id pub-id-type="pmid">24352242</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JM</given-names></name><name><surname>Mao</surname><given-names>S</given-names></name><name><surname>Sam</surname><given-names>B</given-names></name><name><surname>Sopha</surname><given-names>C</given-names></name><name><surname>Chuor</surname><given-names>CM</given-names></name><name><surname>Nguon</surname><given-names>C</given-names></name><name><surname>Sovannaroth</surname><given-names>S</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Jittamala</surname><given-names>P</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Chutasmit</surname><given-names>K</given-names></name><name><surname>Suchatsoonthorn</surname><given-names>C</given-names></name><name><surname>Runcharoen</surname><given-names>R</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Thuy-Nhien</surname><given-names>NT</given-names></name><name><surname>Thanh</surname><given-names>NV</given-names></name><name><surname>Phu</surname><given-names>NH</given-names></name><name><surname>Htut</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>K-T</given-names></name><name><surname>Aye</surname><given-names>KH</given-names></name><name><surname>Mokuolu</surname><given-names>OA</given-names></name><name><surname>Olaosebikan</surname><given-names>RR</given-names></name><name><surname>Folaranmi</surname><given-names>OO</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Khanthavong</surname><given-names>M</given-names></name><name><surname>Hongvanthong</surname><given-names>B</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Onyamboko</surname><given-names>MA</given-names></name><name><surname>Fanello</surname><given-names>CI</given-names></name><name><surname>Tshefu</surname><given-names>AK</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Valecha</surname><given-names>N</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Borrmann</surname><given-names>S</given-names></name><name><surname>Bashraheil</surname><given-names>M</given-names></name><name><surname>Peshu</surname><given-names>J</given-names></name><name><surname>Faiz</surname><given-names>MA</given-names></name><name><surname>Ghose</surname><given-names>A</given-names></name><name><surname>Hossain</surname><given-names>MA</given-names></name><name><surname>Samad</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>MR</given-names></name><name><surname>Hasan</surname><given-names>MM</given-names></name><name><surname>Islam</surname><given-names>A</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>MacInnis</surname><given-names>B</given-names></name><name><surname>Stalker</surname><given-names>J</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Bozdech</surname><given-names>Z</given-names></name><name><surname>Jeeyapant</surname><given-names>A</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Sakulthaew</surname><given-names>T</given-names></name><name><surname>Chalk</surname><given-names>J</given-names></name><name><surname>Intharabut</surname><given-names>B</given-names></name><name><surname>Silamut</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Vihokhern</surname><given-names>B</given-names></name><name><surname>Kunasol</surname><given-names>C</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Tarning</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>WJ</given-names></name><name><surname>Yeung</surname><given-names>S</given-names></name><name><surname>Woodrow</surname><given-names>CJ</given-names></name><name><surname>Flegg</surname><given-names>JA</given-names></name><name><surname>Das</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Venkatesan</surname><given-names>M</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Stepniewska</surname><given-names>K</given-names></name><name><surname>Guerin</surname><given-names>PJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><collab>Tracking Resistance to Artemisinin Collaboration</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Spread of artemisinin resistance in <italic>Plasmodium falciparum</italic> malaria</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>411</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1314981</pub-id><pub-id pub-id-type="pmid">25075834</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assefa</surname><given-names>A</given-names></name><name><surname>Fola</surname><given-names>AA</given-names></name><name><surname>Tasew</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Emergence of <italic>Plasmodium falciparum</italic> strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic?</article-title><source>Malaria Journal</source><volume>23</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-024-04848-8</pub-id><pub-id pub-id-type="pmid">38273360</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asua</surname><given-names>V</given-names></name><name><surname>Vinden</surname><given-names>J</given-names></name><name><surname>Conrad</surname><given-names>MD</given-names></name><name><surname>Legac</surname><given-names>J</given-names></name><name><surname>Kigozi</surname><given-names>SP</given-names></name><name><surname>Kamya</surname><given-names>MR</given-names></name><name><surname>Dorsey</surname><given-names>G</given-names></name><name><surname>Nsobya</surname><given-names>SL</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Changing molecular markers of antimalarial drug sensitivity across Uganda</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>63</volume><elocation-id>e01818-18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01818-18</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ataide</surname><given-names>R</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Powell</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>J-A</given-names></name><name><surname>Malloy</surname><given-names>MJ</given-names></name><name><surname>O’Flaherty</surname><given-names>K</given-names></name><name><surname>Takashima</surname><given-names>E</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Tsuboi</surname><given-names>T</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Htut</surname><given-names>Y</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Faiz</surname><given-names>MA</given-names></name><name><surname>Beeson</surname><given-names>JG</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Simpson</surname><given-names>JA</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Fowkes</surname><given-names>FJI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Host immunity to <italic>Plasmodium falciparum</italic> and the assessment of emerging artemisinin resistance in a multinational cohort</article-title><source>PNAS</source><volume>114</volume><fpage>3515</fpage><lpage>3520</lpage><pub-id pub-id-type="doi">10.1073/pnas.1615875114</pub-id><pub-id pub-id-type="pmid">28289193</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balikagala</surname><given-names>B</given-names></name><name><surname>Fukuda</surname><given-names>N</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Katuro</surname><given-names>OT</given-names></name><name><surname>Tachibana</surname><given-names>S-I</given-names></name><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Opio</surname><given-names>W</given-names></name><name><surname>Emoto</surname><given-names>S</given-names></name><name><surname>Anywar</surname><given-names>DA</given-names></name><name><surname>Kimura</surname><given-names>E</given-names></name><name><surname>Palacpac</surname><given-names>NMQ</given-names></name><name><surname>Odongo-Aginya</surname><given-names>EI</given-names></name><name><surname>Ogwang</surname><given-names>M</given-names></name><name><surname>Horii</surname><given-names>T</given-names></name><name><surname>Mita</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Evidence of artemisinin-resistant malaria in Africa</article-title><source>The New England Journal of Medicine</source><volume>385</volume><fpage>1163</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101746</pub-id><pub-id pub-id-type="pmid">34551228</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baym</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>LK</given-names></name><name><surname>Kishony</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multidrug evolutionary strategies to reverse antibiotic resistance</article-title><source>Science</source><volume>351</volume><elocation-id>aad3292</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad3292</pub-id><pub-id pub-id-type="pmid">26722002</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>HM</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Spielmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The newly discovered role of endocytosis in artemisinin resistance</article-title><source>Medicinal Research Reviews</source><volume>41</volume><fpage>2998</fpage><lpage>3022</lpage><pub-id pub-id-type="doi">10.1002/med.21848</pub-id><pub-id pub-id-type="pmid">34309894</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>HM</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Peigney</surname><given-names>D</given-names></name><name><surname>Sabitzki</surname><given-names>R</given-names></name><name><surname>Henshall</surname><given-names>I</given-names></name><name><surname>May</surname><given-names>J</given-names></name><name><surname>Maïga-Ascofaré</surname><given-names>O</given-names></name><name><surname>Spielmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Impact of different mutations on kelch13 protein levels, ART resistance and fitness cost in <italic>Plasmodium falciparum</italic> parasites</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.05.13.491767</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>HM</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Henshall</surname><given-names>IG</given-names></name><name><surname>López-Barona</surname><given-names>P</given-names></name><name><surname>Peigney</surname><given-names>D</given-names></name><name><surname>Sabitzki</surname><given-names>R</given-names></name><name><surname>May</surname><given-names>J</given-names></name><name><surname>Maïga-Ascofaré</surname><given-names>O</given-names></name><name><surname>Spielmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Impact of different mutations on Kelch13 protein levels, ART resistance, and fitness cost in <italic>Plasmodium falciparum</italic> parasites</article-title><source>mBio</source><volume>15</volume><elocation-id>e0198123</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.01981-23</pub-id><pub-id pub-id-type="pmid">38700363</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>Bisanzio</surname><given-names>D</given-names></name><name><surname>Yukich</surname><given-names>JO</given-names></name><name><surname>Mappin</surname><given-names>B</given-names></name><name><surname>Fergus</surname><given-names>CA</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name><name><surname>Cibulskis</surname><given-names>RE</given-names></name><name><surname>Bhatt</surname><given-names>S</given-names></name><name><surname>Weiss</surname><given-names>DJ</given-names></name><name><surname>Cameron</surname><given-names>E</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name><name><surname>Eisele</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and <italic>Plasmodium falciparum</italic> infection in Africa, 2003-2015: a modelling study using data from national surveys</article-title><source>The Lancet. Global Health</source><volume>5</volume><fpage>e418</fpage><lpage>e427</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30076-1</pub-id><pub-id pub-id-type="pmid">28288746</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Björkman Nyqvist</surname><given-names>M</given-names></name><name><surname>Svensson</surname><given-names>J</given-names></name><name><surname>Yanagizawa-Drott</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Can good products drive out bad? a randomized intervention in the antimalarial medicine market in Uganda</article-title><source>Journal of the European Economic Association</source><volume>20</volume><fpage>957</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1093/jeea/jvab053</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Laxminarayan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Benefits of using multiple first-line therapies against malaria</article-title><source>PNAS</source><volume>105</volume><fpage>14216</fpage><lpage>14221</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804628105</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boni</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Breaking the cycle of malaria treatment failure</article-title><source>Frontiers in Epidemiology</source><volume>2</volume><elocation-id>1041896</elocation-id><pub-id pub-id-type="doi">10.3389/fepid.2022.1041896</pub-id><pub-id pub-id-type="pmid">38455307</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnington</surname><given-names>CA</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Sriprawat</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>DM</given-names></name><name><surname>Proux</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Plasmodium falciparum</italic> kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin state, Myanmar</article-title><source>Malaria Journal</source><volume>16</volume><elocation-id>480</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-017-2128-x</pub-id><pub-id pub-id-type="pmid">29178921</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunditvorapoom</surname><given-names>D</given-names></name><name><surname>Kochakarn</surname><given-names>T</given-names></name><name><surname>Kotanan</surname><given-names>N</given-names></name><name><surname>Modchang</surname><given-names>C</given-names></name><name><surname>Kümpornsin</surname><given-names>K</given-names></name><name><surname>Loesbanluechai</surname><given-names>D</given-names></name><name><surname>Krasae</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Wilairat</surname><given-names>P</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Chookajorn</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fitness loss under amino acid starvation in Artemisinin-resistant <italic>Plasmodium falciparum</italic> isolates from Cambodia</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>12622</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-30593-5</pub-id><pub-id pub-id-type="pmid">30135481</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushman</surname><given-names>M</given-names></name><name><surname>Antia</surname><given-names>R</given-names></name><name><surname>Udhayakumar</surname><given-names>V</given-names></name><name><surname>de Roode</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Within-host competition can delay evolution of drug resistance in malaria</article-title><source>PLOS Biology</source><volume>16</volume><elocation-id>e2005712</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2005712</pub-id><pub-id pub-id-type="pmid">30130363</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bylicka-Szczepanowska</surname><given-names>E</given-names></name><name><surname>Korzeniewski</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Asymptomatic malaria infections in the time of COVID-19 pandemic: experience from the central African republic</article-title><source>International Journal of Environmental Research and Public Health</source><volume>19</volume><elocation-id>e3544</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19063544</pub-id><pub-id pub-id-type="pmid">35329229</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerqueira</surname><given-names>GC</given-names></name><name><surname>Cheeseman</surname><given-names>IH</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>McDew-White</surname><given-names>M</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Melnikov</surname><given-names>A</given-names></name><name><surname>Rogov</surname><given-names>P</given-names></name><name><surname>Birren</surname><given-names>BW</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>TJC</given-names></name><name><surname>Neafsey</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Longitudinal genomic surveillance of <italic>Plasmodium falciparum</italic> malaria parasites reveals complex genomic architecture of emerging artemisinin resistance</article-title><source>Genome Biology</source><volume>18</volume><elocation-id>e78</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-017-1204-4</pub-id><pub-id pub-id-type="pmid">28454557</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Hsiang</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Triple artemisinin-based combination therapies for malaria: a timely solution to counter antimalarial drug resistance</article-title><source>The Lancet Infectious Diseases</source><volume>22</volume><fpage>751</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00748-9</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churcher</surname><given-names>TS</given-names></name><name><surname>Trape</surname><given-names>JF</given-names></name><name><surname>Cohuet</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human-to-mosquito transmission efficiency increases as malaria is controlled</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6054</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7054</pub-id><pub-id pub-id-type="pmid">25597498</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Cotter</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Yamey</surname><given-names>G</given-names></name><name><surname>Sabot</surname><given-names>OJ</given-names></name><name><surname>Moonen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Malaria resurgence: a systematic review and assessment of its causes</article-title><source>Malaria Journal</source><volume>11</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-11-122</pub-id><pub-id pub-id-type="pmid">22531245</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>MD</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antimalarial drug resistance in Africa: the calm before the storm?</article-title><source>The Lancet. Infectious Diseases</source><volume>19</volume><fpage>e338</fpage><lpage>e351</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30261-0</pub-id><pub-id pub-id-type="pmid">31375467</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>MD</given-names></name><name><surname>Asua</surname><given-names>V</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Giesbrecht</surname><given-names>D</given-names></name><name><surname>Niaré</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Namuganga</surname><given-names>JF</given-names></name><name><surname>Katairo</surname><given-names>T</given-names></name><name><surname>Legac</surname><given-names>J</given-names></name><name><surname>Crudale</surname><given-names>RM</given-names></name><name><surname>Tumwebaze</surname><given-names>PK</given-names></name><name><surname>Nsobya</surname><given-names>SL</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Kamya</surname><given-names>MR</given-names></name><name><surname>Dorsey</surname><given-names>G</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Evolution of partial resistance to Artemisinins in malaria parasites in Uganda</article-title><source>The New England Journal of Medicine</source><volume>389</volume><fpage>722</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2211803</pub-id><pub-id pub-id-type="pmid">37611122</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulibaly</surname><given-names>A</given-names></name><name><surname>Diop</surname><given-names>MF</given-names></name><name><surname>Kone</surname><given-names>A</given-names></name><name><surname>Dara</surname><given-names>A</given-names></name><name><surname>Ouattara</surname><given-names>A</given-names></name><name><surname>Mulder</surname><given-names>N</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Diakite</surname><given-names>M</given-names></name><name><surname>Djimde</surname><given-names>A</given-names></name><name><surname>Amambua-Ngwa</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genome-wide SNP analysis of <italic>Plasmodium falciparum</italic> shows differentiation at drug-resistance-associated loci among malaria transmission settings in southern Mali</article-title><source>Frontiers in Genetics</source><volume>13</volume><elocation-id>943445</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.943445</pub-id><pub-id pub-id-type="pmid">36267403</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datoo</surname><given-names>MS</given-names></name><name><surname>Dicko</surname><given-names>A</given-names></name><name><surname>Tinto</surname><given-names>H</given-names></name><name><surname>Ouédraogo</surname><given-names>JB</given-names></name><name><surname>Hamaluba</surname><given-names>M</given-names></name><name><surname>Olotu</surname><given-names>A</given-names></name><name><surname>Beaumont</surname><given-names>E</given-names></name><name><surname>Ramos Lopez</surname><given-names>F</given-names></name><name><surname>Natama</surname><given-names>HM</given-names></name><name><surname>Weston</surname><given-names>S</given-names></name><name><surname>Chemba</surname><given-names>M</given-names></name><name><surname>Compaore</surname><given-names>YD</given-names></name><name><surname>Issiaka</surname><given-names>D</given-names></name><name><surname>Salou</surname><given-names>D</given-names></name><name><surname>Some</surname><given-names>AM</given-names></name><name><surname>Omenda</surname><given-names>S</given-names></name><name><surname>Lawrie</surname><given-names>A</given-names></name><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Rao</surname><given-names>H</given-names></name><name><surname>Chandramohan</surname><given-names>D</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Bharati</surname><given-names>S</given-names></name><name><surname>Stockdale</surname><given-names>L</given-names></name><name><surname>Gairola</surname><given-names>S</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Ewer</surname><given-names>KJ</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Kulkarni</surname><given-names>PS</given-names></name><name><surname>Shaligram</surname><given-names>U</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Mahamar</surname><given-names>A</given-names></name><name><surname>Sanogo</surname><given-names>K</given-names></name><name><surname>Sidibe</surname><given-names>Y</given-names></name><name><surname>Diarra</surname><given-names>K</given-names></name><name><surname>Samassekou</surname><given-names>M</given-names></name><name><surname>Attaher</surname><given-names>O</given-names></name><name><surname>Tapily</surname><given-names>A</given-names></name><name><surname>Diallo</surname><given-names>M</given-names></name><name><surname>Dicko</surname><given-names>OM</given-names></name><name><surname>Kaya</surname><given-names>M</given-names></name><name><surname>Maguiraga</surname><given-names>SO</given-names></name><name><surname>Sankare</surname><given-names>Y</given-names></name><name><surname>Yalcouye</surname><given-names>H</given-names></name><name><surname>Diarra</surname><given-names>S</given-names></name><name><surname>Niambele</surname><given-names>SM</given-names></name><name><surname>Thera</surname><given-names>I</given-names></name><name><surname>Sagara</surname><given-names>I</given-names></name><name><surname>Sylla</surname><given-names>M</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Misidai</surname><given-names>N</given-names></name><name><surname>Simando</surname><given-names>S</given-names></name><name><surname>Msami</surname><given-names>H</given-names></name><name><surname>Juma</surname><given-names>O</given-names></name><name><surname>Gutapaka</surname><given-names>N</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Mswata</surname><given-names>S</given-names></name><name><surname>Sasamalo</surname><given-names>I</given-names></name><name><surname>Johaness</surname><given-names>K</given-names></name><name><surname>Sultan</surname><given-names>M</given-names></name><name><surname>Alexander</surname><given-names>A</given-names></name><name><surname>Kimaro</surname><given-names>I</given-names></name><name><surname>Lwanga</surname><given-names>K</given-names></name><name><surname>Mtungwe</surname><given-names>M</given-names></name><name><surname>Khamis</surname><given-names>K</given-names></name><name><surname>Rugarabam</surname><given-names>L</given-names></name><name><surname>Kalinga</surname><given-names>W</given-names></name><name><surname>Mohammed</surname><given-names>M</given-names></name><name><surname>Kamange</surname><given-names>J</given-names></name><name><surname>Msangi</surname><given-names>J</given-names></name><name><surname>Mwaijande</surname><given-names>B</given-names></name><name><surname>Mtaka</surname><given-names>I</given-names></name><name><surname>Mhapa</surname><given-names>M</given-names></name><name><surname>Mlaganile</surname><given-names>T</given-names></name><name><surname>Mbaga</surname><given-names>T</given-names></name><name><surname>Yerbanga</surname><given-names>RS</given-names></name><name><surname>Samtouma</surname><given-names>W</given-names></name><name><surname>Sienou</surname><given-names>AA</given-names></name><name><surname>Kabre</surname><given-names>Z</given-names></name><name><surname>Ouedraogo</surname><given-names>WJM</given-names></name><name><surname>Yarbanga</surname><given-names>GAB</given-names></name><name><surname>Zongo</surname><given-names>I</given-names></name><name><surname>Savadogo</surname><given-names>H</given-names></name><name><surname>Sanon</surname><given-names>J</given-names></name><name><surname>Compaore</surname><given-names>J</given-names></name><name><surname>Kere</surname><given-names>I</given-names></name><name><surname>Yoni</surname><given-names>FL</given-names></name><name><surname>Sanre</surname><given-names>TM</given-names></name><name><surname>Ouattara</surname><given-names>SB</given-names></name><name><surname>Provstgaard-Morys</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>D</given-names></name><name><surname>Snow</surname><given-names>RW</given-names></name><name><surname>Amek</surname><given-names>N</given-names></name><name><surname>Ngetsa</surname><given-names>CJ</given-names></name><name><surname>Ochola-Oyier</surname><given-names>LI</given-names></name><name><surname>Musyoki</surname><given-names>J</given-names></name><name><surname>Munene</surname><given-names>M</given-names></name><name><surname>Mumba</surname><given-names>N</given-names></name><name><surname>Adetifa</surname><given-names>UJ</given-names></name><name><surname>Muiruri</surname><given-names>CM</given-names></name><name><surname>Mwawaka</surname><given-names>JS</given-names></name><name><surname>Mwaganyuma</surname><given-names>MH</given-names></name><name><surname>Ndichu</surname><given-names>MN</given-names></name><name><surname>Weya</surname><given-names>JO</given-names></name><name><surname>Njogu</surname><given-names>K</given-names></name><name><surname>Grant</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>J</given-names></name><name><surname>Lakhkar</surname><given-names>A</given-names></name><name><surname>Ido</surname><given-names>NFA</given-names></name><name><surname>Traore</surname><given-names>O</given-names></name><name><surname>Tahita</surname><given-names>MC</given-names></name><name><surname>Bonko</surname><given-names>MDA</given-names></name><name><surname>Rouamba</surname><given-names>T</given-names></name><name><surname>Ouedraogo</surname><given-names>DF</given-names></name><name><surname>Soma</surname><given-names>R</given-names></name><name><surname>Millogo</surname><given-names>A</given-names></name><name><surname>Ouedraogo</surname><given-names>E</given-names></name><name><surname>Sorgho</surname><given-names>F</given-names></name><name><surname>Konate</surname><given-names>F</given-names></name><name><surname>Valea</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial</article-title><source>The Lancet</source><volume>403</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02511-4</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Haan</surname><given-names>F</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Thi</surname><given-names>VAC</given-names></name><name><surname>Orng</surname><given-names>LH</given-names></name><name><surname>Vonglokham</surname><given-names>M</given-names></name><name><surname>Quang</surname><given-names>TN</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>Boon</surname><given-names>WPC</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Moors</surname><given-names>EHM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion</article-title><source>Malaria Journal</source><volume>22</volume><elocation-id>261</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-023-04666-4</pub-id><pub-id pub-id-type="pmid">37674172</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Laurent</surname><given-names>ZR</given-names></name><name><surname>Chebon</surname><given-names>LJ</given-names></name><name><surname>Ingasia</surname><given-names>LA</given-names></name><name><surname>Akala</surname><given-names>HM</given-names></name><name><surname>Andagalu</surname><given-names>B</given-names></name><name><surname>Ochola-Oyier</surname><given-names>LI</given-names></name><name><surname>Kamau</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Polymorphisms in the K13 Gene in <italic>Plasmodium falciparum</italic> from different malaria transmission areas of Kenya</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>98</volume><fpage>1360</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.17-0505</pub-id><pub-id pub-id-type="pmid">29582728</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demas</surname><given-names>AR</given-names></name><name><surname>Sharma</surname><given-names>AI</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Early</surname><given-names>AM</given-names></name><name><surname>Redmond</surname><given-names>S</given-names></name><name><surname>Bopp</surname><given-names>S</given-names></name><name><surname>Neafsey</surname><given-names>DE</given-names></name><name><surname>Volkman</surname><given-names>SK</given-names></name><name><surname>Hartl</surname><given-names>DL</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutations in <italic>Plasmodium falciparum</italic> actin-binding protein coronin confer reduced artemisinin susceptibility</article-title><source>PNAS</source><volume>115</volume><fpage>12799</fpage><lpage>12804</lpage><pub-id pub-id-type="doi">10.1073/pnas.1812317115</pub-id><pub-id pub-id-type="pmid">30420498</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>A</given-names></name><name><surname>Komatsu</surname><given-names>R</given-names></name><name><surname>Kc</surname><given-names>A</given-names></name><name><surname>Mshamu</surname><given-names>S</given-names></name><name><surname>Gesase</surname><given-names>S</given-names></name><name><surname>Kapologwe</surname><given-names>N</given-names></name><name><surname>Assefa</surname><given-names>A</given-names></name><name><surname>Opigo</surname><given-names>J</given-names></name><name><surname>Adoke</surname><given-names>Y</given-names></name><name><surname>Ebong</surname><given-names>C</given-names></name><name><surname>Karema</surname><given-names>C</given-names></name><name><surname>Uwimana</surname><given-names>A</given-names></name><name><surname>Mangara</surname><given-names>J-LN</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Callery</surname><given-names>JJ</given-names></name><name><surname>Adhikari</surname><given-names>B</given-names></name><name><surname>Mukaka</surname><given-names>M</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Mutesa</surname><given-names>L</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Barnes</surname><given-names>KI</given-names></name><name><surname>Dondorp</surname><given-names>A</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Artemisinin-resistant malaria in Africa demands urgent action</article-title><source>Science</source><volume>385</volume><fpage>252</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1126/science.adp5137</pub-id><pub-id pub-id-type="pmid">39024426</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimbu</surname><given-names>PR</given-names></name><name><surname>Horth</surname><given-names>R</given-names></name><name><surname>Cândido</surname><given-names>ALM</given-names></name><name><surname>Ferreira</surname><given-names>CM</given-names></name><name><surname>Caquece</surname><given-names>F</given-names></name><name><surname>Garcia</surname><given-names>LEA</given-names></name><name><surname>André</surname><given-names>K</given-names></name><name><surname>Pembele</surname><given-names>G</given-names></name><name><surname>Jandondo</surname><given-names>D</given-names></name><name><surname>Bondo</surname><given-names>BJ</given-names></name><name><surname>Nieto Andrade</surname><given-names>B</given-names></name><name><surname>Labuda</surname><given-names>S</given-names></name><name><surname>Ponce de León</surname><given-names>G</given-names></name><name><surname>Kelley</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Svigel</surname><given-names>SS</given-names></name><name><surname>Talundzic</surname><given-names>E</given-names></name><name><surname>Lucchi</surname><given-names>N</given-names></name><name><surname>Morais</surname><given-names>JFM</given-names></name><name><surname>Fortes</surname><given-names>F</given-names></name><name><surname>Martins</surname><given-names>JF</given-names></name><name><surname>Pluciński</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Continued low efficacy of artemether-lumefantrine in Angola in 2019</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>65</volume><elocation-id>e01949</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01949-20</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimbu</surname><given-names>PR</given-names></name><name><surname>Labuda</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>CM</given-names></name><name><surname>Caquece</surname><given-names>F</given-names></name><name><surname>André</surname><given-names>K</given-names></name><name><surname>Pembele</surname><given-names>G</given-names></name><name><surname>Pode</surname><given-names>D</given-names></name><name><surname>João</surname><given-names>MF</given-names></name><name><surname>Pelenda</surname><given-names>VM</given-names></name><name><surname>Nieto Andrade</surname><given-names>B</given-names></name><name><surname>Horton</surname><given-names>B</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>Svigel</surname><given-names>SS</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Morais</surname><given-names>JFM</given-names></name><name><surname>Rosário</surname><given-names>J do</given-names></name><name><surname>Fortes</surname><given-names>F</given-names></name><name><surname>Martins</surname><given-names>JF</given-names></name><name><surname>Plucinski</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Therapeutic response to four artemisinin-based combination therapies in Angola, 2021</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>68</volume><elocation-id>e01525</elocation-id><pub-id pub-id-type="doi">10.1128/aac.01525-23</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>D</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Tarning</surname><given-names>J</given-names></name><name><surname>Lwin</surname><given-names>KM</given-names></name><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Hanpithakpong</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Silamut</surname><given-names>K</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Herdman</surname><given-names>T</given-names></name><name><surname>An</surname><given-names>SS</given-names></name><name><surname>Yeung</surname><given-names>S</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Lindegardh</surname><given-names>N</given-names></name><name><surname>Socheat</surname><given-names>D</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Artemisinin resistance in <italic>Plasmodium falciparum</italic> malaria</article-title><source>The New England Journal of Medicine</source><volume>361</volume><fpage>455</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0808859</pub-id><pub-id pub-id-type="pmid">19641202</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doolan</surname><given-names>DL</given-names></name><name><surname>Dobaño</surname><given-names>C</given-names></name><name><surname>Baird</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Acquired immunity to malaria</article-title><source>Clinical Microbiology Reviews</source><volume>22</volume><fpage>13</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1128/CMR.00025-08</pub-id><pub-id pub-id-type="pmid">19136431</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffey</surname><given-names>M</given-names></name><name><surname>Blasco</surname><given-names>B</given-names></name><name><surname>Burrows</surname><given-names>JN</given-names></name><name><surname>Wells</surname><given-names>TNC</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Leroy</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Assessing risks of <italic>Plasmodium falciparum</italic> resistance to select next-generation antimalarials</article-title><source>Trends in Parasitology</source><volume>37</volume><fpage>709</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2021.04.006</pub-id><pub-id pub-id-type="pmid">34001441</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebong</surname><given-names>C</given-names></name><name><surname>Sserwanga</surname><given-names>A</given-names></name><name><surname>Namuganga</surname><given-names>JF</given-names></name><name><surname>Kapisi</surname><given-names>J</given-names></name><name><surname>Mpimbaza</surname><given-names>A</given-names></name><name><surname>Gonahasa</surname><given-names>S</given-names></name><name><surname>Asua</surname><given-names>V</given-names></name><name><surname>Gudoi</surname><given-names>S</given-names></name><name><surname>Kigozi</surname><given-names>R</given-names></name><name><surname>Tibenderana</surname><given-names>J</given-names></name><name><surname>Bwanika</surname><given-names>JB</given-names></name><name><surname>Bosco</surname><given-names>A</given-names></name><name><surname>Rubahika</surname><given-names>D</given-names></name><name><surname>Kyabayinze</surname><given-names>D</given-names></name><name><surname>Opigo</surname><given-names>J</given-names></name><name><surname>Rutazana</surname><given-names>D</given-names></name><name><surname>Sebikaari</surname><given-names>G</given-names></name><name><surname>Belay</surname><given-names>K</given-names></name><name><surname>Niang</surname><given-names>M</given-names></name><name><surname>Halsey</surname><given-names>ES</given-names></name><name><surname>Moriarty</surname><given-names>LF</given-names></name><name><surname>Lucchi</surname><given-names>NW</given-names></name><name><surname>Souza</surname><given-names>SSS</given-names></name><name><surname>Nsobya</surname><given-names>SL</given-names></name><name><surname>Kamya</surname><given-names>MR</given-names></name><name><surname>Yeka</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated <italic>Plasmodium falciparum</italic> malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda</article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>e484</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-04021-5</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhunse</surname><given-names>N</given-names></name><name><surname>Sahal</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures</article-title><source>Journal of Pharmaceutical Analysis</source><volume>11</volume><fpage>541</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.07.005</pub-id><pub-id pub-id-type="pmid">34765267</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fola</surname><given-names>AA</given-names></name><name><surname>Feleke</surname><given-names>SM</given-names></name><name><surname>Mohammed</surname><given-names>H</given-names></name><name><surname>Brhane</surname><given-names>BG</given-names></name><name><surname>Hennelly</surname><given-names>CM</given-names></name><name><surname>Assefa</surname><given-names>A</given-names></name><name><surname>Crudal</surname><given-names>RM</given-names></name><name><surname>Reichert</surname><given-names>E</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name><name><surname>Cunningham</surname><given-names>J</given-names></name><name><surname>Mamo</surname><given-names>H</given-names></name><name><surname>Solomon</surname><given-names>H</given-names></name><name><surname>Tasew</surname><given-names>G</given-names></name><name><surname>Petros</surname><given-names>B</given-names></name><name><surname>Parr</surname><given-names>JB</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title><italic>Plasmodium falciparum</italic> resistant to artemisinin and diagnostics have emerged in Ethiopia</article-title><source>Nature Microbiology</source><volume>8</volume><fpage>1911</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01461-4</pub-id><pub-id pub-id-type="pmid">37640962</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gansané</surname><given-names>A</given-names></name><name><surname>Moriarty</surname><given-names>LF</given-names></name><name><surname>Ménard</surname><given-names>D</given-names></name><name><surname>Yerbanga</surname><given-names>I</given-names></name><name><surname>Ouedraogo</surname><given-names>E</given-names></name><name><surname>Sondo</surname><given-names>P</given-names></name><name><surname>Kinda</surname><given-names>R</given-names></name><name><surname>Tarama</surname><given-names>C</given-names></name><name><surname>Soulama</surname><given-names>E</given-names></name><name><surname>Tapsoba</surname><given-names>M</given-names></name><name><surname>Kangoye</surname><given-names>D</given-names></name><name><surname>Compaore</surname><given-names>CS</given-names></name><name><surname>Badolo</surname><given-names>O</given-names></name><name><surname>Dao</surname><given-names>B</given-names></name><name><surname>Tchwenko</surname><given-names>S</given-names></name><name><surname>Tinto</surname><given-names>H</given-names></name><name><surname>Valea</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018</article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-03585-6</pub-id><pub-id pub-id-type="pmid">33468147</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregson</surname><given-names>A</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mechanisms of resistance of malaria parasites to antifolates</article-title><source>Pharmacological Reviews</source><volume>57</volume><fpage>117</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1124/pr.57.1.4</pub-id><pub-id pub-id-type="pmid">15734729</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillot</surname><given-names>C</given-names></name><name><surname>Bouchard</surname><given-names>C</given-names></name><name><surname>Aenishaenslin</surname><given-names>C</given-names></name><name><surname>Berthiaume</surname><given-names>P</given-names></name><name><surname>Milord</surname><given-names>F</given-names></name><name><surname>Leighton</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Criteria for selecting sentinel unit locations in a surveillance system for vector-borne disease: A decision tool</article-title><source>Frontiers in Public Health</source><volume>10</volume><elocation-id>1003949</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.1003949</pub-id><pub-id pub-id-type="pmid">36438246</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hailu</surname><given-names>A</given-names></name><name><surname>Lindtjørn</surname><given-names>B</given-names></name><name><surname>Deressa</surname><given-names>W</given-names></name><name><surname>Gari</surname><given-names>T</given-names></name><name><surname>Loha</surname><given-names>E</given-names></name><name><surname>Robberstad</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Economic burden of malaria and predictors of cost variability to rural households in south-central Ethiopia</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0185315</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185315</pub-id><pub-id pub-id-type="pmid">29020063</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>WL</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Quang</surname><given-names>HH</given-names></name><name><surname>Thuy-Nhien</surname><given-names>NT</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Hongvanthong</surname><given-names>B</given-names></name><name><surname>Chindavongsa</surname><given-names>K</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Huy</surname><given-names>R</given-names></name><name><surname>Leang</surname><given-names>R</given-names></name><name><surname>Huch</surname><given-names>C</given-names></name><name><surname>Dysoley</surname><given-names>L</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>Sovann</surname><given-names>Y</given-names></name><name><surname>Jittamala</surname><given-names>P</given-names></name><name><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Chau</surname><given-names>NH</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Vongpromek</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>XHS</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Rockett</surname><given-names>K</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Gonçalves</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study</article-title><source>The Lancet. Infectious Diseases</source><volume>19</volume><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30392-5</pub-id><pub-id pub-id-type="pmid">31345709</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>WL</given-names></name><name><surname>Ishengoma</surname><given-names>DS</given-names></name><name><surname>Parr</surname><given-names>JB</given-names></name><name><surname>Bridges</surname><given-names>DJ</given-names></name><name><surname>Barry</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Nanopore sequencing for malaria molecular surveillance: opportunities and challenges</article-title><source>Trends in Parasitology</source><volume>39</volume><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2023.09.014</pub-id><pub-id pub-id-type="pmid">37865609</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Advances and roadblocks in the treatment of malaria</article-title><source>British Journal of Clinical Pharmacology</source><volume>88</volume><fpage>374</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1111/bcp.14474</pub-id><pub-id pub-id-type="pmid">32656850</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassett</surname><given-names>MR</given-names></name><name><surname>Roepe</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Origin and spread of evolving artemisinin-resistant <italic>Plasmodium falciparum</italic> malarial parasites in Southeast Asia</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>101</volume><fpage>1204</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.19-0379</pub-id><pub-id pub-id-type="pmid">31642425</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Chaillet</surname><given-names>JK</given-names></name><name><surname>Labbé</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Antigenic strain diversity predicts different biogeographic patterns of maintenance and decline of antimalarial drug resistance</article-title><source>eLife</source><volume>12</volume><elocation-id>RP90888</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.90888</pub-id><pub-id pub-id-type="pmid">38363295</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>LE</given-names></name><name><surname>Goggins</surname><given-names>E</given-names></name><name><surname>Roepe</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Dihydroartemisinin-Ferriprotoporphyrin IX adduct abundance in <italic>Plasmodium falciparum</italic> malarial parasites and the relationship to emerging artemisinin resistance</article-title><source>Biochemistry</source><volume>57</volume><fpage>6935</fpage><lpage>6945</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b00960</pub-id><pub-id pub-id-type="pmid">30512926</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>LE</given-names></name><name><surname>Roepe</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Quantification of free Ferriprotoporphyrin IX Heme and Hemozoin for Artemisinin sensitive versus delayed clearance phenotype <italic>Plasmodium falciparum</italic> malarial parasites</article-title><source>Biochemistry</source><volume>57</volume><fpage>6927</fpage><lpage>6934</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b00959</pub-id><pub-id pub-id-type="pmid">30513202</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henden</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Barry</surname><given-names>A</given-names></name><name><surname>Bahlo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identity-by-descent analyses for measuring population dynamics and selection in recombining pathogens</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007279</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007279</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriques</surname><given-names>G</given-names></name><name><surname>Hallett</surname><given-names>RL</given-names></name><name><surname>Beshir</surname><given-names>KB</given-names></name><name><surname>Gadalla</surname><given-names>NB</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Burrow</surname><given-names>R</given-names></name><name><surname>van Schalkwyk</surname><given-names>DA</given-names></name><name><surname>Sawa</surname><given-names>P</given-names></name><name><surname>Omar</surname><given-names>SA</given-names></name><name><surname>Clark</surname><given-names>TG</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Sutherland</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of <italic>Plasmodium falciparum</italic> in Kenyan children treated with ACT</article-title><source>The Journal of Infectious Diseases</source><volume>210</volume><fpage>2001</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu358</pub-id><pub-id pub-id-type="pmid">24994911</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Tachibana</surname><given-names>S-I</given-names></name><name><surname>Balikagala</surname><given-names>B</given-names></name><name><surname>Sakurai-Yatsushiro</surname><given-names>M</given-names></name><name><surname>Yatsushiro</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Sekihara</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Katuro</surname><given-names>OT</given-names></name><name><surname>Olia</surname><given-names>A</given-names></name><name><surname>Obwoya</surname><given-names>PS</given-names></name><name><surname>Auma</surname><given-names>MA</given-names></name><name><surname>Anywar</surname><given-names>DA</given-names></name><name><surname>Odongo-Aginya</surname><given-names>EI</given-names></name><name><surname>Okello-Onen</surname><given-names>J</given-names></name><name><surname>Hirai</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Palacpac</surname><given-names>NMQ</given-names></name><name><surname>Kataoka</surname><given-names>M</given-names></name><name><surname>Tsuboi</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>E</given-names></name><name><surname>Horii</surname><given-names>T</given-names></name><name><surname>Mita</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Artemisinin-resistant <italic>Plasmodium falciparum</italic> with high survival rates, Uganda, 2014-2016</article-title><source>Emerging Infectious Diseases</source><volume>24</volume><fpage>718</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.3201/eid2404.170141</pub-id><pub-id pub-id-type="pmid">29553316</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Suwannasin</surname><given-names>K</given-names></name><name><surname>Kunasol</surname><given-names>C</given-names></name><name><surname>Sutawong</surname><given-names>K</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Rekol</surname><given-names>H</given-names></name><name><surname>Smithuis</surname><given-names>FM</given-names></name><name><surname>Hlaing</surname><given-names>TM</given-names></name><name><surname>Tun</surname><given-names>KM</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The spread of artemisinin-resistant <italic>Plasmodium falciparum</italic> in the Greater Mekong subregion: a molecular epidemiology observational study</article-title><source>The Lancet. Infectious Diseases</source><volume>17</volume><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30048-8</pub-id><pub-id pub-id-type="pmid">28161569</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Myo Tun</surname><given-names>K</given-names></name><name><surname>Thu</surname><given-names>AM</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Proux</surname><given-names>S</given-names></name><name><surname>Suwannasin</surname><given-names>K</given-names></name><name><surname>Kunasol</surname><given-names>C</given-names></name><name><surname>Srisutham</surname><given-names>S</given-names></name><name><surname>Duanguppama</surname><given-names>J</given-names></name><name><surname>Vongpromek</surname><given-names>R</given-names></name><name><surname>Promnarate</surname><given-names>C</given-names></name><name><surname>Saejeng</surname><given-names>A</given-names></name><name><surname>Khantikul</surname><given-names>N</given-names></name><name><surname>Sugaram</surname><given-names>R</given-names></name><name><surname>Thanapongpichat</surname><given-names>S</given-names></name><name><surname>Sawangjaroen</surname><given-names>N</given-names></name><name><surname>Sutawong</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>KT</given-names></name><name><surname>Htut</surname><given-names>Y</given-names></name><name><surname>Linn</surname><given-names>K</given-names></name><name><surname>Win</surname><given-names>AA</given-names></name><name><surname>Hlaing</surname><given-names>TM</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Pongvongsa</surname><given-names>T</given-names></name><name><surname>Phommasone</surname><given-names>K</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Nguon</surname><given-names>C</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>XHS</given-names></name><name><surname>Rekol</surname><given-names>H</given-names></name><name><surname>Leang</surname><given-names>R</given-names></name><name><surname>Huch</surname><given-names>C</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Kyaw</surname><given-names>MP</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Smithuis</surname><given-names>FM</given-names></name><name><surname>Nosten</surname><given-names>FH</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular epidemiology of resistance to antimalarial drugs in the greater Mekong subregion: an observational study</article-title><source>The Lancet. Infectious Diseases</source><volume>20</volume><fpage>1470</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30228-0</pub-id><pub-id pub-id-type="pmid">32679084</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ippolito</surname><given-names>MM</given-names></name><name><surname>Pringle</surname><given-names>JC</given-names></name><name><surname>Siame</surname><given-names>M</given-names></name><name><surname>Katowa</surname><given-names>B</given-names></name><name><surname>Aydemir</surname><given-names>O</given-names></name><name><surname>Oluoch</surname><given-names>PO</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Aweeka</surname><given-names>FT</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name><name><surname>Meshnick</surname><given-names>SR</given-names></name><name><surname>Shapiro</surname><given-names>TA</given-names></name><name><surname>Moss</surname><given-names>WJ</given-names></name><name><surname>Thuma</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Therapeutic efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in Northern Zambia</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>103</volume><fpage>2224</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.20-0852</pub-id><pub-id pub-id-type="pmid">33078701</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishengoma</surname><given-names>DS</given-names></name><name><surname>Saidi</surname><given-names>Q</given-names></name><name><surname>Sibley</surname><given-names>CH</given-names></name><name><surname>Roper</surname><given-names>C</given-names></name><name><surname>Alifrangis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Deployment and utilization of next-generation sequencing of <italic>Plasmodium falciparum</italic> to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges</article-title><source>Malaria Journal</source><volume>18</volume><elocation-id>e267</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-019-2853-4</pub-id><pub-id pub-id-type="pmid">31477109</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ishengoma</surname><given-names>DS</given-names></name><name><surname>Mandara</surname><given-names>CL</given-names></name><name><surname>Bakari</surname><given-names>C</given-names></name><name><surname>Fola</surname><given-names>AA</given-names></name><name><surname>Madebe</surname><given-names>R</given-names></name><name><surname>Seth</surname><given-names>MD</given-names></name><name><surname>Francis</surname><given-names>F</given-names></name><name><surname>Buguzi</surname><given-names>C</given-names></name><name><surname>Moshi</surname><given-names>R</given-names></name><name><surname>Garimo</surname><given-names>I</given-names></name><name><surname>Lazaro</surname><given-names>S</given-names></name><name><surname>Lusasi</surname><given-names>A</given-names></name><name><surname>Aaron</surname><given-names>S</given-names></name><name><surname>Chacky</surname><given-names>F</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Njau</surname><given-names>RJ</given-names></name><name><surname>Kitau</surname><given-names>J</given-names></name><name><surname>Rasmussen</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name><name><surname>Warsame</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Evidence of artemisinin partial resistance in North-Western Tanzania: clinical and drug resistance markers study</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2024.01.31.24301954</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Thuy-Nhien</surname><given-names>N</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Quang</surname><given-names>HH</given-names></name><name><surname>Hongvanthong</surname><given-names>B</given-names></name><name><surname>Vanisaveth</surname><given-names>V</given-names></name><name><surname>Ngo Duc</surname><given-names>T</given-names></name><name><surname>Rekol</surname><given-names>H</given-names></name><name><surname>van der Pluijm</surname><given-names>R</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Fairhurst</surname><given-names>R</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Hossain</surname><given-names>MA</given-names></name><name><surname>Park</surname><given-names>N</given-names></name><name><surname>Goodwin</surname><given-names>S</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Chindavongsa</surname><given-names>K</given-names></name><name><surname>Newton</surname><given-names>P</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Phalivong</surname><given-names>S</given-names></name><name><surname>Maude</surname><given-names>R</given-names></name><name><surname>Leang</surname><given-names>R</given-names></name><name><surname>Huch</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>LT</given-names></name><name><surname>Nguyen</surname><given-names>K-T</given-names></name><name><surname>Nhat</surname><given-names>TM</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Zdrojewski</surname><given-names>N</given-names></name><name><surname>Canavati</surname><given-names>S</given-names></name><name><surname>Sayeed</surname><given-names>AA</given-names></name><name><surname>Uddin</surname><given-names>D</given-names></name><name><surname>Buckee</surname><given-names>C</given-names></name><name><surname>Fanello</surname><given-names>CI</given-names></name><name><surname>Onyamboko</surname><given-names>M</given-names></name><name><surname>Peto</surname><given-names>T</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Myint Thu</surname><given-names>A</given-names></name><name><surname>Delmas</surname><given-names>G</given-names></name><name><surname>Landier</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>DM</given-names></name><name><surname>Chau</surname><given-names>NH</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Callery</surname><given-names>J</given-names></name><name><surname>Jittamala</surname><given-names>P</given-names></name><name><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Smithuis</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Thant</surname><given-names>M</given-names></name><name><surname>Hlaing</surname><given-names>TM</given-names></name><name><surname>Satpathi</surname><given-names>P</given-names></name><name><surname>Satpathi</surname><given-names>S</given-names></name><name><surname>Behera</surname><given-names>PK</given-names></name><name><surname>Tripura</surname><given-names>A</given-names></name><name><surname>Baidya</surname><given-names>S</given-names></name><name><surname>Valecha</surname><given-names>N</given-names></name><name><surname>Anvikar</surname><given-names>AR</given-names></name><name><surname>Ul Islam</surname><given-names>A</given-names></name><name><surname>Faiz</surname><given-names>A</given-names></name><name><surname>Kunasol</surname><given-names>C</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Kekre</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Love</surname><given-names>K</given-names></name><name><surname>Rajatileka</surname><given-names>S</given-names></name><name><surname>Jeffreys</surname><given-names>AE</given-names></name><name><surname>Rowlands</surname><given-names>K</given-names></name><name><surname>Hubbart</surname><given-names>CS</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Vongpromek</surname><given-names>R</given-names></name><name><surname>Kotanan</surname><given-names>N</given-names></name><name><surname>Wongnak</surname><given-names>P</given-names></name><name><surname>Almagro Garcia</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Ariani</surname><given-names>CV</given-names></name><name><surname>Chookajorn</surname><given-names>T</given-names></name><name><surname>Malangone</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Stalker</surname><given-names>J</given-names></name><name><surname>Jeffery</surname><given-names>B</given-names></name><name><surname>Keatley</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>KJ</given-names></name><name><surname>Muddyman</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>XHS</given-names></name><name><surname>Sillitoe</surname><given-names>J</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Simpson</surname><given-names>V</given-names></name><name><surname>Gonçalves</surname><given-names>S</given-names></name><name><surname>Rockett</surname><given-names>K</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination</article-title><source>eLife</source><volume>10</volume><elocation-id>e62997</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.62997</pub-id><pub-id pub-id-type="pmid">34372970</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalei</surname><given-names>AA</given-names></name><name><surname>Na-Bangchang</surname><given-names>K</given-names></name><name><surname>Muhamad</surname><given-names>P</given-names></name><name><surname>Chaijaroenkul</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Monitoring antimalarial drug-resistance markers in Somalia</article-title><source>Parasites, Hosts and Diseases</source><volume>61</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3347/PHD.22140</pub-id><pub-id pub-id-type="pmid">37170467</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeang</surname><given-names>B</given-names></name><name><surname>Zhong</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Atieli</surname><given-names>H</given-names></name><name><surname>Yewhalaw</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Molecular surveillance of Kelch 13 polymorphisms in <italic>Plasmodium falciparum</italic> isolates from Kenya and Ethiopia</article-title><source>Malaria Journal</source><volume>23</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-023-04812-y</pub-id><pub-id pub-id-type="pmid">38287365</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagoro</surname><given-names>FM</given-names></name><name><surname>Barnes</surname><given-names>KI</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Ekapirat</surname><given-names>N</given-names></name><name><surname>Mercado</surname><given-names>CEG</given-names></name><name><surname>Sinha</surname><given-names>I</given-names></name><name><surname>Humphreys</surname><given-names>G</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Guerin</surname><given-names>PJ</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mapping genetic markers of artemisinin resistance in <italic>Plasmodium falciparum</italic> malaria in Asia: a systematic review and spatiotemporal analysis</article-title><source>The Lancet. Microbe</source><volume>3</volume><fpage>e184</fpage><lpage>e192</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00249-4</pub-id><pub-id pub-id-type="pmid">35265869</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayiba</surname><given-names>NK</given-names></name><name><surname>Yobi</surname><given-names>DM</given-names></name><name><surname>Tshibangu-Kabamba</surname><given-names>E</given-names></name><name><surname>Tuan</surname><given-names>VP</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Devleesschauwer</surname><given-names>B</given-names></name><name><surname>Mvumbi</surname><given-names>DM</given-names></name><name><surname>Okitolonda Wemakoy</surname><given-names>E</given-names></name><name><surname>De Mol</surname><given-names>P</given-names></name><name><surname>Mvumbi</surname><given-names>GL</given-names></name><name><surname>Hayette</surname><given-names>M-P</given-names></name><name><surname>Rosas-Aguirre</surname><given-names>A</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging <italic>Plasmodium falciparum</italic> resistance to artemisinin: a systematic review</article-title><source>The Lancet. Infectious Diseases</source><volume>21</volume><fpage>e82</fpage><lpage>e92</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30493-X</pub-id><pub-id pub-id-type="pmid">33125913</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobasa</surname><given-names>T</given-names></name><name><surname>Talundzic</surname><given-names>E</given-names></name><name><surname>Sug-aram</surname><given-names>R</given-names></name><name><surname>Boondat</surname><given-names>P</given-names></name><name><surname>Goldman</surname><given-names>IF</given-names></name><name><surname>Lucchi</surname><given-names>NW</given-names></name><name><surname>Dharmarak</surname><given-names>P</given-names></name><name><surname>Sintasath</surname><given-names>D</given-names></name><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Whistler</surname><given-names>T</given-names></name><name><surname>MacArthur</surname><given-names>J</given-names></name><name><surname>Udhayakumar</surname><given-names>V</given-names></name><name><surname>Prempree</surname><given-names>P</given-names></name><name><surname>Chinanonwait</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Emergence and spread of <italic>kelch13</italic> mutations associated with artemisinin resistance in <italic>Plasmodium falciparum</italic> parasites in 12 Thai Provinces from 2007 to 2016</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>62</volume><elocation-id>e02141</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.02141-17</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokori</surname><given-names>E</given-names></name><name><surname>Olatunji</surname><given-names>G</given-names></name><name><surname>Akinboade</surname><given-names>A</given-names></name><name><surname>Akinoso</surname><given-names>A</given-names></name><name><surname>Egbunu</surname><given-names>E</given-names></name><name><surname>Aremu</surname><given-names>SA</given-names></name><name><surname>Okafor</surname><given-names>CE</given-names></name><name><surname>Oluwole</surname><given-names>O</given-names></name><name><surname>Aderinto</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts</article-title><source>Malaria Journal</source><volume>23</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-024-04844-y</pub-id><pub-id pub-id-type="pmid">38238781</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Ünlü</surname><given-names>ES</given-names></name><name><surname>White</surname><given-names>NFD</given-names></name><name><surname>Almagro-Garcia</surname><given-names>J</given-names></name><name><surname>Ariani</surname><given-names>C</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Pf-HaploAtlas: an interactive web app for spatiotemporal analysis of <italic>P. falciparum</italic> Genes.</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.07.16.603783</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>EZ</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Tran</surname><given-names>TNA</given-names></name><name><surname>Zupko</surname><given-names>RJ</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Assessing emergence risk of double-resistant and triple-resistant genotypes of <italic>Plasmodium falciparum</italic></article-title><source>Nature Communications</source><volume>15</volume><elocation-id>e1390</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-45547-x</pub-id><pub-id pub-id-type="pmid">38360803</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubell</surname><given-names>Y</given-names></name><name><surname>Dondorp</surname><given-names>A</given-names></name><name><surname>Guérin</surname><given-names>PJ</given-names></name><name><surname>Drake</surname><given-names>T</given-names></name><name><surname>Meek</surname><given-names>S</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>White</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Artemisinin resistance--modelling the potential human and economic costs</article-title><source>Malaria Journal</source><volume>13</volume><elocation-id>e452</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-13-452</pub-id><pub-id pub-id-type="pmid">25418416</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyimo</surname><given-names>BM</given-names></name><name><surname>Popkin-Hall</surname><given-names>ZR</given-names></name><name><surname>Giesbrecht</surname><given-names>DJ</given-names></name><name><surname>Mandara</surname><given-names>CI</given-names></name><name><surname>Madebe</surname><given-names>RA</given-names></name><name><surname>Bakari</surname><given-names>C</given-names></name><name><surname>Pereus</surname><given-names>D</given-names></name><name><surname>Seth</surname><given-names>MD</given-names></name><name><surname>Ngamba</surname><given-names>RM</given-names></name><name><surname>Mbwambo</surname><given-names>RB</given-names></name><name><surname>MacInnis</surname><given-names>B</given-names></name><name><surname>Mbwambo</surname><given-names>D</given-names></name><name><surname>Garimo</surname><given-names>I</given-names></name><name><surname>Chacky</surname><given-names>F</given-names></name><name><surname>Aaron</surname><given-names>S</given-names></name><name><surname>Lusasi</surname><given-names>A</given-names></name><name><surname>Molteni</surname><given-names>F</given-names></name><name><surname>Njau</surname><given-names>R</given-names></name><name><surname>Cunningham</surname><given-names>JA</given-names></name><name><surname>Lazaro</surname><given-names>S</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Ishengoma</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Potential opportunities and challenges of deploying next generation sequencing and CRISPR-Cas systems to support diagnostics and surveillance towards malaria control and elimination in Africa</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>12</volume><elocation-id>e757844</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.757844</pub-id><pub-id pub-id-type="pmid">35909968</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzoni</surname><given-names>G</given-names></name><name><surname>Try</surname><given-names>R</given-names></name><name><surname>Guintran</surname><given-names>JO</given-names></name><name><surname>Christiansen-Jucht</surname><given-names>C</given-names></name><name><surname>Jacoby</surname><given-names>E</given-names></name><name><surname>Sovannaroth</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Banouvong</surname><given-names>V</given-names></name><name><surname>Shortus</surname><given-names>MS</given-names></name><name><surname>Reyburn</surname><given-names>R</given-names></name><name><surname>Chanthavisouk</surname><given-names>C</given-names></name><name><surname>Linn</surname><given-names>NYY</given-names></name><name><surname>Thapa</surname><given-names>B</given-names></name><name><surname>Khine</surname><given-names>SK</given-names></name><name><surname>Sudathip</surname><given-names>P</given-names></name><name><surname>Gopinath</surname><given-names>D</given-names></name><name><surname>Thieu</surname><given-names>NQ</given-names></name><name><surname>Ngon</surname><given-names>MS</given-names></name><name><surname>Cong</surname><given-names>DT</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Kelley</surname><given-names>J</given-names></name><name><surname>Valecha</surname><given-names>NNK</given-names></name><name><surname>Bustos</surname><given-names>MD</given-names></name><name><surname>Rasmussen</surname><given-names>C</given-names></name><name><surname>Tuseo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Progress towards malaria elimination in the Greater Mekong Subregion: perspectives from the World Health Organization</article-title><source>Malaria Journal</source><volume>23</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-024-04851-z</pub-id><pub-id pub-id-type="pmid">38429807</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>LC</given-names></name><name><surname>Cox</surname><given-names>H</given-names></name><name><surname>Early</surname><given-names>AM</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Lazrek</surname><given-names>Y</given-names></name><name><surname>Paquet</surname><given-names>J-C</given-names></name><name><surname>Ade</surname><given-names>M-P</given-names></name><name><surname>Lucchi</surname><given-names>NW</given-names></name><name><surname>Grant</surname><given-names>Q</given-names></name><name><surname>Udhayakumar</surname><given-names>V</given-names></name><name><surname>Alexandre</surname><given-names>JS</given-names></name><name><surname>Demar</surname><given-names>M</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Neafsey</surname><given-names>DE</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Musset</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Local emergence in Amazonia of <italic>Plasmodium falciparum k13</italic> C580Y mutants associated with <italic>in vitro</italic> artemisinin resistance</article-title><source>eLife</source><volume>9</volume><elocation-id>e51015</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51015</pub-id><pub-id pub-id-type="pmid">32394893</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayor</surname><given-names>A</given-names></name><name><surname>Ishengoma</surname><given-names>DS</given-names></name><name><surname>Proctor</surname><given-names>JL</given-names></name><name><surname>Verity</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Sampling for malaria molecular surveillance</article-title><source>Trends in Parasitology</source><volume>39</volume><fpage>954</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2023.08.007</pub-id><pub-id pub-id-type="pmid">37730525</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Meier-Scherling</surname><given-names>CPG</given-names></name><name><surname>Watson</surname><given-names>OJ</given-names></name><name><surname>Asua</surname><given-names>V</given-names></name><name><surname>Ghinai</surname><given-names>I</given-names></name><name><surname>Katairo</surname><given-names>T</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Conrad</surname><given-names>M</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Okell</surname><given-names>LC</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Selection of Artemisinin Partial Resistance Kelch13 Mutations in Uganda in 2016-22 Was at a Rate Comparable to That Seen Previously in South-East Asia</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2024.02.03.24302209</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mensah</surname><given-names>BA</given-names></name><name><surname>Akyea-Bobi</surname><given-names>NE</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genomic approaches for monitoring transmission dynamics of malaria: A case for malaria molecular surveillance in Sub-Saharan Africa</article-title><source>Frontiers in Epidemiology</source><volume>2</volume><elocation-id>e939291</elocation-id><pub-id pub-id-type="doi">10.3389/fepid.2022.939291</pub-id><pub-id pub-id-type="pmid">38455324</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesén-Ramírez</surname><given-names>P</given-names></name><name><surname>Bergmann</surname><given-names>B</given-names></name><name><surname>Elhabiri</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>von Thien</surname><given-names>H</given-names></name><name><surname>Castro-Peña</surname><given-names>C</given-names></name><name><surname>Gilberger</surname><given-names>T-W</given-names></name><name><surname>Davioud-Charvet</surname><given-names>E</given-names></name><name><surname>Bozdech</surname><given-names>Z</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name><name><surname>Spielmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The parasitophorous vacuole nutrient channel is critical for drug access in malaria parasites and modulates the artemisinin resistance fitness cost</article-title><source>Cell Host &amp; Microbe</source><volume>29</volume><fpage>1774</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.11.002</pub-id><pub-id pub-id-type="pmid">34863371</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihreteab</surname><given-names>S</given-names></name><name><surname>Platon</surname><given-names>L</given-names></name><name><surname>Berhane</surname><given-names>A</given-names></name><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Warsame</surname><given-names>M</given-names></name><name><surname>Campagne</surname><given-names>P</given-names></name><name><surname>Criscuolo</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Petiot</surname><given-names>N</given-names></name><name><surname>Doderer-Lang</surname><given-names>C</given-names></name><name><surname>Legrand</surname><given-names>E</given-names></name><name><surname>Ward</surname><given-names>KE</given-names></name><name><surname>Zehaie Kassahun</surname><given-names>A</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Ménard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Increasing prevalence of artemisinin-resistant HRP2-negative malaria in eritrea</article-title><source>New England Journal of Medicine</source><volume>389</volume><fpage>1191</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2210956</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Almagro-Garcia</surname><given-names>J</given-names></name><name><surname>Manske</surname><given-names>M</given-names></name><name><surname>Macinnis</surname><given-names>B</given-names></name><name><surname>Campino</surname><given-names>S</given-names></name><name><surname>Rockett</surname><given-names>KA</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JM</given-names></name><name><surname>Duong</surname><given-names>S</given-names></name><name><surname>Nguon</surname><given-names>C</given-names></name><name><surname>Chuor</surname><given-names>CM</given-names></name><name><surname>Saunders</surname><given-names>D</given-names></name><name><surname>Se</surname><given-names>Y</given-names></name><name><surname>Lon</surname><given-names>C</given-names></name><name><surname>Fukuda</surname><given-names>MM</given-names></name><name><surname>Amenga-Etego</surname><given-names>L</given-names></name><name><surname>Hodgson</surname><given-names>AVO</given-names></name><name><surname>Asoala</surname><given-names>V</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Takala-Harrison</surname><given-names>S</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>X-Z</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Dolecek</surname><given-names>C</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Thai</surname><given-names>CQ</given-names></name><name><surname>Amambua-Ngwa</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><name><surname>Djimdé</surname><given-names>AA</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Zongo</surname><given-names>I</given-names></name><name><surname>Ouedraogo</surname><given-names>J-B</given-names></name><name><surname>Alcock</surname><given-names>D</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Auburn</surname><given-names>S</given-names></name><name><surname>Koch</surname><given-names>O</given-names></name><name><surname>Sanders</surname><given-names>M</given-names></name><name><surname>Hubbart</surname><given-names>C</given-names></name><name><surname>Maslen</surname><given-names>G</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Jyothi</surname><given-names>D</given-names></name><name><surname>Miles</surname><given-names>A</given-names></name><name><surname>O’Brien</surname><given-names>J</given-names></name><name><surname>Gamble</surname><given-names>C</given-names></name><name><surname>Oyola</surname><given-names>SO</given-names></name><name><surname>Rayner</surname><given-names>JC</given-names></name><name><surname>Newbold</surname><given-names>CI</given-names></name><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>CCA</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Bethell</surname><given-names>D</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiple populations of artemisinin-resistant <italic>Plasmodium falciparum</italic> in Cambodia</article-title><source>Nature Genetics</source><volume>45</volume><fpage>648</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/ng.2624</pub-id><pub-id pub-id-type="pmid">23624527</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>MacInnis</surname><given-names>B</given-names></name><name><surname>Almagro-Garcia</surname><given-names>J</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Mead</surname><given-names>D</given-names></name><name><surname>Oyola</surname><given-names>SO</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Woodrow</surname><given-names>C</given-names></name><name><surname>Manske</surname><given-names>M</given-names></name><name><surname>Stalker</surname><given-names>J</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Campino</surname><given-names>S</given-names></name><name><surname>Amenga-Etego</surname><given-names>L</given-names></name><name><surname>Thanh</surname><given-names>T-NN</given-names></name><name><surname>Tran</surname><given-names>HT</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Bethell</surname><given-names>D</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Chuor</surname><given-names>CM</given-names></name><name><surname>Nguon</surname><given-names>C</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Khanthavong</surname><given-names>M</given-names></name><name><surname>Hongvanthong</surname><given-names>B</given-names></name><name><surname>Htut</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>KT</given-names></name><name><surname>Kyaw</surname><given-names>MP</given-names></name><name><surname>Faiz</surname><given-names>MA</given-names></name><name><surname>Fanello</surname><given-names>CI</given-names></name><name><surname>Onyamboko</surname><given-names>M</given-names></name><name><surname>Mokuolu</surname><given-names>OA</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Takala-Harrison</surname><given-names>S</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Spencer</surname><given-names>CCA</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic architecture of artemisinin-resistant <italic>Plasmodium falciparum</italic></article-title><source>Nature Genetics</source><volume>47</volume><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/ng.3189</pub-id><pub-id pub-id-type="pmid">25599401</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Amambua-Ngwa</surname><given-names>A</given-names></name><name><surname>Amenga-Etego</surname><given-names>L</given-names></name><name><surname>Abdel Hamid</surname><given-names>MM</given-names></name><name><surname>Adam</surname><given-names>I</given-names></name><name><surname>Aninagyei</surname><given-names>E</given-names></name><name><surname>Apinjoh</surname><given-names>T</given-names></name><name><surname>Awandare</surname><given-names>GA</given-names></name><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Bertin</surname><given-names>GI</given-names></name><name><surname>Bouyou-Akotet</surname><given-names>M</given-names></name><name><surname>Claessens</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><name><surname>D’Alessandro</surname><given-names>U</given-names></name><name><surname>Diakite</surname><given-names>M</given-names></name><name><surname>Djimdé</surname><given-names>A</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Duffy</surname><given-names>P</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Fanello</surname><given-names>CI</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name><name><surname>Ishengoma</surname><given-names>D</given-names></name><name><surname>Lawniczak</surname><given-names>M</given-names></name><name><surname>Maïga-Ascofaré</surname><given-names>O</given-names></name><name><surname>Auburn</surname><given-names>S</given-names></name><name><surname>Rosanas-Urgell</surname><given-names>A</given-names></name><name><surname>Wasakul</surname><given-names>V</given-names></name><name><surname>White</surname><given-names>NF</given-names></name><name><surname>Almagro-Garcia</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Goncalves</surname><given-names>S</given-names></name><name><surname>Ariani</surname><given-names>C</given-names></name><name><surname>Bozdech</surname><given-names>Z</given-names></name><name><surname>Hamilton</surname><given-names>W</given-names></name><name><surname>Simpson</surname><given-names>V</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A Complex <italic>Plasmodium falciparum</italic> Cryptotype Circulating at Low Frequency across the African Continent</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.01.20.576496</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Bharti</surname><given-names>PK</given-names></name><name><surname>Shukla</surname><given-names>MM</given-names></name><name><surname>Ali</surname><given-names>NA</given-names></name><name><surname>Kashyotia</surname><given-names>SS</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Dhariwal</surname><given-names>AC</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical and molecular monitoring of    <italic>Plasmodium falciparum</italic>    resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012–2014</article-title><source>Pathogens and Global Health</source><volume>111</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1080/20477724.2017.1331875</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Kita</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Spread and evolution of <italic>Plasmodium falciparum</italic> drug resistance</article-title><source>Parasitology International</source><volume>58</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.parint.2009.04.004</pub-id><pub-id pub-id-type="pmid">19393762</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>AO</given-names></name><name><surname>Hussien</surname><given-names>M</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Suliman</surname><given-names>A</given-names></name><name><surname>Elkando</surname><given-names>NS</given-names></name><name><surname>Abdelbagi</surname><given-names>H</given-names></name><name><surname>Malik</surname><given-names>EM</given-names></name><name><surname>Abdelraheem</surname><given-names>MH</given-names></name><name><surname>Hamid</surname><given-names>MMA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Assessment of <italic>Plasmodium falciparum</italic> drug resistance molecular markers from the Blue Nile State, Southeast Sudan</article-title><source>Malaria Journal</source><volume>19</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-020-03165-0</pub-id><pub-id pub-id-type="pmid">32070355</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Ferreira</surname><given-names>PE</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Yeo</surname><given-names>T</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Nguon</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Htut</surname><given-names>Y</given-names></name><name><surname>Faiz</surname><given-names>MA</given-names></name><name><surname>Onyamboko</surname><given-names>MA</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Woodrow</surname><given-names>CJ</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Preiser</surname><given-names>PR</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Bozdech</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance</article-title><source>Science</source><volume>347</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1126/science.1260403</pub-id><pub-id pub-id-type="pmid">25502316</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriarty</surname><given-names>LF</given-names></name><name><surname>Nkoli</surname><given-names>PM</given-names></name><name><surname>Likwela</surname><given-names>JL</given-names></name><name><surname>Mulopo</surname><given-names>PM</given-names></name><name><surname>Sompwe</surname><given-names>EM</given-names></name><name><surname>Rika</surname><given-names>JM</given-names></name><name><surname>Mavoko</surname><given-names>HM</given-names></name><name><surname>Svigel</surname><given-names>SS</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Ntamabyaliro</surname><given-names>NY</given-names></name><name><surname>Kaputu</surname><given-names>AK</given-names></name><name><surname>Lucchi</surname><given-names>N</given-names></name><name><surname>Subramaniam</surname><given-names>G</given-names></name><name><surname>Niang</surname><given-names>M</given-names></name><name><surname>Sadou</surname><given-names>A</given-names></name><name><surname>Ngoyi</surname><given-names>DM</given-names></name><name><surname>Muyembe Tamfum</surname><given-names>JJ</given-names></name><name><surname>Schmedes</surname><given-names>SE</given-names></name><name><surname>Plucinski</surname><given-names>MM</given-names></name><name><surname>Chowell-Puente</surname><given-names>G</given-names></name><name><surname>Halsey</surname><given-names>ES</given-names></name><name><surname>Kahunu</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Therapeutic efficacy of artemisinin-based combination therapies in democratic republic of the congo and investigation of molecular markers of antimalarial resistance</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>105</volume><fpage>1067</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.21-0214</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Bopp</surname><given-names>S</given-names></name><name><surname>Magistrado</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Daniels</surname><given-names>R</given-names></name><name><surname>Demas</surname><given-names>A</given-names></name><name><surname>Schaffner</surname><given-names>S</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Woodrow</surname><given-names>C</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Wirth</surname><given-names>D</given-names></name><name><surname>Fairhurst</surname><given-names>R</given-names></name><name><surname>Volkman</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Artemisinin resistance without pfkelch13 mutations in <italic>Plasmodium falciparum</italic> isolates from Cambodia</article-title><source>Malaria Journal</source><volume>16</volume><elocation-id>195</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-017-1845-5</pub-id><pub-id pub-id-type="pmid">28494763</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Rosenfeld</surname><given-names>LC</given-names></name><name><surname>Lim</surname><given-names>SS</given-names></name><name><surname>Andrews</surname><given-names>KG</given-names></name><name><surname>Foreman</surname><given-names>KJ</given-names></name><name><surname>Haring</surname><given-names>D</given-names></name><name><surname>Fullman</surname><given-names>N</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Global malaria mortality between 1980 and 2010: a systematic analysis</article-title><source>The Lancet</source><volume>379</volume><fpage>413</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60034-8</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers-Hansen</surname><given-names>JL</given-names></name><name><surname>Abuaku</surname><given-names>B</given-names></name><name><surname>Oyebola</surname><given-names>MK</given-names></name><name><surname>Mensah</surname><given-names>BA</given-names></name><name><surname>Ahorlu</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Awandare</surname><given-names>G</given-names></name><name><surname>Koram</surname><given-names>KA</given-names></name><name><surname>Ngwa</surname><given-names>AA</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Assessment of antimalarial drug resistant markers in asymptomatic <italic>Plasmodium falciparum</italic> infections after 4 years of indoor residual spraying in Northern Ghana</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0233478</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0233478</pub-id><pub-id pub-id-type="pmid">33284800</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Arya</surname><given-names>GA</given-names></name><name><surname>McDew-White</surname><given-names>M</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>TJC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fitness costs and the rapid spread of <italic>kelch13</italic>-C580Y substitutions conferring artemisinin resistance</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>62</volume><fpage>00605</fpage><lpage>00618</lpage><pub-id pub-id-type="doi">10.1128/AAC.00605-18</pub-id><pub-id pub-id-type="pmid">29914963</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>Kucharski</surname><given-names>M</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Callery</surname><given-names>JJ</given-names></name><name><surname>Quang Huy</surname><given-names>DT</given-names></name><name><surname>Gendrot</surname><given-names>M</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>Nghia</surname><given-names>HDT</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Dong</surname><given-names>N</given-names></name><name><surname>Long</surname><given-names>LT</given-names></name><name><surname>Vongpromek</surname><given-names>R</given-names></name><name><surname>Rekol</surname><given-names>H</given-names></name><name><surname>Hoang Chau</surname><given-names>N</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Mukaka</surname><given-names>M</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Roca</surname><given-names>X</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Bozdech</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Population genomics and transcriptomics of <italic>Plasmodium falciparum</italic> in Cambodia and Vietnam uncover key components of the artemisinin resistance genetic background</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>10625</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-54915-6</pub-id><pub-id pub-id-type="pmid">39639029</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ndiaye</surname><given-names>YD</given-names></name><name><surname>Hartl</surname><given-names>DL</given-names></name><name><surname>McGregor</surname><given-names>D</given-names></name><name><surname>Badiane</surname><given-names>A</given-names></name><name><surname>Fall</surname><given-names>FB</given-names></name><name><surname>Daniels</surname><given-names>RF</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Ndiaye</surname><given-names>D</given-names></name><name><surname>Volkman</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genetic surveillance for monitoring the impact of drug use on <italic>Plasmodium falciparum</italic> populations</article-title><source>International Journal for Parasitology. Drugs and Drug Resistance</source><volume>17</volume><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2021.07.004</pub-id><pub-id pub-id-type="pmid">34333350</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neafsey</surname><given-names>DE</given-names></name><name><surname>Taylor</surname><given-names>AR</given-names></name><name><surname>MacInnis</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Advances and opportunities in malaria population genomics</article-title><source>Nature Reviews. Genetics</source><volume>22</volume><fpage>502</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/s41576-021-00349-5</pub-id><pub-id pub-id-type="pmid">33833443</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>Fernandez</surname><given-names>F</given-names></name><name><surname>Green</surname><given-names>MD</given-names></name><name><surname>Sunjio</surname><given-names>M</given-names></name><name><surname>Bruneton</surname><given-names>C</given-names></name><name><surname>Phanouvong</surname><given-names>S</given-names></name><name><surname>Millet</surname><given-names>P</given-names></name><name><surname>Whitty</surname><given-names>CJM</given-names></name><name><surname>Talisuna</surname><given-names>AO</given-names></name><name><surname>Proux</surname><given-names>S</given-names></name><name><surname>Christophel</surname><given-names>EM</given-names></name><name><surname>Malenga</surname><given-names>G</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>Bojang</surname><given-names>K</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Palmer</surname><given-names>K</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Manslaughter by fake artesunate in Asia--will Africa be next?</article-title><source>PLOS Medicine</source><volume>3</volume><elocation-id>e197</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030197</pub-id><pub-id pub-id-type="pmid">16752952</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Baird</surname><given-names>JK</given-names></name><name><surname>Lam</surname><given-names>HM</given-names></name><name><surname>Farrar</surname><given-names>J</given-names></name><name><surname>Thwaites</surname><given-names>GE</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Optimum population-level use of artemisinin combination therapies: a modelling study</article-title><source>The Lancet. Global Health</source><volume>3</volume><elocation-id>e758</elocation-id><pub-id pub-id-type="doi">10.1016/S2214-109X(15)00162-X</pub-id><pub-id pub-id-type="pmid">26545449</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>TN-A</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Aguas</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Preventing antimalarial drug resistance with triple artemisinin-based combination therapies</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>4568</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-39914-3</pub-id><pub-id pub-id-type="pmid">37516752</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Tran</surname><given-names>TNA</given-names></name><name><surname>Parker</surname><given-names>DM</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Antimalarial mass drug administration in large populations and the evolution of drug resistance</article-title><source>PLOS Global Public Health</source><volume>3</volume><elocation-id>e0002200</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgph.0002200</pub-id><pub-id pub-id-type="pmid">37494337</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noedl</surname><given-names>H</given-names></name><name><surname>Se</surname><given-names>Y</given-names></name><name><surname>Schaecher</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>BL</given-names></name><name><surname>Socheat</surname><given-names>D</given-names></name><name><surname>Fukuda</surname><given-names>MM</given-names></name><collab>Artemisinin Resistance in Cambodia 1 Study Consortium</collab></person-group><year iso-8601-date="2008">2008</year><article-title>Evidence of artemisinin-resistant malaria in western Cambodia</article-title><source>The New England Journal of Medicine</source><volume>359</volume><fpage>2619</fpage><lpage>2620</lpage><pub-id pub-id-type="doi">10.1056/NEJMc0805011</pub-id><pub-id pub-id-type="pmid">19064625</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Artemisinin-based combination treatment of falciparum malaria</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>77</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2007.77.181</pub-id><pub-id pub-id-type="pmid">18165491</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nsanzabana</surname><given-names>C</given-names></name><name><surname>Djalle</surname><given-names>D</given-names></name><name><surname>Guérin</surname><given-names>PJ</given-names></name><name><surname>Ménard</surname><given-names>D</given-names></name><name><surname>González</surname><given-names>IJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape</article-title><source>Malaria Journal</source><volume>17</volume><elocation-id>e75</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-018-2185-9</pub-id><pub-id pub-id-type="pmid">29422048</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nsanzabana</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa</article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>e401</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-03942-5</pub-id><pub-id pub-id-type="pmid">34645475</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouattara</surname><given-names>A</given-names></name><name><surname>Kone</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Fofana</surname><given-names>B</given-names></name><name><surname>Maiga</surname><given-names>AW</given-names></name><name><surname>Hampton</surname><given-names>S</given-names></name><name><surname>Coulibaly</surname><given-names>D</given-names></name><name><surname>Thera</surname><given-names>MA</given-names></name><name><surname>Diallo</surname><given-names>N</given-names></name><name><surname>Dara</surname><given-names>A</given-names></name><name><surname>Sagara</surname><given-names>I</given-names></name><name><surname>Gil</surname><given-names>JP</given-names></name><name><surname>Bjorkman</surname><given-names>A</given-names></name><name><surname>Takala-Harrison</surname><given-names>S</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Djimde</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Polymorphisms in the K13-propeller gene in artemisinin-susceptible <italic>Plasmodium falciparum</italic> parasites from Bougoula-Hameau and Bandiagara, Mali</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>92</volume><fpage>1202</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.14-0605</pub-id><pub-id pub-id-type="pmid">25918205</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owoloye</surname><given-names>A</given-names></name><name><surname>Olufemi</surname><given-names>M</given-names></name><name><surname>Idowu</surname><given-names>ET</given-names></name><name><surname>Oyebola</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prevalence of potential mediators of artemisinin resistance in African isolates of <italic>Plasmodium falciparum</italic></article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>451</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-03987-6</pub-id><pub-id pub-id-type="pmid">34856982</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandit</surname><given-names>K</given-names></name><name><surname>Surolia</surname><given-names>N</given-names></name><name><surname>Bhattacharjee</surname><given-names>S</given-names></name><name><surname>Karmodiya</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The many paths to artemisinin resistance in <italic>Plasmodium falciparum</italic></article-title><source>Trends in Parasitology</source><volume>39</volume><fpage>1060</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2023.09.011</pub-id><pub-id pub-id-type="pmid">37833166</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parobek</surname><given-names>CM</given-names></name><name><surname>Parr</surname><given-names>JB</given-names></name><name><surname>Brazeau</surname><given-names>NF</given-names></name><name><surname>Lon</surname><given-names>C</given-names></name><name><surname>Chaorattanakawee</surname><given-names>S</given-names></name><name><surname>Gosi</surname><given-names>P</given-names></name><name><surname>Barnett</surname><given-names>EJ</given-names></name><name><surname>Norris</surname><given-names>LD</given-names></name><name><surname>Meshnick</surname><given-names>SR</given-names></name><name><surname>Spring</surname><given-names>MD</given-names></name><name><surname>Lanteri</surname><given-names>CA</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Saunders</surname><given-names>DL</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PArtner-drug resistance and population substructuring of artemisinin-resistant <italic>Plasmodium falciparum</italic> in Cambodia</article-title><source>Genome Biology and Evolution</source><volume>9</volume><fpage>1673</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1093/gbe/evx126</pub-id><pub-id pub-id-type="pmid">28854635</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Callery</surname><given-names>JJ</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>Nghia</surname><given-names>HDT</given-names></name><name><surname>Nguon</surname><given-names>C</given-names></name><name><surname>Thuong</surname><given-names>NTH</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Dung</surname><given-names>NTP</given-names></name><name><surname>Sokha</surname><given-names>M</given-names></name><name><surname>Van Luong</surname><given-names>V</given-names></name><name><surname>Long</surname><given-names>LT</given-names></name><name><surname>Sovann</surname><given-names>Y</given-names></name><name><surname>Duanguppama</surname><given-names>J</given-names></name><name><surname>Waithira</surname><given-names>N</given-names></name><name><surname>Hoglund</surname><given-names>RM</given-names></name><name><surname>Chotsiri</surname><given-names>P</given-names></name><name><surname>Chau</surname><given-names>NH</given-names></name><name><surname>Ruecker</surname><given-names>A</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Rekol</surname><given-names>H</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Tarning</surname><given-names>J</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Mukaka</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial</article-title><source>The Lancet. Infectious Diseases</source><volume>22</volume><fpage>867</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00692-7</pub-id><pub-id pub-id-type="pmid">35276064</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pongtavornpinyo</surname><given-names>W</given-names></name><name><surname>Yeung</surname><given-names>S</given-names></name><name><surname>Hastings</surname><given-names>IM</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies</article-title><source>Malaria Journal</source><volume>7</volume><elocation-id>e229</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-7-229</pub-id><pub-id pub-id-type="pmid">18976503</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>C</given-names></name><name><surname>Alonso</surname><given-names>P</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Current and emerging strategies to combat antimalarial resistance</article-title><source>Expert Review of Anti-Infective Therapy</source><volume>20</volume><fpage>353</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1080/14787210.2021.1962291</pub-id><pub-id pub-id-type="pmid">34348573</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Redding</surname><given-names>DW</given-names></name><name><surname>Gibb</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Ecological impacts of climate change will transform public health priorities for zoonotic and vector-borne disease</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2024.02.09.24302575</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocamora</surname><given-names>F</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic approaches to drug resistance in malaria</article-title><source>Annual Review of Microbiology</source><volume>74</volume><fpage>761</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-012220-064343</pub-id><pub-id pub-id-type="pmid">32905749</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodó</surname><given-names>X</given-names></name><name><surname>Martinez</surname><given-names>PP</given-names></name><name><surname>Siraj</surname><given-names>A</given-names></name><name><surname>Pascual</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Malaria trends in Ethiopian highlands track the 2000 “slowdown” in global warming</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1555</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21815-y</pub-id><pub-id pub-id-type="pmid">33692343</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The interplay between drug resistance and fitness in malaria parasites</article-title><source>Molecular Microbiology</source><volume>89</volume><fpage>1025</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1111/mmi.12349</pub-id><pub-id pub-id-type="pmid">23899091</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>John</surname><given-names>CC</given-names></name><name><surname>Rabinovich</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Malaria: how are we doing and how can we do better?</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>100</volume><fpage>239</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.18-0997</pub-id><pub-id pub-id-type="pmid">30628572</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Has artemisinin resistance emerged in Africa?</article-title><source>The Lancet Infectious Diseases</source><volume>21</volume><fpage>1056</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00168-7</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Asua</surname><given-names>V</given-names></name><name><surname>Conrad</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa</article-title><source>Nature Reviews Microbiology</source><volume>22</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/s41579-024-01008-2</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>LS</given-names></name><name><surname>Dhingra</surname><given-names>SK</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Yeo</surname><given-names>T</given-names></name><name><surname>Wicht</surname><given-names>KJ</given-names></name><name><surname>Kümpornsin</surname><given-names>K</given-names></name><name><surname>Takala-Harrison</surname><given-names>S</given-names></name><name><surname>Witkowski</surname><given-names>B</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Emerging Southeast Asian PfCRT mutations confer <italic>Plasmodium falciparum</italic> resistance to the first-line antimalarial piperaquine</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>e3314</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05652-0</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>De Smet</surname><given-names>M</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><name><surname>Kindermans</surname><given-names>J-M</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Emergence of <italic>Plasmodium falciparum</italic> triple mutant in Cambodia</article-title><source>The Lancet. Infectious Diseases</source><volume>17</volume><elocation-id>e1233</elocation-id><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30635-7</pub-id><pub-id pub-id-type="pmid">29173875</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>AT</given-names></name><name><surname>Maharaj</surname><given-names>L</given-names></name><name><surname>Oyegoke</surname><given-names>O</given-names></name><name><surname>Akoniyon</surname><given-names>OP</given-names></name><name><surname>Adeleke</surname><given-names>MA</given-names></name><name><surname>Maharaj</surname><given-names>R</given-names></name><name><surname>Okpeku</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Chloroquine and sulfadoxine-pyrimethamine resistance in sub-Saharan Africa-a review</article-title><source>Frontiers in Genetics</source><volume>12</volume><elocation-id>668574</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.668574</pub-id><pub-id pub-id-type="pmid">34249090</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>SJ</given-names></name><name><surname>Lippi</surname><given-names>CA</given-names></name><name><surname>Zermoglio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Shifting transmission risk for malaria in Africa with climate change: a framework for planning and intervention</article-title><source>Malaria Journal</source><volume>19</volume><elocation-id>170</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-020-03224-6</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satimai</surname><given-names>W</given-names></name><name><surname>Sudathip</surname><given-names>P</given-names></name><name><surname>Vijaykadga</surname><given-names>S</given-names></name><name><surname>Khamsiriwatchara</surname><given-names>A</given-names></name><name><surname>Sawang</surname><given-names>S</given-names></name><name><surname>Potithavoranan</surname><given-names>T</given-names></name><name><surname>Sangvichean</surname><given-names>A</given-names></name><name><surname>Delacollette</surname><given-names>C</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>Kaewkungwal</surname><given-names>J</given-names></name><name><surname>Lawpoolsri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Artemisinin resistance containment project in Thailand II: responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia</article-title><source>Malaria Journal</source><volume>11</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-11-300</pub-id><pub-id pub-id-type="pmid">22929621</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Ataide</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>DP</given-names></name><name><surname>Hellard</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>RN</given-names></name><name><surname>Simpson</surname><given-names>JA</given-names></name><name><surname>Fowkes</surname><given-names>FJI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model</article-title><source>Malaria Journal</source><volume>17</volume><elocation-id>279</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-018-2418-y</pub-id><pub-id pub-id-type="pmid">30071877</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherrard-Smith</surname><given-names>E</given-names></name><name><surname>Ngufor</surname><given-names>C</given-names></name><name><surname>Sanou</surname><given-names>A</given-names></name><name><surname>Guelbeogo</surname><given-names>MW</given-names></name><name><surname>N’Guessan</surname><given-names>R</given-names></name><name><surname>Elobolobo</surname><given-names>E</given-names></name><name><surname>Saute</surname><given-names>F</given-names></name><name><surname>Varela</surname><given-names>K</given-names></name><name><surname>Chaccour</surname><given-names>CJ</given-names></name><name><surname>Zulliger</surname><given-names>R</given-names></name><name><surname>Wagman</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>ML</given-names></name><name><surname>Rowland</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>MJ</given-names></name><name><surname>Gonahasa</surname><given-names>S</given-names></name><name><surname>Staedke</surname><given-names>SG</given-names></name><name><surname>Kolaczinski</surname><given-names>J</given-names></name><name><surname>Churcher</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inferring the epidemiological benefit of indoor vector control interventions against malaria from mosquito data</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>e3862</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-30700-1</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sibley</surname><given-names>CH</given-names></name><name><surname>Barnes</surname><given-names>KI</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The rationale and plan for creating a World Antimalarial Resistance Network (WARN)</article-title><source>Malaria Journal</source><volume>6</volume><elocation-id>e118</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-6-118</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>FA</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title><italic>Plasmodium falciparum</italic> resistance to ACTs: Emergence, mechanisms, and outlook</article-title><source>International Journal for Parasitology. Drugs and Drug Resistance</source><volume>16</volume><fpage>102</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2021.05.007</pub-id><pub-id pub-id-type="pmid">34090067</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinka</surname><given-names>ME</given-names></name><name><surname>Bangs</surname><given-names>MJ</given-names></name><name><surname>Manguin</surname><given-names>S</given-names></name><name><surname>Coetzee</surname><given-names>M</given-names></name><name><surname>Mbogo</surname><given-names>CM</given-names></name><name><surname>Hemingway</surname><given-names>J</given-names></name><name><surname>Patil</surname><given-names>AP</given-names></name><name><surname>Temperley</surname><given-names>WH</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name><name><surname>Kabaria</surname><given-names>CW</given-names></name><name><surname>Okara</surname><given-names>RM</given-names></name><name><surname>Van Boeckel</surname><given-names>T</given-names></name><name><surname>Godfray</surname><given-names>HCJ</given-names></name><name><surname>Harbach</surname><given-names>RE</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The dominant Anopheles vectors of human malaria in Africa, Europe and the Middle East: occurrence data, distribution maps and bionomic précis</article-title><source>Parasites &amp; Vectors</source><volume>3</volume><elocation-id>117</elocation-id><pub-id pub-id-type="doi">10.1186/1756-3305-3-117</pub-id><pub-id pub-id-type="pmid">21129198</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>HC</given-names></name><name><surname>Griffin</surname><given-names>JT</given-names></name><name><surname>Ghani</surname><given-names>AC</given-names></name><name><surname>Okell</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa</article-title><source>Malaria Journal</source><volume>15</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-015-1075-7</pub-id><pub-id pub-id-type="pmid">26739092</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Klein</surname><given-names>EY</given-names></name><name><surname>McKenzie</surname><given-names>FE</given-names></name><name><surname>Laxminarayan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty</article-title><source>Malaria Journal</source><volume>9</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-9-217</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Dhingra</surname><given-names>SK</given-names></name><name><surname>Rubiano</surname><given-names>K</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Straimer</surname><given-names>J</given-names></name><name><surname>Gnädig</surname><given-names>NF</given-names></name><name><surname>Deni</surname><given-names>I</given-names></name><name><surname>Schindler</surname><given-names>KA</given-names></name><name><surname>Bath</surname><given-names>JR</given-names></name><name><surname>Ward</surname><given-names>KE</given-names></name><name><surname>Striepen</surname><given-names>J</given-names></name><name><surname>Yeo</surname><given-names>T</given-names></name><name><surname>Ross</surname><given-names>LS</given-names></name><name><surname>Legrand</surname><given-names>E</given-names></name><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Cunningham</surname><given-names>CH</given-names></name><name><surname>Souleymane</surname><given-names>IM</given-names></name><name><surname>Gansané</surname><given-names>A</given-names></name><name><surname>Nzoumbou-Boko</surname><given-names>R</given-names></name><name><surname>Ndayikunda</surname><given-names>C</given-names></name><name><surname>Kabanywanyi</surname><given-names>AM</given-names></name><name><surname>Uwimana</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name><name><surname>Kolley</surname><given-names>O</given-names></name><name><surname>Ndounga</surname><given-names>M</given-names></name><name><surname>Warsame</surname><given-names>M</given-names></name><name><surname>Leang</surname><given-names>R</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Ménard</surname><given-names>D</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title><italic>Plasmodium falciparum</italic> K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness</article-title><source>eLife</source><volume>10</volume><elocation-id>e66277</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.66277</pub-id><pub-id pub-id-type="pmid">34279219</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Ward</surname><given-names>KE</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evidence of artemisinin-resistant malaria in Africa</article-title><source>The New England Journal of Medicine</source><volume>386</volume><fpage>1385</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2117480</pub-id><pub-id pub-id-type="pmid">35388682</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straimer</surname><given-names>J</given-names></name><name><surname>Gnädig</surname><given-names>NF</given-names></name><name><surname>Witkowski</surname><given-names>B</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Duru</surname><given-names>V</given-names></name><name><surname>Ramadani</surname><given-names>AP</given-names></name><name><surname>Dacheux</surname><given-names>M</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name><name><surname>Urnov</surname><given-names>FD</given-names></name><name><surname>Mercereau-Puijalon</surname><given-names>O</given-names></name><name><surname>Benoit-Vical</surname><given-names>F</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Ménard</surname><given-names>D</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Drug resistance: K13-propeller mutations confer artemisinin resistance in <italic>Plasmodium falciparum</italic> clinical isolates</article-title><source>Science</source><volume>347</volume><fpage>428</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1126/science.1260867</pub-id><pub-id pub-id-type="pmid">25502314</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straimer</surname><given-names>J</given-names></name><name><surname>Gnädig</surname><given-names>NF</given-names></name><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Ehrenberger</surname><given-names>M</given-names></name><name><surname>Crane</surname><given-names>AA</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Plasmodium falciparum</italic> K13 mutations differentially impact ozonide susceptibility and parasite fitness <italic>in vitro</italic></article-title><source>mBio</source><volume>8</volume><elocation-id>e17</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00172-17</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straimer</surname><given-names>J</given-names></name><name><surname>Gandhi</surname><given-names>P</given-names></name><name><surname>Renner</surname><given-names>KC</given-names></name><name><surname>Schmitt</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>High Prevalence of <italic>Plasmodium falciparum</italic> K13 Mutations in Rwanda Is associated with slow parasite clearance after treatment with Artemether-Lumefantrine</article-title><source>The Journal of Infectious Diseases</source><volume>225</volume><fpage>1411</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab352</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takala-Harrison</surname><given-names>S</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Arze</surname><given-names>C</given-names></name><name><surname>Cummings</surname><given-names>MP</given-names></name><name><surname>Silva</surname><given-names>JC</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Fukuda</surname><given-names>MM</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Noedl</surname><given-names>H</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Kyaw</surname><given-names>MP</given-names></name><name><surname>Nhien</surname><given-names>NTT</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Bethell</surname><given-names>D</given-names></name><name><surname>Se</surname><given-names>Y</given-names></name><name><surname>Lon</surname><given-names>C</given-names></name><name><surname>Tyner</surname><given-names>SD</given-names></name><name><surname>Saunders</surname><given-names>DL</given-names></name><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Mercereau-Puijalon</surname><given-names>O</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Khanthavong</surname><given-names>M</given-names></name><name><surname>Hongvanthong</surname><given-names>B</given-names></name><name><surname>Starzengruber</surname><given-names>P</given-names></name><name><surname>Fuehrer</surname><given-names>H-P</given-names></name><name><surname>Swoboda</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>WA</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Nyunt</surname><given-names>MM</given-names></name><name><surname>Nyunt</surname><given-names>MH</given-names></name><name><surname>Brown</surname><given-names>TS</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Pepin</surname><given-names>CS</given-names></name><name><surname>Bailey</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>JC</given-names></name><name><surname>Ferdig</surname><given-names>MT</given-names></name><name><surname>Clark</surname><given-names>TG</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>MacInnis</surname><given-names>B</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Independent emergence of artemisinin resistance mutations among <italic>Plasmodium falciparum</italic> in Southeast Asia</article-title><source>The Journal of Infectious Diseases</source><volume>211</volume><fpage>670</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu491</pub-id><pub-id pub-id-type="pmid">25180241</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SM</given-names></name><name><surname>Parobek</surname><given-names>CM</given-names></name><name><surname>DeConti</surname><given-names>DK</given-names></name><name><surname>Kayentao</surname><given-names>K</given-names></name><name><surname>Coulibaly</surname><given-names>SO</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Tagbor</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Bojang</surname><given-names>K</given-names></name><name><surname>Njie</surname><given-names>F</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Gutman</surname><given-names>J</given-names></name><name><surname>Mathanga</surname><given-names>DP</given-names></name><name><surname>Mårtensson</surname><given-names>A</given-names></name><name><surname>Ngasala</surname><given-names>B</given-names></name><name><surname>Conrad</surname><given-names>MD</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Tshefu</surname><given-names>AK</given-names></name><name><surname>Moormann</surname><given-names>AM</given-names></name><name><surname>Vulule</surname><given-names>JM</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Ter Kuile</surname><given-names>FO</given-names></name><name><surname>Meshnick</surname><given-names>SR</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Absence of putative artemisinin resistance mutations among <italic>Plasmodium falciparum</italic> in Sub-Saharan Africa: a molecular epidemiologic study</article-title><source>The Journal of Infectious Diseases</source><volume>211</volume><fpage>680</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu467</pub-id><pub-id pub-id-type="pmid">25180240</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tindana</surname><given-names>P</given-names></name><name><surname>de Haan</surname><given-names>F</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations</article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>119</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-03649-7</pub-id><pub-id pub-id-type="pmid">33639946</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Trape</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2001">2001</year><chapter-title>The intolerable burden of malaria: a new look at the numbers</chapter-title><person-group person-group-type="editor"><name><surname>Andréa Egan</surname><given-names>E</given-names></name></person-group><source>The Intolerable Burden of Malaria: A New Look at the Numbers: Supplement to Volume 64 of the American Journal of Tropical Medicine and Hygiene</source><publisher-name>American Society of Tropical Medicine and Hygiene</publisher-name><fpage>121</fpage><lpage>126</lpage></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumwebaze</surname><given-names>PK</given-names></name><name><surname>Conrad</surname><given-names>MD</given-names></name><name><surname>Okitwi</surname><given-names>M</given-names></name><name><surname>Orena</surname><given-names>S</given-names></name><name><surname>Byaruhanga</surname><given-names>O</given-names></name><name><surname>Katairo</surname><given-names>T</given-names></name><name><surname>Legac</surname><given-names>J</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Giesbrecht</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>SR</given-names></name><name><surname>Ceja</surname><given-names>FG</given-names></name><name><surname>Nsobya</surname><given-names>SL</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Decreased susceptibility of <italic>Plasmodium falciparum</italic> to both dihydroartemisinin and lumefantrine in northern Uganda</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>6353</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33873-x</pub-id><pub-id pub-id-type="pmid">36289202</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tun</surname><given-names>KM</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Lwin</surname><given-names>KM</given-names></name><name><surname>Win</surname><given-names>AA</given-names></name><name><surname>Hlaing</surname><given-names>TM</given-names></name><name><surname>Hlaing</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Kyaw</surname><given-names>MP</given-names></name><name><surname>Plewes</surname><given-names>K</given-names></name><name><surname>Faiz</surname><given-names>MA</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Anderson</surname><given-names>TJC</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>McDew-White</surname><given-names>M</given-names></name><name><surname>Flegg</surname><given-names>JA</given-names></name><name><surname>Grist</surname><given-names>EPM</given-names></name><name><surname>Guerin</surname><given-names>P</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Smithuis</surname><given-names>F</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Woodrow</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spread of artemisinin-resistant <italic>Plasmodium falciparum</italic> in Myanmar: a cross-sectional survey of the K13 molecular marker</article-title><source>The Lancet. Infectious Diseases</source><volume>15</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)70032-0</pub-id><pub-id pub-id-type="pmid">25704894</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tun</surname><given-names>STT</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Pongvongsa</surname><given-names>T</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Saralamba</surname><given-names>S</given-names></name><name><surname>Kyaw</surname><given-names>SS</given-names></name><name><surname>Chanthavilay</surname><given-names>P</given-names></name><name><surname>Celhay</surname><given-names>O</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Tran</surname><given-names>TN-A</given-names></name><name><surname>Parker</surname><given-names>DM</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>White</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Towards malaria elimination in Savannakhet, Lao PDR: mathematical modelling driven strategy design</article-title><source>Malaria Journal</source><volume>16</volume><elocation-id>483</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-017-2130-3</pub-id><pub-id pub-id-type="pmid">29183370</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tun</surname><given-names>KM</given-names></name><name><surname>Jeeyapant</surname><given-names>A</given-names></name><name><surname>Myint</surname><given-names>AH</given-names></name><name><surname>Kyaw</surname><given-names>ZT</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Mukaka</surname><given-names>M</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Hlaing</surname><given-names>T</given-names></name><name><surname>Kyaw</surname><given-names>TH</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Dondorp</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>Smithuis</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar</article-title><source>Malaria Journal</source><volume>17</volume><elocation-id>258</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-018-2404-4</pub-id><pub-id pub-id-type="pmid">29996844</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uwimana</surname><given-names>A</given-names></name><name><surname>Legrand</surname><given-names>E</given-names></name><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Ndikumana</surname><given-names>J-LM</given-names></name><name><surname>Warsame</surname><given-names>M</given-names></name><name><surname>Umulisa</surname><given-names>N</given-names></name><name><surname>Ngamije</surname><given-names>D</given-names></name><name><surname>Munyaneza</surname><given-names>T</given-names></name><name><surname>Mazarati</surname><given-names>J-B</given-names></name><name><surname>Munguti</surname><given-names>K</given-names></name><name><surname>Campagne</surname><given-names>P</given-names></name><name><surname>Criscuolo</surname><given-names>A</given-names></name><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Murindahabi</surname><given-names>M</given-names></name><name><surname>Ringwald</surname><given-names>P</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Mbituyumuremyi</surname><given-names>A</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emergence and clonal expansion of in vitro artemisinin-resistant <italic>Plasmodium falciparum</italic> kelch13 R561H mutant parasites in Rwanda</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1602</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1005-2</pub-id><pub-id pub-id-type="pmid">32747827</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uwimana</surname><given-names>A</given-names></name><name><surname>Umulisa</surname><given-names>N</given-names></name><name><surname>Venkatesan</surname><given-names>M</given-names></name><name><surname>Svigel</surname><given-names>SS</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Munyaneza</surname><given-names>T</given-names></name><name><surname>Habimana</surname><given-names>RM</given-names></name><name><surname>Rucogoza</surname><given-names>A</given-names></name><name><surname>Moriarty</surname><given-names>LF</given-names></name><name><surname>Sandford</surname><given-names>R</given-names></name><name><surname>Piercefield</surname><given-names>E</given-names></name><name><surname>Goldman</surname><given-names>I</given-names></name><name><surname>Ezema</surname><given-names>B</given-names></name><name><surname>Talundzic</surname><given-names>E</given-names></name><name><surname>Pacheco</surname><given-names>MA</given-names></name><name><surname>Escalante</surname><given-names>AA</given-names></name><name><surname>Ngamije</surname><given-names>D</given-names></name><name><surname>Mangala</surname><given-names>J-LN</given-names></name><name><surname>Kabera</surname><given-names>M</given-names></name><name><surname>Munguti</surname><given-names>K</given-names></name><name><surname>Murindahabi</surname><given-names>M</given-names></name><name><surname>Brieger</surname><given-names>W</given-names></name><name><surname>Musanabaganwa</surname><given-names>C</given-names></name><name><surname>Mutesa</surname><given-names>L</given-names></name><name><surname>Udhayakumar</surname><given-names>V</given-names></name><name><surname>Mbituyumuremyi</surname><given-names>A</given-names></name><name><surname>Halsey</surname><given-names>ES</given-names></name><name><surname>Lucchi</surname><given-names>NW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Association of <italic>Plasmodium falciparum</italic> kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study</article-title><source>The Lancet. Infectious Diseases</source><volume>21</volume><fpage>1120</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00142-0</pub-id><pub-id pub-id-type="pmid">33864801</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Hoglund</surname><given-names>RM</given-names></name><name><surname>Pyae Phyo</surname><given-names>A</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>ul Islam</surname><given-names>A</given-names></name><name><surname>Anvikar</surname><given-names>AR</given-names></name><name><surname>Satpathi</surname><given-names>P</given-names></name><name><surname>Satpathi</surname><given-names>S</given-names></name><name><surname>Behera</surname><given-names>PK</given-names></name><name><surname>Tripura</surname><given-names>A</given-names></name><name><surname>Baidya</surname><given-names>S</given-names></name><name><surname>Onyamboko</surname><given-names>M</given-names></name><name><surname>Chau</surname><given-names>NH</given-names></name><name><surname>Sovann</surname><given-names>Y</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>S</given-names></name><name><surname>Oun</surname><given-names>S</given-names></name><name><surname>Yen</surname><given-names>S</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Chutasmit</surname><given-names>K</given-names></name><name><surname>Saelow</surname><given-names>C</given-names></name><name><surname>Runcharern</surname><given-names>R</given-names></name><name><surname>Kaewmok</surname><given-names>W</given-names></name><name><surname>Hoa</surname><given-names>NT</given-names></name><name><surname>Thanh</surname><given-names>NV</given-names></name><name><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name><surname>Callery</surname><given-names>JJ</given-names></name><name><surname>Mohanty</surname><given-names>AK</given-names></name><name><surname>Heaton</surname><given-names>J</given-names></name><name><surname>Thant</surname><given-names>M</given-names></name><name><surname>Gantait</surname><given-names>K</given-names></name><name><surname>Ghosh</surname><given-names>T</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Gonçalves</surname><given-names>S</given-names></name><name><surname>Mukaka</surname><given-names>M</given-names></name><name><surname>Waithira</surname><given-names>N</given-names></name><name><surname>Woodrow</surname><given-names>CJ</given-names></name><name><surname>Grobusch</surname><given-names>MP</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Winterberg</surname><given-names>M</given-names></name><name><surname>Thuy-Nhien</surname><given-names>NT</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Jittamala</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Hlaing</surname><given-names>TM</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Huy</surname><given-names>R</given-names></name><name><surname>Fanello</surname><given-names>C</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Valecha</surname><given-names>N</given-names></name><name><surname>Smithuis</surname><given-names>F</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Faiz</surname><given-names>A</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Tarning</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Hoglund</surname><given-names>RM</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Lek</surname><given-names>D</given-names></name><name><surname>ul Islam</surname><given-names>A</given-names></name><name><surname>Anvikar</surname><given-names>AR</given-names></name><name><surname>Satpathi</surname><given-names>P</given-names></name><name><surname>Satpathi</surname><given-names>S</given-names></name><name><surname>Behera</surname><given-names>PK</given-names></name><name><surname>Tripura</surname><given-names>A</given-names></name><name><surname>Baidya</surname><given-names>S</given-names></name><name><surname>Onyamboko</surname><given-names>M</given-names></name><name><surname>Chau</surname><given-names>NH</given-names></name><name><surname>Sovann</surname><given-names>Y</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>S</given-names></name><name><surname>Oun</surname><given-names>S</given-names></name><name><surname>Yen</surname><given-names>S</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Chutasmit</surname><given-names>K</given-names></name><name><surname>Saelow</surname><given-names>C</given-names></name><name><surname>Runcharern</surname><given-names>R</given-names></name><name><surname>Kaewmok</surname><given-names>W</given-names></name><name><surname>Hoa</surname><given-names>NT</given-names></name><name><surname>Thanh</surname><given-names>NV</given-names></name><name><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name><surname>Callery</surname><given-names>JJ</given-names></name><name><surname>Mohanty</surname><given-names>AK</given-names></name><name><surname>Heaton</surname><given-names>J</given-names></name><name><surname>Thant</surname><given-names>M</given-names></name><name><surname>Gantait</surname><given-names>K</given-names></name><name><surname>Ghosh</surname><given-names>T</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Gonçalves</surname><given-names>S</given-names></name><name><surname>Mukaka</surname><given-names>M</given-names></name><name><surname>Waithira</surname><given-names>N</given-names></name><name><surname>Woodrow</surname><given-names>CJ</given-names></name><name><surname>Grobusch</surname><given-names>MP</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Cheah</surname><given-names>PY</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Winterberg</surname><given-names>M</given-names></name><name><surname>Thuy-Nhien</surname><given-names>NT</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Jittamala</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Hlaing</surname><given-names>TM</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Huy</surname><given-names>R</given-names></name><name><surname>Fanello</surname><given-names>C</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Valeche</surname><given-names>N</given-names></name><name><surname>Smithuis</surname><given-names>F</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Faiz</surname><given-names>A</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name><name><surname>Tarning</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <italic>Plasmodium falciparum</italic> malaria: a multicentre, open-label, randomised clinical trial</article-title><source>The Lancet</source><volume>395</volume><fpage>1345</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30552-3</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Triple artemisinin-based combination therapies for malaria - a new paradigm?</article-title><source>Trends in Parasitology</source><volume>37</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2020.09.011</pub-id><pub-id pub-id-type="pmid">33060063</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verity</surname><given-names>R</given-names></name><name><surname>Aydemir</surname><given-names>O</given-names></name><name><surname>Brazeau</surname><given-names>NF</given-names></name><name><surname>Watson</surname><given-names>OJ</given-names></name><name><surname>Hathaway</surname><given-names>NJ</given-names></name><name><surname>Mwandagalirwa</surname><given-names>MK</given-names></name><name><surname>Marsh</surname><given-names>PW</given-names></name><name><surname>Thwai</surname><given-names>K</given-names></name><name><surname>Fulton</surname><given-names>T</given-names></name><name><surname>Denton</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>AP</given-names></name><name><surname>Parr</surname><given-names>JB</given-names></name><name><surname>Tumwebaze</surname><given-names>PK</given-names></name><name><surname>Conrad</surname><given-names>M</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Ishengoma</surname><given-names>DS</given-names></name><name><surname>Ngondi</surname><given-names>J</given-names></name><name><surname>Gutman</surname><given-names>J</given-names></name><name><surname>Mulenga</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>DE</given-names></name><name><surname>Moss</surname><given-names>WJ</given-names></name><name><surname>Mensah</surname><given-names>BA</given-names></name><name><surname>Myers-Hansen</surname><given-names>JL</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name><name><surname>Tshefu</surname><given-names>AK</given-names></name><name><surname>Ghani</surname><given-names>AC</given-names></name><name><surname>Meshnick</surname><given-names>SR</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The impact of antimalarial resistance on the genetic structure of <italic>Plasmodium falciparum</italic> in the DRC</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2107</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15779-8</pub-id><pub-id pub-id-type="pmid">32355199</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LT</given-names></name><name><surname>Bwambale</surname><given-names>R</given-names></name><name><surname>Keeler</surname><given-names>C</given-names></name><name><surname>Reyes</surname><given-names>R</given-names></name><name><surname>Muhindo</surname><given-names>R</given-names></name><name><surname>Matte</surname><given-names>M</given-names></name><name><surname>Ntaro</surname><given-names>M</given-names></name><name><surname>Mulogo</surname><given-names>E</given-names></name><name><surname>Sundararajan</surname><given-names>R</given-names></name><name><surname>Boyce</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Private sector drug shops frequently dispense parenteral anti-malarials in a rural region of Western Uganda</article-title><source>Malaria Journal</source><volume>17</volume><elocation-id>305</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-018-2454-7</pub-id><pub-id pub-id-type="pmid">30134987</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasakul</surname><given-names>V</given-names></name><name><surname>Disratthakit</surname><given-names>A</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Chindavongsa</surname><given-names>K</given-names></name><name><surname>Sengsavath</surname><given-names>V</given-names></name><name><surname>Thuy-Nhien</surname><given-names>N</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Phalivong</surname><given-names>S</given-names></name><name><surname>Xayvanghang</surname><given-names>S</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Gonçalves</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Malaria outbreak in Laos driven by a selective sweep for <italic>Plasmodium falciparum</italic> kelch13 R539T mutants: a genetic epidemiology analysis</article-title><source>The Lancet. Infectious Diseases</source><volume>23</volume><fpage>568</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00697-1</pub-id><pub-id pub-id-type="pmid">36462526</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellems</surname><given-names>TE</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Chloroquine-resistant malaria</article-title><source>The Journal of Infectious Diseases</source><volume>184</volume><fpage>770</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1086/322858</pub-id><pub-id pub-id-type="pmid">11517439</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Antimalarial drug resistance</article-title><source>The Journal of Clinical Investigation</source><volume>113</volume><fpage>1084</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1172/JCI21682</pub-id><pub-id pub-id-type="pmid">15085184</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Pongtavornpinyo</surname><given-names>W</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Saralamba</surname><given-names>S</given-names></name><name><surname>Aguas</surname><given-names>R</given-names></name><name><surname>Stepniewska</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>White</surname><given-names>LJ</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance</article-title><source>Malaria Journal</source><volume>8</volume><elocation-id>253</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-8-253</pub-id><pub-id pub-id-type="pmid">19906307</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitlock</surname><given-names>AOB</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name><name><surname>Mideo</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immune selection suppresses the emergence of drug resistance in malaria parasites but facilitates its spread</article-title><source>PLOS Computational Biology</source><volume>17</volume><elocation-id>e1008577</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008577</pub-id><pub-id pub-id-type="pmid">34280179</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2006">2006</year><article-title>Guidelines for the treatment of malaria</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/guidelines-for-malaria">https://www.who.int/publications/i/item/guidelines-for-malaria</ext-link><date-in-citation iso-8601-date="2025-08-13">August 13, 2025</date-in-citation></element-citation></ref><ref id="bib159"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2009">2009</year><article-title>Minutes of the drug resistance and containment technical expert group</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789241597531">https://www.who.int/publications/i/item/9789241597531</ext-link><date-in-citation iso-8601-date="2009-10-13">October 13, 2009</date-in-citation></element-citation></ref><ref id="bib160"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Minutes of the drug resistance and containment technical expert group</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/minutes-of-the-drug-resistance-and-containment-technical-expert-group-june-2013">https://www.who.int/publications/m/item/minutes-of-the-drug-resistance-and-containment-technical-expert-group-june-2013</ext-link><date-in-citation iso-8601-date="2013-06-27">June 27, 2013</date-in-citation></element-citation></ref><ref id="bib161"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2015">2015a</year><article-title>Guidelines for the treatment of malaria</article-title><ext-link ext-link-type="uri" xlink:href="https://www.paho.org/en/node/64471">https://www.paho.org/en/node/64471</ext-link><date-in-citation iso-8601-date="2015-11-07">November 7, 2015</date-in-citation></element-citation></ref><ref id="bib162"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2015">2015b</year><article-title>Strategy for malaria elimination in the greater mekong subregion</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789290617181">https://www.who.int/publications/i/item/9789290617181</ext-link><date-in-citation iso-8601-date="2015-05-21">May 21, 2015</date-in-citation></element-citation></ref><ref id="bib163"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Minutes of the evidence review group meeting on the emergence and spread of multidrugresistant <italic>Plasmodium falciparum</italic> lineages in the greater mekong subregion</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/minutes-of-the-evidence-review-group-meeting-on-the-emergence-and-spread-of-multidrug-resistant-plasmodium-falciparum-lineages-in-the-greater-mekong-subregion">https://www.who.int/publications/m/item/minutes-of-the-evidence-review-group-meeting-on-the-emergence-and-spread-of-multidrug-resistant-plasmodium-falciparum-lineages-in-the-greater-mekong-subregion</ext-link><date-in-citation iso-8601-date="2016-12-29">December 29, 2016</date-in-citation></element-citation></ref><ref id="bib164"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2021">2021</year><article-title>World Malaria Report</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240040496">https://www.who.int/publications/i/item/9789240040496</ext-link><date-in-citation iso-8601-date="2021-12-06">December 6, 2021</date-in-citation></element-citation></ref><ref id="bib165"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2022">2022a</year><article-title>WHO guidelines for malaria</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/18-11-2022-tackling-emerging-antimalarial-drug-resistance-in-africa">https://www.who.int/news/item/18-11-2022-tackling-emerging-antimalarial-drug-resistance-in-africa</ext-link><date-in-citation iso-8601-date="2022-11-18">November 18, 2022</date-in-citation></element-citation></ref><ref id="bib166"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2022">2022b</year><article-title>WHO guidelines for malaria</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/guidelines-for-malaria">https://www.who.int/publications/i/item/guidelines-for-malaria</ext-link><date-in-citation iso-8601-date="2022-06-03">June 3, 2022</date-in-citation></element-citation></ref><ref id="bib167"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2023">2023</year><article-title>World malaria report</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023">https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023</ext-link><date-in-citation iso-8601-date="2023-11-30">November 30, 2023</date-in-citation></element-citation></ref><ref id="bib168"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization, Global Malaria Programme</collab></person-group><year iso-8601-date="2024">2024</year><article-title>WHO malaria threats map.world health organisation</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240090149">https://www.who.int/publications/i/item/9789240090149</ext-link><date-in-citation iso-8601-date="2024-04-23">April 23, 2024</date-in-citation></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>WWARN K13 Genotype-Phenotype Study Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Association of mutations in the <italic>Plasmodium falciparum</italic> Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis</article-title><source>BMC Medicine</source><volume>17</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-018-1207-3</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Yeoh</surname><given-names>LM</given-names></name><name><surname>Tutor</surname><given-names>MV</given-names></name><name><surname>Dixon</surname><given-names>MW</given-names></name><name><surname>McMillan</surname><given-names>PJ</given-names></name><name><surname>Xie</surname><given-names>SC</given-names></name><name><surname>Bridgford</surname><given-names>JL</given-names></name><name><surname>Gillett</surname><given-names>DL</given-names></name><name><surname>Duffy</surname><given-names>MF</given-names></name><name><surname>Ralph</surname><given-names>SA</given-names></name><name><surname>McConville</surname><given-names>MJ</given-names></name><name><surname>Tilley</surname><given-names>L</given-names></name><name><surname>Cobbold</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Decreased K13 abundance reduces Hemoglobin catabolism and proteotoxic stress, underpinning artemisinin resistance</article-title><source>Cell Reports</source><volume>29</volume><fpage>2917</fpage><lpage>2928</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.095</pub-id><pub-id pub-id-type="pmid">31775055</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeka</surname><given-names>A</given-names></name><name><surname>Wallender</surname><given-names>E</given-names></name><name><surname>Mulebeke</surname><given-names>R</given-names></name><name><surname>Kibuuka</surname><given-names>A</given-names></name><name><surname>Kigozi</surname><given-names>R</given-names></name><name><surname>Bosco</surname><given-names>A</given-names></name><name><surname>Kyambadde</surname><given-names>P</given-names></name><name><surname>Opigo</surname><given-names>J</given-names></name><name><surname>Kalyesubula</surname><given-names>S</given-names></name><name><surname>Senzoga</surname><given-names>J</given-names></name><name><surname>Vinden</surname><given-names>J</given-names></name><name><surname>Conrad</surname><given-names>M</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comparative efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the treatment of uncomplicated malaria in ugandan children</article-title><source>The Journal of Infectious Diseases</source><volume>219</volume><fpage>1112</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy637</pub-id><pub-id pub-id-type="pmid">30418593</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>S</given-names></name><name><surname>Pongtavornpinyo</surname><given-names>W</given-names></name><name><surname>Hastings</surname><given-names>IM</given-names></name><name><surname>Mills</surname><given-names>AJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>71</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">15331836</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zupko</surname><given-names>RJ</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Ngabonziza</surname><given-names>JCS</given-names></name><name><surname>Kabera</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>TN-A</given-names></name><name><surname>Tran</surname><given-names>KT</given-names></name><name><surname>Uwimana</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda</article-title><source>Nature Medicine</source><volume>29</volume><fpage>2775</fpage><lpage>2784</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02551-w</pub-id><pub-id pub-id-type="pmid">37735560</pub-id></element-citation></ref></ref-list></back></article>